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FOREWORD 
The Scientific Committee for Pesticides was set up by Commission Decision 
78/436/EEC of 21 April 1978 (OJ N° L 124 of 12.05.78, p. 16) in order to provide the 
Commission with informed opinions on scientific and technical matters relating to the 
use and marketing of pesticides and to their residues, particularly in food and 
feedingstuffs. 
The members of the Committee are independent and highly qualified in the fields of 
applied biology, toxicology, ecotoxicology and chemistry. The Secretariat of the 
Committee is provided by the Commission's Directorate-General for Agriculture. 
The Committee's third series of reports, published in this volume, relate to questions put 
to it by the Commission on the safety in use, for man and environment, of certain 
pesticides and on the maximum permitted levels of their residues in foodstuffs. 
Questions in this connection had arisen in the course of the Commission's work on the 
approximation of Member States' legislation concerning pesticides. 
Ill 
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REPORT OF THE SCIENTIFIC COUilTTEE FOR PESTICIDES 
ON THE USE OF CHLOROTHALONIL 
(Opinion expressed by the SCP on 11 February 1992) 
BACKGROUND AND TERMS OF REFERENCE. 
Chlorothalonil is authorized for use as a fungicide in all Member 
States on a wide range of fruit and vegetable crops. It has been 
evaluated by the Joint Meeting on Pesticide Residues (JMPR) in 1974, 
1977, 1979, 1981, 1983, 1985, 1987 and 1990 (1). The temporary 
acceptable daily intake (ADI) of 0.03 mg/kg bw estimated in 1974 was 
reduced in 1981 and 1985 to 0.005 mg/kg bw and 0.0005 mg/kg/bw 
respectively due to inadequate metabolism data and concern for 
oncogenicity. In 1987, additional data allowed the temporary ADI to be 
increased to 0.003 mg/kg/bw. Since then additional data has become 
available which permitted the 1990 JMPR to estimate an increased ADI 
of 0.03 mg/kg/bw. 
In the context of its work relating to the establishment of Community 
maximum pesticide residue levels in various foodstuffs covered by 
Community legislation, the Commission requested thè Scientific 
Committee for Pesticides to review the basis of the ADI, paying 
particular attention to the carcinogenic effects observed in 
laboratory animals and the relevance of these effects for man. 
1. TOXICOLOGI CAL ASPECTS. 
1.1. PHYSICAL-CHEMICAL PROPERTIES 
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Chlorothalonil is the common 
name for 2,4,5,6-tetrachloro-
isophtalonitri le (C8CI4N2, 
CAS n': 1897-45-6). 
The molecular weight is 265.92. 
Its colourless crystals (melting 
point 250'C) are slightly soluble 
in water (0.6 mg/l at 25'C). 
It is soluble in organic solvents 
It is easily adsorbed on suspended 
coefficient (log Kac) is 5.7. 
It is stable to UV light and in alkaline aqueous 
and its log Pow is 4.4. 
particulates. The partition 
med i um. 
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1.2. METABOLIC STUDIES 
1.2.1. Oral route 
Rats 
In vitro experiments on the incubation of 14C-chlorothaIoni I with 
stomach and intestinal mucosal cells show that 14C-chlorothaIoni I is 
not absorbed as such by the gastro-intestinal tract and must be 
converted to polar metabolites prior to its absorption (2). Studies, 
in which radio-labelled chlorothalonil introduced Into "sacs" formed 
from the upper section of the small intestine of the rat show that 
only the polar metabolites pass through the intestinal mucosa and are 
transferred to the serosal side of the sac. No chlorothalonil passes 
through the mucosa (3). 
Radio-labelled chlorothaloniI.administered orally to rats at doses of 
5, 50 and 200 mg/kg/bw is only partially but rapidly absorbed by the 
gastro-intestinal tract . The concentration in blood (within 30 
minutes) is proportional to the dose but non linear between 50 and 
200 mg/kg/bw dosages showing some saturation of the metabolic capacity 
to form polar metabolites. The percentage of urinary elimination of 
the compound goes up to 6 % of the administered dose but appears to 
decrease with increasing dose levels. Most of the radioactivity is 
eliminated in the faeces (4). 
The absorbed radio-material is distributed among body tissues. The 
kidney contains the highest concentration of radioactivity (up to 7 % 
of the dose), the radio-labelled compound being bound to kidney 
proteins. At a subcellular level, approximately 81 % of the radio-
label present in the kidney is found in the cytosol . More than 10 % 
of the compound found in the organelles of the kidney cells is 
associated with mitochondria (5). 
The identification of urinary and biliary metabolites shows that the 
major pathway in the rat metabolism involves the formation of 
conjugates with glutathione (6). Degradation of the conjugate 
derivatives gives rise to generation of thiol metabolites including 
the 4,6-dithiol derivative of chlorothalonil which is known to inhibit 
mitochondrial oxygen consumption and prevent energy production 
through ATP (7). 
Rats germ free 
A single dose of 14C-chlorothaIon i I at 50 mg/kg/bw was given orally 
to germ-free Sprague-Dawley rats. Urine and faeces were collected at 
24 and 96 hours and blood, kidneys and the carcass at 98 hours. 
Urinary excretion of radioactivity accounted for about 3 % of the 
administered dose and the fecal excretion for 84 % . Blood levels 
accounted for 0.01 % , the kidneys containing 0.05 % . Faecal and 
urinary excretion of the test material occurred mainly in the first 24 
hours after dosing. Urine samples were analyzed for thiol derivatives. 
Mono-thiol was not detected in any sample. Dithlol was detected only 
in one 24-48 h sample and the trithiol in two samples of 0-24 h and 
two of the 24-48 h period ( 3 positive rats out of 9 ) . The highest 
concentration of thiols detected accounted for 0.053 % of the 
administered dose (8). 
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In a comparative study with non germ free rats it was found that 1.7 % 
of the dose was excreted as thiols. Thiol excretion was much less in 
germ free rats than normal rats. 
Dogs 
Two male beagle dogs were given 14C-chlorothaloniI by gelatin 
capsule at 50 mg/kg bw. Samples were collected every 24 hours for a 
period of 10 days for urine and for 12 days for faeces. Recovery of 
test material was virtually complete. Most of the material was 
excreted in the faeces with only small amounts in urine (0.2 and 0.3 
% ) . Urine samples were analyzed for thiol derivatives and none were 
detected at the detection limit of 3 ng/ml (9). 
A second study was performed on 3 dogs given a single oral dose of the 
same radio-labelled material at 50 mg/kg bw. The animals were 
observed for a period of 8 days, urine being obtained by 
catheterization. Faecal radioactivity in the first 24 hours accounted 
for 60 to 96 % of the nominal dose administered and a further amount 
during days 2 and 3. Urinary excretion accounted for 0.6 to 1 .7 % of 
the nominal dose which was recovered predominantly in the first 24 
hours, and mostly during the first 10 h after dosing. Urine was 
analysed for thiol derivatives and none were detected in any of the 
samp les (10). 
Monkeys 
Four male Chinese Rhesus monkeys were given the same radio-labelled 
material by gavage at 50 mg/kg bw. Urine and blood were collected by 
catheters for 48 h after dosing and the animal housed in metabolism 
cages up to 96 h after dosing. 
Blood concentrations versus time plots, as well as blood elimination 
half-life (from 6.9 to 35 h ) , showed great variability between 
animals, . Over 96 h, 1.75 - 4.13 % and 52-91 % of the administered 
doses were excreted in urine and faeces respectively. Monothiols were 
not detected in any sample, dithiols were characterized in the urine 
of one monkey and trithiols in all urine samples but the total amount 
was very low, 0.001 to 0.01 % of the administered dose (11). 
1.2.2. Derma I Route 
Rats 
A total of twenty male CD Sprague-Dawley rats were treated dermal ly 
with 14C-chlorothaIon i I in acetone at a dose of about 5 mg/kg bw. 
Urine was collected from 4 metabolic cages each containing 5 animals. 
Considerable variability was noted in results, urinary excretion in 
the first 48 h accounted for about 3 % of the administered dose with 
total thiols representing 0.001 to 0.07 %. In the 0-24h period 
samples, monothiols were detected in samples from one cage, dithiol 
samples from two cages and trithiols in samples from all cages (12). 
3-
Monkeys 
Four monkeys were treated dermal ly with 5 mg/kg bw of 1 4C-
chlorothalonil under a non-occlusive patch. After 48 hours the patch 
was taken off and the skin was washed. About 90% of the dose was 
recovered from the surface and about 2.26% was completely absorbed 
through the skin. The urine contained 1% of the dose, but methylated 
mono,di- and trithiols were not detectable in the urine. This means 
that significantly less than 0.008% of the dose was excreted as thiols 
(13). 
1.2.3. In vitro metabolism. 
Liver and kidney mitochondrial preparations ( Sprague-Dawley rats) 
were incubated with sulfur derivatives of chlorothalonil such as the 
monothiol, the dithiol, the monoglutathione and the diglutath¡one 
analogs. Based on oxygen consumption, none of the glutathione analogs 
had an effect on oxygen uptake whereas 
the dithiol inhibited respiration in liver and kidney anrj the 
monothiol in liver only. The authors suggest that these results 
support the fact that glutathione conjugates, while not toxic per se, 
may be metabolized in the kidneys to nephrotoxic thiols (7). 
1.3. TOXICITY. 
The acute oral LD50 of chlorothalonil for rats has been estimated 
above 10,000 mg/kg. The LC50 by inhalation in rats ( 4 hours) is 0.9 
mg/l. The percutaneous LD50 is above 10,000 mg/kg (rabbits). 
Chlorothalonil is irritating to the eye of rabbits (14)->and to skin 
after repeated applications for 21 days (15). 
Earlier chronic toxicity studies have been reviewed by the 1974 JMPR. 
Since then newer carcinogenicity studies have become available. 
1.4. TUMORIGENICITY 
Several studies in rats and mice have been completed to investigate 
the tumorigenic potential of chlorothalonil. 
RATS 
1.4.1. National Cancer Institute (1978). 
In an inadequate carcinogenicity study (18), chlorothalonil was 
administered to male and female Osborne Mendel rats in the diet at 
dose levels of 5063 and 10126 ppm (approximately 250 and 500 mg/kg 
bw/day ) . 
Chlorothalonil administration was associated with tumours in the 
tubular epithelium of the kidneys at each dose. 
1.4.2. Fermenta ASC Corporation (1985). 
Chlorothalonil was administered (19) to Fischer 344 rats in the diet 
at dose levels of 40, 80 and 175 mg/kg bw/day for 27 months in males 
and 30 months in the females. 
Kidneys: a statistically significantly higher incidence of tubular 
adenomas and carcinomas in the kidneys was observed in rats of all 
treated groups when compared to the control group, with the exception 
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of the 40 mçf/kg bw/day females group. 
In addition to these renal tumors, proximal tubular hyperplasia was 
present in the kidneys of male and female rats from all dose groups. 
The severity of the hyperplasia increased in a dose-related fashion. A 
correlation between renal tumors and this hyperplastic lesion was 
evident, confirming the conclusion that the tubular hyperplasia was 
preneoplast ic. 
Forestomach: an increased incidence of hyperplasia and hyperkeratosis 
of the squamous mucosa was observed in all treated groups compared 
with the control group and the severity of the lesion increased in a 
dose-related fashion. Increased incidences of focal necrosis or 
ulceration of the squamous mucosa and submucosal inflammation also 
were observed. These effects in the forestomach were considered to be 
related to chronic irritation of the mucosa caused by the test 
mater ¡al. 
In addition, papillomas and carcinomas were present in the forestomach 
of treated rats. The incidence was low and not statistically 
significant in the low and the mid-dose groups but significant in the 
high dose females group. 
The forestomach tumors are considered to be sequelae to the 
hyperplasia/hyperkeratosis noted in the squamous mucosa and therefore 
related to the irritant properties of the test material. 
1.4.3. Fermenta ASC Corporation (1989). 
Another study in Fischer 344 rats (20) was conducted to determine the 
no-effect-levels (NOAEL) on one hand for hyperplasia and tumors in 
the kidney and on the other hand for irritation and tumours in the 
forestomach. Chlorothalonil was given to males up to 26 months and to 
females for·29 months at dietary dose levels of 1.8, 3.8, 15 and 175 
mg/kg/day . 
H istopathologi ca I evaluation of the kidneys showed that focal 
epithelial hyperplasia was significantly increased in males and 
females at 175 mg/kg bw and slightly increased in females at 3.8 and 
15 mg/kg bw. Kidney tubular carcinomas were observed in both sexes at 
175 mg/kg bw but in no other group. Tubular adenomas were seen in 
1/55, 1/54, 1/54, 3/54 and 17/55 in males at 0, 1.8. 3.8, 15 and 175 
mg/kg bw respectively. In females, 24/55 were found at 175 mg/kg/bw 
on I y . 
Epithelial hyperplasia and hyperkeratosis of the non-glandular stomach 
were seen at doses of 3.8 mg/kg bw and higher and were dose related in 
incidence and severity. Non-glandular papillomas in the stomach were 
seen in 0, 0.3, 2 and 5 males and 1, 1.2, 4 and 7 females at 0, 1.8, 
3.8, 15 and 175 mg/kg bw respectively. No squamous cell carcinomas 
were observed in males, but one was seen in each of the control and 15 
mg/kg bw female groups and 3 in the 175 mg/kg bw females. 
In conclusion kidney and stomach tumours were observed at 175 mg/kg 
bw/day. There was a possible treatment related slight increase in 
kidney tubular adenomas and non-glandular stomach papillomas at 15 
mg/kg bw/day, but no evidence of tumourgenicity at lower dose levels. 
The NOEL for hyperplastic lesions in kidneys and stomach was 1.8 mg/kg 
bw/day. 
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MICE 
1.4.4. National Cancer Institute (1978). 
In an inadequate carcinogenicity study (18), chlorothalonil was 
administered to B6C3F1 mice at dose levels of 2688 and 5375 ppm 
(approximately 385 and 770 mg/kg bw/day) In males and at dose level of 
3000 and 6000 ppm (approximately 430 and 860 mg/kg bw/day) in females. 
Chlorothalonil administration was not associated with renal tumour 
formation in mice In this study. 
1.4.5. Diamond Shamrock Corporation (1983). 
Chlorothalonil was administered in the diet (21) to Charles River CD-1 
mice at dose levels of 750, 1500 and 3000 ppm (approximately 
equivalent to 125, 250 and 550 mg/kg bw/day) for 24 months. 
Kidneys: an increased Incidence of renal adenomas and carcinomas 
related to chlorothalonil administration was observed only in male 
mice. The incidence was low ( 10 % or less) , not dose-related and 
statistically significant only at the low dose level. Renal neoplasia 
was not observed In female mice. 
Examination of the kidneys also revealed a distinct proximal tubular 
hyperplasia in males and females from all groups treated with 
chlorothalonil, incidence and severity being greater in males than in 
fema les. 
τ 
Forestomach: The incidence of squamous cell tumors in the forestomach 
in male and female mice in the ch lorotha Ioni l-treated groups were 
higher than in the control group but statistically significant only in 
females of the mid-dose group. 
Hyperplasia/hyperkeratosis of the mucosa of the forestomach were also 
noted in mice of both sexes in all treated groups. 
1.4.6. Fermenta ASC Corporation (1987). 
Another 2-year study in male Charles River CD-1 mice (22) was 
conducted in order to establish NOEL's. The dietary dose levels of 
chlorothalonil were 10, 40, 175 and 750 ppm. At week 18 , the low 
dose level was increased to 15 ppm to assure that the substance 
consumption in this group would be at least 1.5 mg/kg bw/day 
throughout the study. 
Kidneys: No treatment-related renal tumours were observed in mice from 
any of the groups, Including the high dose group. In the 1983 
tumor igenici ty study in mice, treatment-related effects did occur in 
the kidneys of males at 750 ppm. Therefore, the NOEL for renal tumors 
in mice must be fixed at 21.3 mg/kg bw/day (175 ppm) in males and 550 
mg/kg bw/day (3000 ppm) in females. 
A clear increased incidence and severity of tubular hyperplasia was 
revealed in the 750 ppm dose group and a slight one was noted in the 
175 ppm dose group. Based on these results the NOEL for tubular 
hyperplasia is 40 ppm equal to 4.5 mg/kg/day. 
Forestomach: The NOEL for tumours in the forestomach was evaluated at 
21.3 mg/kg bw/day . Histopathologic evaluation of the forestomachs 
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demonstrated that the NOEL for hyperplasia/ hyperkeratosis was 10ppm 
equal to 1.6 mg/kg bw/day. 
Since this study was only on male mice, it must be assumed that 
females and males are of equal sensitivity. 
1.5. INVESTIGATIVE STUDIES. 
The pathologic effects in the kidney associated with chlorothalonil 
administration have been further evaluated in three sub-chronic 
toxicity studies in rats. 
1.5.1. Charles River CD rats (1985). 
Charles River rats (23) received dietary dose levels of chlorothalonil 
equivalent to 1.5, 3.0, 10 and 40 mg/kg bw during a 13-week period. 
A high Incidence of hyperplasia of the epithelium of the proximal 
tubules was observed only in the males of the high dose group. 
Examination of the kidney of the rats receiving the dose of 40.mg/kg 
bw/day was made by electron microscopy. The only alteration noted was 
the presence of irregular, intracytoplasmic inclusion bodies in 
otherwise normal cells in the proximal tubules of male rats. The 
phenomenon was not observed in females. The toxicologicaI significance 
of the inclusions is unclear. 
1.5.2. Fischer 344 rats ( first experiment-1987). 
Chlorothalonil was administered in the diet to rats at dose levels 
equivalent to 175 mg/kg for 91 days (24). ι 
In the kidney, vacuolar degeneration and loss of some proximal tubular 
cells were observed. Continued administration resulted primarily in 
tubular hyperplasia which may have been a consequence of the initial 
damage. 
1.5.3. Fisher 344 rats (second experiment-1987). 
A 90 day study in male Fischer 344 rats was performed (25). Equimolar 
doses of chlorothalonil (75 mg/kg bw/day) and of its monoglutathione 
conjugate (150 mg/kg bw/day) were administered to the animals daily 
by oral gavage. Metabolites indicative of a common metabolic pathway 
for both substances were found in urine. 
Similar histopathologic effects were observed for the two substances 
in the kidney including tubular hyperplasia, tubular dilatation, 
vacuolar degeneration and interstitial fibrosis. 
Hyperplasia/hyperkeratosis, erosions and ulcerations of the 
forestomach mucosa were observed only in the ehlorothaIonil-treated 
group, not in the other one. Forestomach lesions seem to be associated 
with chlorothalonil itself, the local irritant effects of which are 
we I I known. 
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1.6. MUTAGENICITY 
The genotoxicity of chlorothalonil has been investigated with many 
tests which have been reported in reference (26) and are summarized 
be low. 
1.6.1. Gene mutation tests 
1.6.1.1. Ames test. 
Mutation assays with chlorothalonil were conducted with 5 strains of 
Salmonella typhimurium with and without metabolic activation. Doses 
ranged from 0.33 to 6.6 ¿ig/plate. The results were negative. To 
investigate the mutagenic potential of possible metabolites and 
manufacturing impurities of chlorothalonil, a series of Ames tests 
with S.typh¡murium were conducted with selected compounds without or 
with activation by S­9 homqgenates from kidney ( the target organ). 
Four manufacturing impurities and 13 known or potential metabolites 
have been tested. The results were negative for all compounds. 
1.6.1.2. In vitro mammalian systems. 
Chlorothalonil was tested in the Chinese hamster V­79 cells at a 
dosage level of 0.3 ¿tg/ml without activation. Difficulties encountered 
with the high spontaneous mutation rates of these cells necessitated 
use of a second cell line (BALB/3T3). Gene mutation in the mouse 
fibroblast BALB/3T3 cells was evaluated at a dosage level of 0.03 
/¿g/ml without and 0.3 /¿g/ml with activation. The results were 
negative. ι 
1.6.1.3. In vivo host­mediated assay. 
Mice were dosed on five consecutive days with 6.5 mg/kg bw/day of 
chlorothalonil. Eight strains of S. typhimurium were used. The result 
was negat i ve. 
1.6.2. Cytogenic tests. 
In a dominant lethal assay male mice were treated with 6.5 mg/kg 
bw/day for five consecutive days and then mated for 8 weeks. No 
dominant lethal effects were observed. 
A series of micronucleus assays was conducted in male rats (0, 8, 40, 
200, 1000 or 5000 mg/kg bw/day chlorothalonil oral dose), in male mice 
and male Chinese hamsters (0, 4, 20, 100, 500 or 2500 mg/kg bw/day 
oral dose). All animals were dosed twice with a 24­hour interval 
between doses. There was no increased incidence of micronuclei in 
polychromatic erythrocytes in the bone marrow. 
A chromosome aberration test was conducted in rats. Male rats were 
dosed in 2 different ways. In the first one, animals were dosed orally 
twice with a 24­hour interval between doses of 0, 8, 40, 200, 1000 or 
5000 mg/kg bw/day. In the second one, a single oral dose of 0, 500, 
2500 or 5000 mg/kg was given. In both studies no increased incidence 
of chromosomal aberrations was noted in bono marrow cells. 
A chromosome aberration test was conducted in male mice with the same 
protocol but the doses were 0. 4, 20, 100, 500 or 2500 mg/kg bw given 
twice with a 24­hour interval, and 0, 250, 1250 or 2500 mg/kg bw in a 
single oral dose. The results were negative. 
In a chromosome aberration study Chinese hamsters were dosed with 0, 
8, 40, 200, 1000 and 5000 mg/kg bw/day for 2 days. The results were 
inconclusive. 
A new chromosome aberration study in Chinese hamster included both an 
acute and a subchronic dosing regimen. In the acute study, animals 
were given a single oral dose of 0. 500, 2500 or 5000 mg/kg. In the 
subchronic study, the animals were dosed for five days with 0, 50, 125 
or 250 mg/kg/day. Data suggested a marginal ( non dose­related) 
increase in chromosomal aberrations 48 h after a single dose of 
chlorothalonil and with repeated doses. Results were considered 
equ ivocaI. 
An in vitro chromosomal aberration assay was conducted in Chinese 
hamster ovary (CHO) cells exposed to chlorothalonil at 0.03, 0.08, 
0.15 and 0.30 /ig/ml without metabolic activation and at 0.6, 1.5, 3.0 
and 6.0 /zg/ml with metabol ic'act i vat ion. Chlorothalonil was considered 
positive without metabolic activation and negative with metabolic 
act ivat ion. 
1.6.3. DNA repa i r . 
A DNA damage test has been performed in 2 bacterial systems using the 
disk diffusion method. 
Salmonella typhimurium cells were exposed to 2, 10 and 20 /¿g per 
disk of chlorothalonil. Significant killing of the repair deficient 
bacteria was noted, indicating DNA damage. "> 
Bacillus subtil is was exposed to doses ranging from 2 to 200 μ§ per 
disk. No DNA damage was noted because there was no difference between 
repair deficient and repair proficient strains. 
Isolation of DNA from kidneys of rats orally administered 1 4 C ­
chlorothalonil indicate that the radio­label is not covalently bound 
to DNA (27). 
1.6.4. Cell transformation test. 
A cell transformation assay with F1706 P95 and H4536 P+2 cells was 
performed with technical chlorothalonil. The cells were cultured in 
medium containing 0.01, 0.1 or 1 ng/ml chlorothalonil. The cells were 
injected into newborn Fischer rats. Chlorothalonil was not a 
transforming agent and the cells exposed to the highest dose did not 
grow in the newborn rats. 
1.6.5. Cone lus ions. 
Chlorothalonil was found positive in the S.typhimurium assay for DNA 
damage but negative with B.subtilis., An in vivo DNA binding study 
was negative and the AMES test is also negative. 
An in vitro chromosomal aberration study in CHO cells of Chinese 
hamster ovary was considered positive only without activation. 
However, in vivo chromosomal aberration assays, chlorothalonil was 
equivocal in Chinese hamster but clearly negative in rats and mice. 
Chlorothalonil is considered not to present a genotoxic risk to man. 
2. GENERAL CONCLUSIONS 
2.1. Dietary administration of chlorothalonil to rats and mice results 
in tubular hyperplasia in the kidneys and hyperplasia/hyperkera-
tosis in the forestomach. These changes are sometimes accompanied 
by tubular adenomas and carcinomas in the kidneys and papillomas 
and carcinomas in the stomach. 
2.2. The results of the battery of tests indicate that chlorothalonil 
is considered not to present a genotoxic risk. 
2.3. Hyperplasia/hyperkeratosis in the forestomach is considered to 
be caused by local irritation of the mucosa by chlorothalonil 
itself. 
2.4. The specific nephrotoxicity of chlorothalonil appears to be 
related to a metabolic pathway involving conjugation with 
glutathione. 
2.5. Mono-, di- and tri-thiol metabolites of chlorothalonil have been 
found in significant amounts in urines of rat orally administered 
chlorothalonil and not, or at a very much lower extent, in urines 
of germ-free rats, monkeys and dogs. In these species, the thiol 
metabolites are minor end-products of the metabolism of 
chlorothalonil. This finding could be related to the differences 
in the gut microflora of these species. 
2.6. In man, the microbial population in the upper gastrointestinal 
tract is much smaller than in the rat. Therefore, it is probable 
that, as in dogs and monkeys, thiol metabolites of chlorothalonil 
would be formed to a much lesser extent in man than in the rat, 
and that man would therefore be expected to be less susceptible 
to the nephrotoxic effects associated with chlorothalonil. 
2.7. Chlorothalonil is evidently tumorigenic in rats and mice but this 
finding is not associated with mutagenicity and a plausible 
mechanism of action has been demonstrated for the tumorigenic 
effects in both the kidneys and the forestomach. An ADI may 
therefore be calculated based upon no effect levels for the 
mechanism of action. 
2.8. The rat is the most susceptible species for tumour formation. 
Kidney and stomach tumours are clearly found at 175 mg/kg bw per 
day. Slight increase in kidney tubular adenomas and non-
glandular stomach carcinomas occur at 15 mg/kg bw per day. A 
NOAEL based upon non neoplastic lesions (indicative of the 
mechanism of action for tumourgenicity) is 1.8 mg/kg bw/day from 
the long term rat study. Although there are indications that man 
is less susceptible than the rat a prudent approach is to base 
the ADI on the results of the rat studies. 
2.9. Since the effect is associated with carcinogenicity a safety 
factor of 200 is applied to the NOAEL of 1.8 mg/kg bw/day giving 
an ADI of 0.01 mg/kg bw. When the lower susceptibility of man 
compared to the rat is completely proven a conventional safety 
factor of 100 could be used. 
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REPORT OF THE SCIENTIFIC COUUITTEE FOR PESTICIDES 
ON THE USE OF H8Ns 
(Opinion expressed by the SCP on 11 February 1992) 
BACKGROUND AND TERMS OF REFERENCE 
HydroxybenzonitrI les (HBNs) have been used as herbicides for more 
than 20 years. The main representatives of this group are 
bromoxynil, ioxynil and their salts and esters. 
Bromoxynil and ioxynil are the common names for 4-hydroxy-3,5-
dibromo-benzonltri le and for 4-hydroxy-3,5-diiodobenzonitri le, 
respect i ve ly. 
They are contact herbicides with some systemic activity, used in 
most Member States to control broad leaved weeds In maize 
(especially bromoxynil), cereal crops (mainly ioxynil), sorghum, 
onions, garlic and other crops. They inhibit photosynthesis by 
uncoupling oxidative phosphorylation. Both of the compounds and 
their derivatives are decomposed rapidly in soils (half-life 10 
days). Their solubility in water is 130 mg/l (bromoxynil) and 50 
mg/I (ioxyniI). 
The main concern for these compounds relates to possible 
developmental effects and for this reason the Commission decided to 
request the Scientific Committee for Pesticides to examine their 
toxicology and to give an opinion on the following questions: 
Is the use of HBNs, in accordance with good agricultural practice, 
prejudicial to human health or the environment and if so, can such 
dangers be eliminated by reduction of potential exposure? 
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1. DISCUSSION - TOXI (»LOGICAL ASPECTS OF BROMOXYNIL 
1.1. Penetration. Metabolism and Excretion 
14c-Bromoxyni I octanoate has been administered to rats by the 
oral route. In male rats ca. 87% was excreted via the urine and 
3,6% via the faeces. In females 80 and 5,4% were excreted via urine 
and faeces, respectively. The T1/2 for urinary excretion was 
approximately 25 and approximately 50 hours for males and females, 
respectively. Elimination from plasma occurred with half -lives of 
approximately 40-50 hours. After 7 days 3 and 6% of the dose was 
retained in the body for males and females, respectively. Highest 
concentrations were found in plasma, liver, kidneys and in females 
In the thyroid. In the urine 60% of the dose was present as free 
bromoxynil and 13% as bromoxynil conjugates, while in the faeces 
bromoxynil octanoate and free bromoxynil were present. In plasma 
bromoxynil was bound to plasma proteins which may explain the 
relatively long half-life of bromoxynil in plasma (1, 2 ) . 
In a dermal experiment 14c-bromoxyniI phenol has been applied to 
the skin of male rats. After 10 hours the highest percentage (90-
95%) was recovered in the skin wash. One to 2% of the dose remained 
in the body and 0,2-0,3% was. excreted in the urine. Systemic 
absorption varied from 5-10%, inversely related to the dose. (3) 
In vitro absorption with the formulation Advance (containing 
bromoxynil octanoate and ioxynil octanoate, together approximately 
185 g/l) was studied in human and rat epidermis. It was found that 
absorption by rat skin was higher than by human epidermis, but no 
factor for the difference can be given (4).The formulation Oxytril 
(containing the same substances with a total amount of 
approximately 580 g/l) was only studied in human epidermis. The 
data obtained indicated that both substances are slowly absorbed 
across human epidermis (5). 
1.2 BROMOXYNIL 
1.2.1 Acute/short term toxicity 
The oral L D 5 0 in the rat for bromoxynil is approximately 190 
mg/kg bw and higher than 2000 mg/kg bw by the dermal route. The 
LC50 for inhalation (4 hours) is approximately 0.4 mg/I air. 
Bromoxynil and the octanoate ester are not irritating to the skin 
and slightly irritating to the eye. 
In short term toxicity studies in rats the main effects were growth 
inhibition, an increase in red blood cell parameters (Hb, Ht. R8C), 
urea and SAP activity in blood, a decrease in glucose and thyroid 
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hormones In blood and an Increase In liver, kidney and thyroid 
weight. HistopathologicaI effects were observed In liver and 
kidney. These effects are consistent with the uncoupling effects of 
bromoxynil on oxidative phosphorylation. In short term dog studies 
a decreased weight gain, an increased urea content in blood and an 
Increased liver weight were also observed, but red blood cell 
parameters were decreased (see table 1). 
1.2.2 Long term toxicity 
Two long term studies In the rat and one In the mouse are available 
(see table 1). 
In the rat study with the highest dose levels the same effects were 
observed as in the short term studies in the rat. In the other only 
an increased liver and kidney weight was found. Both rat studies 
did not show an increased tumour incidence. In the mouse study 
liver and kidney weights were increased. Male animals showed a 
slightly increased Incidence of liver adenomas and carcinomas. The 
combined incidences were 3, 7, 8 and 15% for 0, 10, 30 and 100 ppm, 
respect i ve ly. 
1.2.3 Mutagenicity 
Bromoxynil was not mutagenic in various Ames tests (18, 19, 20), a 
gene mutation test in V79 cells (21) and a chromosome aberration 
test in human lymphocytes (22). Positive effects were obtained in a 
mouse lymphoma test (possibly due to a pH-effect) and a chromosome 
aberration test in CHO cells, but only after metabolic activation 
(23, 24). An SCE test in CHO cells was negative (25). 
Negative results were obtained in a dominant lethal test in rats 
(26) and 3 micronucleus tests in mice (27, 28, 29). A chromosome 
aberration test in Chinese hamsters gave equivocal results (31). 
Negative results were also obtained in a UDS test in rat liver 
cells (32) and a transformation test in mice (33). A DNA-repair 
test in E coli was positive (34). 
1.2.4 Developmental toxicity 
1.2.4.1. Reproduction toxicity 
Two reproduction studies have been carried out in rats (see table 
1). The main effects were decreased maternal body weight and pup 
weight, with in one study a decrease in litter size and pup 
viability and in the other a delayed pup development, both at the 
h ighest dose leve I . 
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1.2.4.2. Teratogenicity 
Nine studies have been performed with bromoxynil on rats and 
rabbits by the oral or percutaneous routes. 
Two general reviews have been carried out by J.C. Lamb & B. Neal 
(35) and by E.M. Johnson & M.S. Christian (36). The main studies 
are summarized as follows: 
- RATS experiments by oral route. 
Three gavage studies on bromoxynil phenol were carried out in rats 
(37, 38, 39). The doses used and the main observations reported in 
these studies are summarized in table 2. 
At the highest dose level (35-40 mg/kg bw), a number of embryotoxic 
and teratogenic effects are present at a maternal toxic dose level 
(mortality, effect on growth and food consumption) 
Besides litter loss, post-implantation loss, fetal loss, reduced 
fetal weight, extra ribs and delayed ossification irreversible 
structural defects were present (an/microphthaImia). 
At 12,5-15 mg/kg bw the same maternal toxic and embryotoxic effects 
were present, but there were no irreversible structural 
abnormalities. At 5 mg/kg bw slight embryotoxic effects were 
present. Although at 4 mg/kg bw extra ribs were found, this is 
considered as a marginal effect level. The NOAEL for maternal 
toxicity is 5 mg/kg bw. 
A clear NOAEL cannot be established in the experiment (a) (Ref. 37) 
using doses of 1.5, 5 and 15 mg/kg/day. However, this study did not 
demonstrate statistically significant effects In either dams or 
offspring at any dose tested. In addition, this study, prior to 
GLP, had a weak study design. 
- RABBITS experiments by oral route. 
Two gavage studies on bromoxynil phenol were carried out in rabbits 
(40, 41). The doses used and the main observations reported in 
these studies are summarized in table 3. 
At the highest level (45-60 mg/kg/day) embryotoxic effects were 
seen (increased post-implantation loss, increased incidence of 
fused and supernumerary ribs) along with evidence of teratogenicity 
(hydrocephaly and microphthalmia/anophthalmia). 
The dose of 15 mg/kg/day, according to the extra ribs and the 
slight decrease in fetal weight can be regarded as a marginal 
effect leve I . 
Maternal toxicity is demonstrated by a slightly reduced weight gain 
and food intake occurring at 30 and 45 mg/kg/day and mortality at 
60 mg/kg/day. The NOAEL for maternal toxicity in rabbits can be 
estimated at 15 mg/kg/day. 
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- RATS experiments by dermal route. 
Two dermal studies with bromoxynil phenol and bromoxynil octanoate 
were carried out in rats. The doses used In these studies were: 
0,5, 10, 50 and 100 mg/kg/day in the first study (42) and 0, 2, 5, 
10, 15, 20 and 75 mg/kg/day in the second one (43). The main 
observations from these studies are reported below. 
Embryotoxicity: Using bromoxynil-phenol, an Increased incidence of 
supernumerary ribs was reported at 50 and 100 mg/kg/day. With 75 
mg/kg bw bromoxynil octanoate mean fetal body weight was decreased 
and the incidence of supernumerary ribs was increased. This last 
effect was also observed at 20 mg/kg bw. 
From both studies it can be concluded that the NOAEL for 
embryotoxicity is 15 mg/kg bw/day. 
Maternal toxicity: The maternal weight gain was decreased at 50 
mg/kg/day and above (decreased food consumption was evident for the 
highest dose) for bromoxynil-phenol and at 20 and 75 mg/kg/day for 
bromoxynil octanoate. In the latter case, erythema and fissuring of 
skin were also observed. 
The NOAEL for maternal toxicity of bromoxynil phenol and bromoxynil 
octanoate administered by dermal route in rats can be estimated at 
15 mg/kg/day. 
- RABBITS experiments by dermal route. 
Two dermal studies were carried out in rabbits. Bromoxynil phenol 
was used in the first study (44) at 0, 10, 50 and 150 mg/kg/day, 
bromoxynil octanoate in the second (45) at 0, 5, 10, 15, 20, 40 and 
80 mg/kg/day. 
Embryotoxicity: An increased incidence of agenesis of intermediate 
lobe of lung at 50 and 150 mg bromoxynil phenol/kg/day is 
considered to be an incidental finding not related to treatment. 
No dosage-dependent increased incidence of malformations or 
variations has occurred with bromoxynil octanoate. The NOAEL is 
higher than 80 mg/kg/day for octanoate and >150 mg/kg for phenol. 
Maternal toxicity: With bromoxynil-phenol, maternal weight gain and 
food consumption are decreased at 50 mg/kg/day and above. The NOAEL 
is 10 mg/kg/day. 
With bromoxynil octanoate, skin irritation is observed from 20 
mg/kg/day and decreased maternal weight gain and food consumption 
are observed from 40 mg/kg/day. The NOAEL for systemic effects may 
be estimated at 20 mg/kg/day. 
From both studies, it can be concluded that 20 mg/kg bw/day is the 
NOAEL for maternal toxicity. 
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1.3 IOXYNIL 
1.3.1. Acute/short term toxicity 
The oral L D 5 0 in the rat for ioxynil Is ca. 110 mg/kg b.w. and 
1050 mg/kg b.w. by the dermal route. The L C 5 0 for Inhalation (4 
hours) is ca. 0,4 mg/l air. Ioxynil and the octanoate ester are not 
irritating to the skin and only very slightly irritating to the 
eye. The sodium salt, however, is strongly irritating. 
t 
In short term studies in rats the main effects were growth 
inhibition and an increased liver and kidney weight (see table 4 ) . 
1.3.2 Long term toxicity 
Chronic/care inogenicity studies have been carried out in mice and 
rats (see table 4 ) . 
In rats an increased thyroid weight, histopathologicaI 
abnormalities and an increased incidence of thyroid tumours were 
found at 30 and 100 ppm. The thyroid tumours are associated with 
the hyperplastic effects caused by ioxynil on the thyroids. 
At 10 ppm (equivalent to 0.5 mg/kg bw.) no effects were observed. 
In mice mortality was increased at 100 ppm . At all dose levels 
body weight gain was lower and relative weights of kidneys and 
thyroid were increased. Liver weight was increased at 30 and 100 
ppm. At 100 ppm a slightly higher incidence of liver tumours 
(hepatocellular adenomas and carcinomas) was observed in male 
animals. The combined incidence was 5% for control animals and 15% 
for high dose animals. 
1.3.3 Mutagenicity 
Ioxynil was not mutagenic in various Ames test (52, 53, 54, 55) and 
with mutagenicity tests in Saccharomyces cerevisiae (56) and 
Aspergillus nidulans (57). In two mouse lymphoma tests (58, 59) 
equivocal results were observed. The same was found in a 
chromosomal aberration test in human lymphocytes (only without 
metabolic activation) (60), but an SCE-test in human lymphocytes 
was negat i ve (61). 
Dominant lethal tests in rats (62) and mice (63) and two 
micronucleus tests in mice (64, 65) were negative. An UDS-test in 
rats hepatocytes (66) and two bacterial tests for DNA repair were 
also negative (67, 68). 
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1.3.4 Developmental toxicity 
1.3.4.1. Reproduction toxicity 
In a 3-generation reproduction study in the rat a decreased 
maternal body weight gain was observed at all dose levels. At 100 
and 300 ppm litter size and pup weight were decreased. At these 
dose levels.also liver and thyroid weight were increased 
(see table 4). 
1.3.4.2 Teratogenicity 
- Rats and rabbits experiments by oral route. 
Three gavage studies on ioxynil phenol were carried out in rats 
(69, 70, 71) and one in rabbit (72). The doses used and the main 
observations reported in these studies are summarized in Table 5 
and 6 for rats and rabbits, respectively. 
From the results obtained in the rat studies the following can be 
concluded. 
At the highest dose level of 35-36 mg/kg bw a number of embryotoxic 
and teratogenic effects were present at a maternal toxic dose level 
(mortality, effect on growth and food consumption). Besides litter 
loss, post-implantation loss, fetal loss, reduced fetal weight, 
extra ribs, hydroureters and minor abnormalities, irreversible 
structural defects were present (an/microphthaImia) at 36 mg/kg bw. 
At 12-15 mg/kg bw some embryotoxic effects were present but no 
irreversible structural abnormalities. A dose of 5 mg/kg bw can be 
considered as an NOAEL for embryotoxicity and 12-15 mg/kg bw for 
maternal toxicity. 
In the rabbit study (72) the doses administered were 0 - 1 5 - 3 0 
and 60 mg/kg bw/day. The results are summarized in table 6. 
Maternai toxicity was observed at 60 mg/kg bw (mortality, effect on 
growth and food consumption). At 30 mg/kg bw only effects on growth 
and food consumption were present. At both dose levels litter loss, 
post-implantation loss, reduced fetal weight, extra ribs, rib 
malformations, hydrocephaly and an/microphthaImia were present. 
Ioxynil shows therefore irreversible structural abnormalities. At 
15 mg/kg bw only one animal showed hydrocephaly. This dose level 
can be considered as a marginal effect level. The NOAEL for 
maternal toxicity is 15 mg/kg bw. 
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- Rats and rabbits experiments by dermal route. 
Two dermal studies with ioxynil phenol were carried out, one In 
rats with doses of 0, 5, 10, 40 and 120 mg/kg bw/day (73) and one 
in rabbits with doses of 0, 10, 50 and 150 mg/kg bw/day (74). 
- rat study 
Decreased maternal body weight gain was observed at 40 and 120 
mg/kg bw and reduced food consumption from 10 mg/kg bw on. Skin 
reactions were present at the highest dose level. At 120 mg/kg b.w. 
the Incidence of supernumerary ribs and wavy ribs was Increased. 
The NOAEL for embryotoxicity is 40 mg/kg bw. For maternal toxicity 
10 mg/kg bw can be considered as the NOAEL. 
- rabbit study 
At 150 mg/kg bw only maternal body weight gain and food consumption 
were decreased. NOAEL's for embryotoxicity and maternal toxicity 
are > 150 and 50 mg/kg bw, respectively. 
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2. HUMAN DATA - OCCUPATIONAL EXPOSURE 
Four studies have been carried out in USA (76, 77), UK (78) and 
Canada (79) to assess the degree of contamination of workers during 
the application of HBN formulations. The main observations and the 
conclusions of these studies are summarized below and in Table 7. 
2.1. USA ( BUCTRIL - Bromoxynil octanoate) 
In the 1988 (7p) four workers experienced in mixing, loading, 
application, and clean up procedures of pesticides were selected to 
participate in the exposure study. Buctril was applied to a mint 
field and a barley field as recommended In practice. Two work days 
were mon i tored. 
Airborne exposure was measured with a sampling system. Dermal 
exposure assessment was evaluated with gauze-pad dosimeters located 
underneath and on the outside of coveralls. Hands were washed with 
a detergent solution at the end of each work cycle to assess 
dermal exposure of the hands. Urinary samples were taken for the 
metabolic study. 
Mixer-loaders handled, without gloves, approximately 15 kg of 
bromoxynil per day. Almost all the exposure was to the hands. The 
total dermal exposure during mix ing/loading without gloves can be 
estimated between 0.8 and 1.3 mg/kg bw/day. During application, 
exposure was about 0.05 mg/kg/day. The levels of bromoxynil in the 
urine were negligible. 
The 1990 study (77), was conducted at 20 sites throughout the 
United States where corn, wheat and sorghum are grown. Buctril, 
utilizing revised container designs and up-to-date application 
technology, was applied at the highest rate for these crops (420 
g/ha). At each site, a mixer/loader and an applicator volunteered 
to participate to the study and two replicates were conducted. The 
sprays were made with .enclosed or open cabin equipment. Both 
inhalation and dermal exposure were monitored and potential and 
actual exposure were calculated for protected and not protected 
exposures (enclosed or open cabin, gloves or not in the open 
cabin). 
During mi χ ing/loading dermal exposure was estimated at 0.004 mg/kg 
bw/day. 
During application dermal exposure in the enclosed cabin was 
negligible. Dermal exposure (open cabin) was estimated at 0.003 
mg/kg bw/day without gloves and 0.002 with gloves. 
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2.2. UK ( OXYTRIL CM - Bromoxynil octanoate and ioxynil octanoate 
200 g/l each). 
In a 1989 study by Lamb et al. (78) (which also reviews dermal 
penetration and worker exposure), four workers were examined during 
the application of oxytrll to 20 hectares of land, using equipment 
and clothing typical of UK farming practice. The degree of 
contamination of coveralls, gloves, air, hands. Inner clothing, 
blood and urine was monitored. 
t 
As with external contamination the hands received the bulk 
(60 %) of the exposure. Inhalation was not found to be a 
significant route of exposure. Levels of bromoxynil and ioxynil in 
plasma and urine were extremely low. 
Mixer-loaders, wearing gloves, handled about 32 kg of bromoxynil + 
ioxynil per day.. The overall dermal exposure of workers was 
estimated at 0.013 mg/kg bw/day. 
2.3. CANADA ( BUCTRIL M - bromoxynil as octanoate and heptanoate 
esters + MCPA as iso-octyl ester 200 g/l each). 
In 1988 an exposure study was conducted at five farm locations in 
Manitoba (79). Buctril M was applied at the recommended rate of 
0.56 kg active ingredient per hectare. Mixer-loaders handled 
approximately 18 kg of bromoxynil per day. Because the actual 
field-use conditions were so variable, the resulting exposure data 
showed great variability. 
Bromoxynil recovered from hand washes ranged from 0 to 650 /xg/hr. 
This exposure was significantly influenced by wearing protective 
gloves ( 273 - 657 μg/hr without gloves, 0- 114 /xg/hr with gloves). 
The dermal exposure of these workers may be estimated at 0.02 mg/kg 
bw/day with gloves and 0.05 without them. 
2.4. Skin penetration experiments. 
Comparing the in vivo skin penetration experiments in rats and the 
in vitro comparison between rats and human skin, the following 
results are obtained. In the rat in vivo, dermal penetrations of 
bromoxynil and ioxynil are comparable. The absorption rates for 
bromoxynil phenol, bromoxynil octanoate and ioxynil in rats were 
all about 1 % of the applied dose per hour. This corresponds to a 
10 % exposure dose during a 10-hour work/day. According to three in 
vitro tests, HBN penetration through human skin seems to be lower 
than through rat skin (4)(5). 
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2.5. Comments 
2.5.1 Discrepancies are naturally found between the four studies, 
due partly to the ways of handling the formulations in the 
different countries and partly to the assumptions and the 
conditions of sampling for exposure. Only orders of magnitude 
have to be taken Into account. 
2.5.2 Skin surface contamination is the main route of exposure. 
Respiratory exposure Is very low ( approximately 3.5 % of 
total contamination). Levels of bromoxynil and ioxynil in 
plasma and urine are also very low, indicating that in 
practice very little is absorbed. 
2.5.3 Mixer-loaders are much more exposed than the applicators. 
Gloves insured a very good protection and In the second US 
study it was established that special containers resulted in 
a lower exposure. 
3. ENVIRONMENTAL ASPECTS 
3.1. Aquatic toxicity 
3.1.1. Algae. 
Bromoxynil phenol was tested for toxicity to the green fresh-water 
alga Scenedesmus subspica tus. The EC50 (growth rate inhibition 
96 h) was 140 mg/l and the EC50 ( plateau growth level inhibition 
96" h. ) was 44 mg/ I . 
3.1.2. Daphnia. 
Bromoxynil phenol was tested for toxicity to daphn i a magna. The 
EC50 (24h or 48h) was 12.5 mg/l (79). 
Bromoxynil octanoate in identical conditions was much more toxic, 
the EC50 (48h) being 0.11 mg/l (80). 
Daphnia were continuously exposed to measured bromoxynil octanoate 
concentrations ranging from 0.91 to 24 /¿g/l through one generation. 
The estimated (NOAEL) after 21 days exposure was found to be 
between 2.6 and 5.3 /¿g/l (81). 
3.1.3. Fish. 
The LC50 for fish are the following: 
Bromoxynil phenol (96h) : Rainbow trout - 23 mg/l (82). The 
substance was used after neutralization with KOH. It has to be 
noted that the aquatic toxicity of bromoxynil phenol is mostly 
depending on the pH of the water ranging from 0.2 mg/l at pH 6.2 to 
20 mg/l at pH 8.2 . 
Bromoxynil octanoate(96h): Rainbow trout - 0.1 mg/l, Bluegill -
0.061 mg/l (83) 
Ioxynil octanoate(48h): Harlequin fish - 4 mg/l 
3.1.4. Effect on early stage aquatic organisms. 
Fathead minnow (P imephales promelas) embryos and larvae were 
continuously exposed for 35 days to nominal concentrations of 3, 6, 
12, 25 and 50 ¿tg/1 Bromoxynil octanoate in pH 7.1-7.6 ketone -water 
solutions. The most sensitive indicator of toxicity was larval 
survival. According to the analytical doses verification, the 
NOAEL was estimated to be between 9 and 18 /¿g /I (84). 
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3.2. Toxicity to birds. 
The acute oral LDSQ'S of bromoxynil to avian species range from 
50 (bromoxynil-phenol and bromoxynil-K salt, pheasant) to 240 mg/kg 
bw (bromoxynil-phenol, hen). The LDSQ'S for ioxynil range from 35 
(ioxynil-Na salt, pheasant) to over 1200 mg/kg bw (ioxynll-
octanoate, Mallard duck). 
The most sensitive species appears to be the pheasant. The 
approximate acute oral LDSQ'S (mg/kg) for this species are 
summarized in Table 8. 
3.3. Effects on soil and soil organisms. 
3.3.1. Microorganisms. 
Ioxynil and bromoxynil are fairly inhibitory to fungi and bacteria 
at low concentrations but these concentrations are far in excess 
of what are likely to be found in soil during current agricultural 
pract ice. 
3.3.2. Earthworms. 
An artificial soil test was done in accordance with OECD protocols 
to investigate the toxicity of ioxynil to E i sen i a foetida. The 
LC50 (7 and 14 days) was approximately 35 mg/kg soil (85). 
3.4. Leaching. 
The leaching of ioxynil-ring 14ς has been studied in sand, loam, 
peat and clay soils in laboratory tests. Data indicate that ioxynil 
should demonstrate low mobility when freshly applied in solution to 
these soil types. Absorption appears to increase with increasing 
organic matter content (37). 
3.5. Soi I dégradât Ion. 
The rate of degradation of radio-labelled ioxynil has been studied 
in sand, loam, clay and organic loam soils (peat). The half-lives 
of both extractlble herbicide-derived material (iodo-
hydroxybenzamide) and ioxynil were greatest in the peat (75 days 
at 10"C , 15 to 23 days at 20'C). In the other soils the 
degradation was much faster ( 3 to 10 days at 10'C and 1.5 to 3.5 
at '20"O. 
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4. GENERAL CONCLUSIONS 
4.1 Hydroxybenzonitr I le (HBN) products are widely used in Europe 
and sold currently In 68 countries In the world. They are 
used primarily in cereal crops including maize and in onions. 
They are associated with many other herbicides in 
formulations. Bromoxynil and ioxynil are the most 
representative substances of the series. 
4.2 In general the toxicologlcal profiles for bromoxynil and 
Ioxynil are comparable. Both compounds are uncouplers of 
oxidative phosphorylation. Effects of this are more clearly 
demonstrated for bromoxynil, for which more toxicity data are 
available. In general a decreased body weight gain and an 
increased liver and kidney weight are observed as the most 
sensitive parameters. An increased thyroid weight is more 
prominently, found with ioxynil, possibly because of, the high 
Iodine content of the compound, although this effects Is also 
found with bromoxynil. With both compounds a slightly 
increased incidence of liver tumours is found in male mice, 
at the highest dose level. An increase in thyroid tumours Is 
found in the long term rat ioxynil study. Since these tumours 
are related to the toxicity effects on these organs and 
mutagenicity data are generally negative the compounds are 
considered not to be genotoxic substances and not to present 
a carcinogenic risk to man. From the short term, long term 
and reproduction toxicity experiments with bromoxynil an 
overall NOAEL of 1 mg/kg bw is chosen based on a short term 
study in dogs. 
For ioxynil the overall NOAEL of 0,5 mg/kg bw is based on the 
long term rat study. Although lower NOAEL's were derived for 
individual studies, the seiected doses are the highest 
NOAEL's which are still lower than the actual adverse effect 
levels from all studies. Based on these NOAEL's ADI's of 0.01 
and 0.005 mg/kg bw can be estimated for bromoxynil and 
ioxynil, respectively. 
4.3 Teratogenic and embryotoxic effects for both compounds are 
found at higher dose levels than for general toxicity. 
However, these effects may be of more concern for the 
evaluation of the risk for occupâtionaIly exposed people. 
Teratogenic effect are only found by the oral route at high, 
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maternally toxic, dose levels both in rats and rabbits. 
Embryotoxic effects are found at lower levels, which are 
sometimes not maternally toxic. Dermal application gave 
embryotoxic effects at high dose levels. In this respect the 
rat was the most sensitive species. The NOAEL's for maternal 
toxicity are based on growth inhibition, which is also one of 
the most sensitive parameters In the short and long term 
toxicity experiments. 
NOAEL's for developmental effects are summarized in table 9. 
Table 9: Maternal and fetotox i c i ty NOAELs (mg/kg/day) for bromoxynil and 
ioxyni I. 
RATS RABBITS 
fetal maternal fetal maternal 
BROMOXYN I L 
oral route 4* 5 15* 15 
dermal route 15 15 >80 >20 
IOXYNIL 
oral route 5 15 15* 15 
dermal route 40 10 >150 · 50 
marginal effects 
Because the main exposure for application is dermal, NOAEL's 
for maternal toxicity by the dermal route are chosen to 
calculate the maximum allowable exposure for operators. 
For bromoxynil and ioxynil the NOAEL's are 15 and 10 mg/kg 
bw/day respectively. Taking into account a safety margin of 
100 the maximum allowable exposure is 0.15 mg/kg bw/day for 
bromoxynil and 0.10 for ioxynil. 
-29-
4.4 Application of bromoxynil and ioxynil is generally in such a 
way that no residues in crops are to be expected. Therefore 
when consumer exposure is compared to the ADI, the risk for 
consumers Is very limited. 
A higher risk is present for applicators. For unprotected 
workers (without gloves) the dermal exposure is approximately 
1 mg/kg bw/day which is higher than the maximum allowable 
exposure derived in paragraph 4.3. For protected workers, 
however, with a maximum exposure of 0.02 mg/kg bw/day the 
margin of safety is acceptable. 
Therefore it should be strongly recommended that protective 
gloves should always be used and the other protective 
measures, such as specially adapted containers, should be 
introduced to reduce exposure. 
Safety margins will be even more favourable since, from the 
limited studies available, It can be concluded that 
penetration through human epidermis is lower than through rat 
skin. 
4.5 From ecotox icological data it can be concluded that 
bromoxynil and ioxynil phenol are moderately to very toxic to 
Daphnia and fish, strongly depending on the pH of the test 
solution. Bromoxynil octanoate is very toxic. HBN's have a 
short half life and a low mobility in soil. HBN's should be 
used with care to avoid contamination .of water, so that 
exposure to aquatic life is minimized. 
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Table 1: Short term, long term and reproduction toxicity studies with 
bromoxyniI 
dose levels NOAEL Effects Ref 
Short term 
rat (1) (90 d) 0-20-50-125-312 
-781-1953 ppm 
125 ppm eq. to 
6.25mg/kg bw/d 
deer, body wt, Incr. 
red blood eel Is, 
incr. urea, incr. 
IIver/kidney wt 6 
Short term rat 
(2) (90 d) 0-800-1200-1600 
ppm and higher 
< 800 ppm eq. to 
< 40 mg/kg bw/d 
mortal Ity (1200 ppm 
and hIgher), deer. 
body wt, incr. red 
blood ce I Is, urea, 
SAP, deer, glucose 
T3/T4, Incr. liver/ 
kidney/thyroid wt, 
histopath. I iver, 
thyroid. 7 
Short term rat 
(3) (90 d) 0-30-150-600 ppm 30 ppm_eq. to 
1.5 mg/kg bw/d 
deer, body wt, incr. 
red blood cells, urea 
SAP deer, glucose, 
incr. liver/kidney wt 
8 
Short term rat 
(4) (90 d) 0-150-400-950 ppm < 150 ppm eq. to 
<7.5 mg/kg bw/d 
deer. body wt, incr. 
red blood col Is, 
urea, SAP deer, 
glucose, incr. I iver/ 
kidney/thyroid wt.,' 
I Iver/h istopath. 9 
Short term rat 
(5) (90 d) 0-10-50-400-800 ppm 10 ppm eq. to 
0.5 mg/kg bw/d 
deer, body wt, incr. 
red blood ce I Is, 
urea, SAP, deer. 
T3/T4, incr. liver/ 
k idney/thyrold wt. , 
liver/thyroid histop. 
10 
Short term 
(1) (90 d) 
dog 0-1-5-25 mg/kg 1 mg/kg/bw/d deer. body wt, deer. 
red blood eel Is, 
incr. urea, incr. 
I iver wt. 11 
-34-
Short term dog 
(2) (1 yr) 0-0.1-0.3-1.5 
7.5 mg/kg bw/d 
0.3 mg/kg bw/d decr. body wt, decr. 
red blood cel Is, SAP, 
incr. glucose, urea, 
incr. I Iver wt. 12 
Long term rat 0-10-30-100 ppm 
(1) (2 yr) 
30 ppm eq. to 
1.5 mg/kg bw/d 
decr. spleen wt, 
Iiver/kidney wt 
(no tumours) 13 
Long term rat 
(2) (2 yr) 0-60-190-600 ppm 60 ppm eq. to 
3 mg/kg bw/d 
decr. body wt, incr. 
red blood eel Is, 
decr. glucose, incr. 
I iver wt, I iver 
h istopathology 
(no tumours) 14 
Long term 0-10-30-100 ppm 
mouse (18 mo) 
10 ppm eq. to 
1.4 mg/kg bw/d 
incr . I iver/k idney 
wt, incr . 11 ver 
tumours (males) 15 
Reproduction 0-30-100-300 ppm 
rat (1) (3 gen) 
30 ppm eq. to 
1.5 mg/kg bw/d 
decr. body wt, decr. 
I Itter s¡ze, decr. 
pup wt, lower v i ab i-
I i ty 16 
Reproduct ion 
rat (2) (2 gen) 0-10-50-250 ppm 50 ppm eq. to 
2.5mg/kg bw/d 
decr. body wt, decr. 
pup wt, delayed eye 
opening, incr. liver/ 
kidney wt 17 
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Table 2: Teratogenic and embryotoxic effects of Bromoxynil phenol in rats 
by oral route. 
Effects Dose in mg/kg b.w./day ref 
a — > 0 1.5 5 15 37 
b — > 0 5 15 35 38 
c — > 0 4 12.5 40 39 
Litter loss a N N N 
b N N 
C N N N 
L« J.« 
Post-implant a N N N N 
loss b N N + + 
e N N + +* 
Fetal loss a N + + + 
b N N +* +* 
C N N + + 
Fetal weight a N N N 
b N N N 
c N N N 
Extra ribs a N N N + 
b N + +* +* 
c N + +* +* 
Wavy ribs a N + 
Delayed b N + + + 
ossification e N N +* 
An/Microph. b N N N + 
c N N N +* 
statistically significant; N - normal; + - increased; - - decreased. 
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Table 3: Teratogenic and embryotoxic effects of bromoxynil phenol in 
rabbits by oral route. 
Effects Dose in mg/kg b.w./day ref 
a — > 0 15 30 60 40 
b — > 0 30 45 60 41 
L i t t e r loss a N N N +» 
b N N N +* 
Post - implant a N N + +* 
loss b N N N N 
Fetal weight a N 
b N 
Extra r i b s a N + + +* 
b N N + + 
Fused r ¡bs b N 
An/Micropht . a N N N 
b N N + 
Hydrocephaly a N N N +* 
b N N + + 
Minor a N N N +* 
abnormalities b N + +* +* 
- statistically significant; N-normal; + - increased; - - decreased. 
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Table 4: Short term, long term and reproduction toxicity studies with 
ioxynlI. 
dose levels NOAEL Effects Ref 
Short term (1) , 
rat (90 d) 0-20-80-320 ppm <20 ppm eq. to decr. body weight, 
<1 mg/kg bw/d incr. liver/thyroid 
wt 46 
Short term (2) 
rat (90 d) 0-12-37-111-333- 37 ppm eq. to mortality, decr. b.w., 
1000-3000 ppm 2 mg/kg bw/d incr. liver wt (thyroid 
wt not measured) 47 
Long term 0-10-30-100 ppm 10 ppm eq. to incr. liver/kidney/ 
rat (2 yr) 0.5 mg/kg bw/d thyroid wt, 
thyroid tumours 48 
Long term 
mouse (18 mo) 0-10-30-100 ppm < 10 ppm eq. to decr.body wt., incr. 
< 1.4 mg/kg bw/d liver/kidney/ 
thyroid wt, incr. 
liver tumours (males) 
49/50 
reproduct ion 
rat (3 gen.) 0-30-100-300 ppm < 30 ppm eq. to decr.body wt., reduced 
<1.5 mg/kg bw/d litter size, reduced 
pup wt, incr. I iver/ 
thyroid wt. 51 
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Table 5: Teratogenicity and embryotoxic effects of ioxynil phenol in rats 
by oral route. 
Effects Dose in mg/kg b.w./day ref 
a — > 0 5 15 35 69 
b — > 0 35 70 
c — > 0 4 12 36 71 
L i t t e r loss a N N N + 
b N N 
C N N N N 
Post - imp lant a N N N N 
loss b N N 
C N N N +» 
Fetal loss a N N N + 
b N N 
c N N N + 
Fetal weight a N 
b N 
c N 
Extra r i b s a N . + +* +* 
b N +* 
c N N N +* 
Minor a N N + +* 
abnorma I i t ies b N +* 
c N + + +* 
Hydroueters a N N N +* 
b N +* 
An/micropht. a N N N N 
b N N 
c N N N +* 
- statistically significant; N=normaI ; + - increased; - - decreased.Tab I e 
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Table 6: Effect of ioxynil phenol in rabbits by oral route (72), 
Effects Dose In mg/kg/ bw/day 
15 30 60 
+ + 
+* +» 
+ +* 
+ +* 
+ +* 
+ +* 
statistically significant; N«normal; + ­ increased; ­ ­ decreased. 
Litter loss 
Post­implant, loss 
Fetal weight 
Extra rlbs 
Rib ma I format Ions 
An/Microphta 
Hydrocephaly 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
+ 
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Table 7: Exposure of workers in different mixing-loading situations. 
USA USA UK CANADA 
bromoxynil bromoxynil brom.oct brom. oct. 
octanoate octanoate +loxynll +ioxynll+MCPA 
(Refs) (76) (77) (78) (79) 
Quantity handled 5. 17 32 18 
(kg/day) 
Total dermal exposure 
mi xer-loaders 
without gloves .. 0.8-1.3 - - 0.05 
with gloves - 0.004 0.013 0.02 
(mg/kg bw/day) 
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Table 8: Acute oral LD50's of Ioxynil and Bromoxynil derivatives 
for pheasant. 
Formulation Ioxynil Bromoxynil 
(mg/kg) (mg/kg) 
Phenol 75 35 
K salt 35 50 
Octanoate 1000 175 
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REPORT OF" TUE SCIENTIFIC COMMITTEE FOR PESTICIDES 
ON THE TOXICITY OF CHLORPYRIFOS-METHYL 
(Opinion expressed by the SCP on 2 June 1992) 
BACKGROUND AND TERMS OF REFERENCE 
Chlorpyrifos-methyl is an organophosphate insecticide and acaricide for grain 
store use which was discussed at the JMPR meeting in Geneva in September 
1991. The WHO panel of experts reviewed the available toxicology data and 
the Meeting concluded that the ADI should be reduced by a factor of 10 from 
0.01 mg/kg bw to 0.001 mg/kg bw. 
After the meeting the major registrant of chlorpyrifos-methyl products (Dow-
Elanco) stated that they did not agree with the conclusions of the JMPR 
meeting regarding the ADI for chlorpyrifos-methyl. FuPther data were 
submitted and considered by the JMPR meeting in Rome in September 1992. 
At that meeting the JMPR ADI was returned to its original value of 0.01 
mg/kg bw. 
In the context of its work relating to the establishment of community 
maximum pesticide residue levels in various foodstuffs covered by community 
legislation, the Commission requested the Scientific Committee for Pesticides 
to review the basis of the ADI, paying particular attention to the data 
considered by the JMPR in 1991 and 1992. 
1. ORIGINAL JMPR ADI 
In 1975 the JMPR meeting reviewed the available toxicology data on 
chlorpyrifos-methyl and allocated an ADI of 0.01 mg/kg bw. The most 
critical study leading to this conclusion was a human volunteer study in which 
groups of 5 males were given doses of 0.03 or 0.1 mg/kg bw/day for 4 weeks. 
Treated subjects remained comparable to Λ male control subjects with respect 
to plasma and erythrocyte Cholinesterase activity, and other laboratory and 
clinical investigations. The NOAEL was therefore the highest dose tested, 0.1 
mg/kg bw, and the ADI was allocated using a 10 fold safety factor. (Ref. 1) 
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2. JMPR MEETING IN 1991 
2.1. EVALUATION OF DATA 
Acute toxicity studies, short-term studies in mice, rats and dogs, long-term/ 
carcinogenicity studies in mice and rats, studies on delayed neurotoxicity, a 
teratogenicity study and a range of mutagenicity studies were submitted for 
evaluation by the I99I JMPR meeting. These studies are briefly described 
below, along with the NOAEL's from each experiment and the adverse 
findings on which the NOAEL was based. 
Evaluation of the acute toxicity data revealed that chlorpyrifos-methyl is 
moderately acutely toxic by the oral route (LD 50: 2680->5000 mg/kg bw). 
No specific signs of toxicity 'were observed and there was no significant 
difference between sexes. (Refs. 2, 3) 
In a 28-day dietary study in mice (0, 1, 5, 10, 1000 and 10000 ppm) the 
NOAEL was 10 ppm, equal to 1.4 mg/kg bw/day based on brain Cholinesterase 
inhibition and alterations in the adrenal glands at 1000 ppm. (Ref. 4) 
In a 13-week dietary study in rats at constant doses of 0, 0.1, 1, 10, and 250 
mg/kg bw/day the NOAEL was 1 mg/kg bw/day, based on histological 
alterations in the adrenal glands at 10 mg/kg bw/day. (Ref. 5) 
1 
In a 13-week dietary study in dogs at doses of 0, 0.1, 10 and 50 mg/kg 
bw/day, the NOAEL was 10 mg/kg bw/day based on inhibition of brain 
Cholinesterase activity, increased liver weight and reduced body weight gain at 
50 mg/kg bw/day. (Ref. 6) 
In a 78-week study in mice using dietary concentrations of 0, 1, 5, 50 and 
500 ppm, the NOAEL was 50 ppm, equal to 4 mg/kg bw/day. At 500 ppm, 
inhibition of brain Cholinesterase activity was observed along with 
centrilobular hepatocyte fatty change and cortical cellular swelling in the 
adrenals. There was no treatment-related effect on the incidence of 
neoplastic changes. (Ref. 7) 
In a 2-year dietary study in rats using dietary concent ra t ions of 0, 1, 2, 20 
and 1000 ppm, the NOAEL was considered to be 2 ppm, equal to 0.1 mg/kg 
bw/day. A slight increase in the incidence of adrenal cor t ical vacuo la t ion 
compared to controls was seen at 20 ppm and a marked increase in inc idence 
and sever i ty was seen at 1000 ppm. Brain Cholinesterase inhib i t ion was 
cons is ten t ly observed at 1000 ppm. There was no evidence that ch lorpyr i fos -
methyl was carc inogenic in ra ts . (Ref. 8) 
Chlorpyrifos methyl did not cause delayed neurotoxicity in hens. (Refs. 9, 10) 
An oral teratology study in rabbits (0, 4, 8 and 16 mg/kg bw/day) was 
negative at all doses. (Ref. ¡1) 
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The results of a range of mutagenici ty studies were examined (an Ames test, 
a CHO/HGPRT mutat ion assay, a chromosome aberration assay in CHO cells, 
a UDS assay in cul tured ra t l iver cells and an in vivo mouse micronucleus 
test). I t was concluded that chlorpyri fos-methyl was not genotoxic; the 
clastogenic response in the presence of metabolic act ivat ion was considered 
not to be of any relevance in the presence of a negative in vivo micronucleus 
test. (Refs. 12-16) 
2.2. ESTIMATION OF ADI 
The ADI was based on the results of the long-term rat study, using a 100 
fold safety factor. Adrenal changes were seen consistently in rats and mice 
and the use of the human acetylcholinesterase inhibition data (reviewed by the 
JMPR in 1975) for ADI est imation was not possible .because adverse effects 
on the adrenals were found in the rats in the absence of Cholinesterase 
inhibi t ion. 
3. JMPR MEETING IN 1992 
No new toxicological studies were submitted for evaluation at the 1992 JMPR 
meeting, but fur ther, explanatory data were considered. The meet ing re-
evaluated the long-term rat dietary study on which the ADI was based in 
1991. The major interest was the vacuolation of the adrenal gland. 
Interpretat ion of these data was aided by exarninatioh of relevant, 
contemporary control data f rom other rat studies performed in the same 
laboratory. (These background data were not supplied to the 1991 meeting) 
The incidence and severi ty of adrenal vacuolation at al l dose levels except 
the high dose was wi th in the control range. The historical contro l incidence 
ranged up to 42% in males and 10% in females, while the incidence in the 
control and lower dose groups was up to 20% in males and 4% in females. In 
the high dose group approximately 100% of animals were a f fec ted. The 
NOAEL for the long-term ra t study was therefore set at 20 ppm, equal to 1 
mg/kg bw/day. The ADI was revised accordingly, and based pr imar i ly on the 
human data. (Ref. 17) 
4. OVERVIEW AND ESTIMATION OF ADI 
The scient i f ic commi t tee endorsed the principles used by the JMPR in sett ing 
an ADI for ch lorpyr i fos-methy l . 
In part icular, the principles used in assessment of data re lat ing to inhibit ion 
of Cholinesterase are worthy of note. Inhibition of plasma (or 'pseudo') 
Cholinesterase in animal studies is not considered to be an adverse e f fec t 
useful in der ivat ion of an ADI , but ¡s a useful indicator of exposure. 
Inhibit ion of erythrocyte Cholinesterase (a true acetylcholinesterase) is 
considered to be indicat ive of tox ic i ty , but inhibition of around 25% compared 
to controls is required, before the ef fect is considered to be adverse. 
Inhibit ion of Cholinesterase act iv i ty in brain is also considered to be indicative 
of tox ic i ty , but in this case inhibit ion greater that 10% compared to controls 
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is considered adverse. When results from human volunteer studies are 
available these are generally used in risk evaluation in preference to results 
of animal studies, provided the human studies are of adequate quality and, 
most importantly, that the crucial parameters identified by the animal studies 
are investigated in the human volunteer studies. 
In the case of chlorpyrifos-methyl, all the animal studies indicate that 
inhibition of acetylcholinesterase is the crucial paramenter. Adrenal effects 
were seen consistently in rats and mice, but the latest evaluation indicates 
that adrenal effects were only seen in the presence of Cholinesterase 
inhibition. Allocation of the ADI may thus be based on the no adverse effect 
level for Cholinesterase inhibition in the human volunteer study (0.1 mg/kg 
bw/day), utilising a 10 fold safety factor. The resultant ADI of 0.01 mg/kg 
bw is further supported by the no effect level from the rat study (1 mg/kg 
bw/day, based on Cholinesterase inhibition and adrenal changes), and a 100 
fold safety factor. 
•50· 
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REPORT OF THE SCIENTIFIC COMMITTEE FOR PESTICIDES 
ON THE TOXICITY OF ETHYLENE AND PROPYLENE Β ISOITHIOCARBAMATES 
AND THEIR METABOLITES / CONTAMINANT ETHYLENE THIOUREA (ETU) 
AND PROPYLENE THIOUREA (PTU) 
(Opinion expressed by the SCP on 2 June 1992) 
BACKGROUND AND TERMS OF REFERENCES 
Ethylene b ¡sd i thiocarbamates (EBDC compounds) have been used as fungicides in 
agriculture in the Community since the early 1960s. Examination of the 
historical toxicologica I database reveals consistent thyroid effects and 
liver effects with all EBDCs. The reason for this common toxicity, ethylene 
thiourea has been identified since the early 1960s. ETU is a contaminant of 
EBDCs and metabolic product in both plants and animals. Crops treated with 
EBDCs have residues of ETU as well as the parent EBDC. While levels of parent 
compounds decrease during storage, processing or cooking, levels of ETU 
increase . 
The current toxicologica I appreciation of EBDCs in Member States is. based on 
the conclusion that all the relevant toxicology is related to ETU and 
directly associated with the effects of ETU on thyroid hormone homeostati s. 
In the context of its work to establish maximum pesticide residue levels 
pursuant to the relevant Community legislation, the Commission invited the 
Scientific Committee for Pesticides to examine the toxi co log icaI data 
relating to the EBDCs and its metabolite ETU and to estimate their acceptable 
da i I y intake . 
Propineb has a similar qualitative toxicity profile to the EBDCs and may have 
a similar relationship with PTU as that noted for ETU and EBDCs. Propineb and 
PTU are therefore dealt with in parallel with EBDCs and ETU. 
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1. TOXICOLOGI CAL ASPECTS 
1.1. Metabol ism 
Investigations of the in vivo metabolism of the ethylene bisdithiocarbamates 
(EBDCs) indicate that ethylene thiourea (ETU) is the major common metabolite 
responsible for the toxicity of the EBDCs [IPCS 1988 - (1)]. Data for maneb 
suggest that up to 13.6 % of a 25 mg/kg dose may be converted to ETU, in the 
case of met i ram a conversion of up to 9.5 % of a 5 mg/kg dose has been 
reported whilst for zineb a conversion of 22 X of a 50 mg/kg dose has been 
recorded for the rat and marmoset. It can be concluded from the study by 
Nelson [1986 - (2)] that up to 23 X of a 100 mg/kg mancozeb - dose can be 
converted to ETU in the rat. The figures for the conversion of E B D C s to ETU 
quoted above are all based on total ^ 4C with no conversion for relative 
molecular weights. Application of the conversion factor for the relative 
molecular weights of mancozeb and ETU shows that the maximum worst case in 
ν ivo conversion of EBDCs to ETU being no greater than of 10% on a weight for 
weight basis. 
1.2. Sub-chronic studies - ETU 
Thyroid and liver effects. 
In a number of sub-chronic studies in rats (3-9), the thyroid has been 
identified as the target organ. Relevant findings are summarized in Table 1. 
The study by Freudenthal et al. (6) was chosen as the basis for establishing 
the NOAEL for the rat and it was established at 25 ppm equal to 
1.78 mg/kg/day. The study of Leuschner (7) was not considered to be relevant 
for setting an overall NOAEL because the dose levels used were considered to 
be too low to see real effects of ETU and the findings were opposite to those 
expected for treatment with ETU. Effects on thyroid were also found in mice 
and monkeys (10, 11, 12). However it was difficult to establish NOAELs for 
these species because the two mouse studies gave quantitatively different 
results to one another. The monkey studies were unreliable because one was 
compromised by ill health of the animals whilst little reliance could be 
placed on the effects at the lowest dose used in the second(12). 
In some of these studies in rats and mice, effects on the liver were also 
observed. These effects included increased liver weight, hepatocyte 
hypertrophy and induction of mixed function oxidases at relatively high dose 
levels compared to NOAELs based on thyroid effects. 
-54-
1.3. Chronic studies - ETU 
In a chronic study on rats by Graham et al. (1975) the thyroid was again the 
target organ (table 2). The conduct of the histological examination and the 
presentation of the results in the paper were not adequate to establish a 
NOAEL for thyroid hyperplasia. The incidence of thyroid follicular cell 
adenomas and carcinomas was increased at 250 and 500 and thyroid weights 
increased at 125 ppm and higher giving 25 ppm as the NOAEL equivalent to 
1.25 mg/kg/day (13). 
A further study by GAK et al. (1978) was not sufficiently wel I-supported to 
estabiish a NOAEL. 
In a recent (1989) National Toxicology Programme (NTP) study on rats (15), 
which has not yet been fully reported, groups of 50 male and 50 female rats 
were exposed in utero to doses of 25, 83 and 250 ppm for 2 years. It was 
found that the incidence of thyroid tumours (follicular cell adenomas and 
adenocarcinomas) increased at 250 ppm, in males and females. There was also 
some indication of treatment related effects in males at 83 ppm. 
In the NTP mouse feeding study of similar design, dietary levels of 0, 100, 
333 and 1000 ppm were used In a 2 years carcinogenicity study (15). Thyroid 
tumours (follicular cell adenomas and adenocarcinomas) were observed at 
1000 ppm in both sexes and in the females there was some Indication of 
treatment related effects at 333 ppm. Liver tumours (hepatoblastomas and 
hepatocellular adenomas and carcinomas) were observed in a dose related 
manner at 333 and 1000 ppm in males and females. 
From these studies it can be concluded that the NOAEL is 25 ppm for the rat 
(equivalent to 1.25 mg/kg bw) and 100 ppm for the mouse (equivalent to 15 
mg/kg bw). 
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1.4. Sub­chronic studies ­ EBDCs 
In a number of sub­chronic studies (11, 16­21) using different EBDCs 
(mancozeb, maneb and metlram), the thyroid was identified as the target organ 
(table 3 ) . With the exception of one study using 10,000 ppm mancozeb and 
1000 ppm ETU, no effects were reported on the liver for EBDCs. This was not 
an unexpected resul t .consider ing the dietary concentrations of EBDCs used in 
the other rodent studies (up to 1000 ppm). The thyroid effects in the EBDC 
studies are qualitatively comparable to those for ETU. In studies in which a 
direct comparison could be made, the dose of mancozeb required was ten times 
higher than the dose of ETU to produce an equivalent effect on the thyroid. 
1.5. Chronic studies ­ EBDCs 
In the chronic studies (22­25) the thyroid was again identified as the target 
organ (table 4 ) . No Increased tumour Incidence was observed in any of the 
long­term studies with EBDCs. 
·> 
From both subchronic and chronic toxicity studies of EBDCs an overall NOAEL 
of 100 ppm in rats can be chosen equivalent to 5 mg/kg b.w./day. NOAELs of 
the other species (monkeys, dogs, mice) are of the same order of magnitude 
within the limitations of data available. 
For mancozeb and ζ¡neb new chronic studies are in progress. 
1.6. Mutagenicity of ETU 
Ethylene thiourea has been tested extensively for genotoxicity in a variety 
of in­vitro and in­vivo systems (26­28). With a few exceptions the results 
are negative (table 5 ) . In a few studies ETU Induced aneuploldy and mutation 
in yeast and occasionally mutations in bacteria have been observed. No 
mutagenicity was demonstrated in insects and in in­vitro or in­vivo mammalian 
systems. ETU is considered not to present a mutagenic risk to mammals. 
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1.7. Mutagenicity of EBDCs (mancozeb, maneb, met I ram and ζ i neb) 
In most of the test systems for genotoxlcity the four ethylene 
bisdlthiocarbamates gave negative results (table 6 ) . However, there are 
indications that the compounds cause in-vitro chromosomal aberrations. This 
is reflected in the positive sister chromatid exchange assays with mancozeb 
(41) and metiram (43). [equivocal with maneb (42)] and the positive in-vltro 
cytogenetic assay with zineb (40). This chromosomal damaging effect Is not 
found in the in-vivo cytogenetic assays. Chromosome aberrations are not 
related to the formation of ETU since all tests of ETU in this respect are 
negative. . 
In an operator monitoring study peripheral blood lymphocytes of workers in 
Czechoslovakia exposed to the fungicide Novozir Mn 80 containing mancozeb 
were analysed. There was a slight increase of chromosome aberrations in the 
group exposed to mancozeb in comparison with the control group [Jablonicka 
1986 - (60)]. However, the study was severely compromised because of uneven 
distribution of smokers or non-smokers since smoking is known to increase 
chromosome aberrations. 
Moreover, in-vivo tests of chromosome aberrations with EBDCs in experimental 
animals were all negative. 
1.8. Reproductive toxicity of ETU 
Reproductive toxicity studies have demonstrated the teratogenic potential of 
ETU in rats. Relevant findings are summarized in Table 7. Other species have 
not been adequately investigated to draw firm conclusions. In rats, 
abnormalities induced by ETU included exencephaly, cleft palate and 
hydrocephaly at doses in excess of 10-20 mg/kg bw/day. Investigative studies 
involving co-administration of ETU and thyroid hormones confirmed that the 
teratogenic potential of ETU could be reduced. Because of the doses used and 
the known relationship between fetal development and hormonal balance, it is 
considered acceptable to conclude that the teratogenic potential of ETU is 
associated with its effects on thyroid hormone balance. 
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1.9. Reproductive toxicity of E B D C s 
Reproductive toxicity investigations carried out with E B D C s are summarized 
In Table 8. Teratogenicity and associated effects were clearly seen in rat 
studies, but not in rabbits. These findings are consistent with the proposal 
that the teratogenic potential Is associated with ETU and its effects on 
thyroid hormones, where the rat is the most susceptible species. The 
possibility of metal chelation being associated with dithiocarbamates having 
an effect on the outcome of pregnancy cannot be discounted. However there Is 
no indication of toxicológica! effects caused by metal chelation in any other 
EBDC studies and therefore this seems to be an unlikely explanation of 
effects seen in teratology studies. Teratogenicity was generally seen at 
doses around 500 mg/kg/day or greater. NOAELs were approximately 
200 mg/kg/day for teratogenicity and 50 mg/kg/day for maternal toxicity and 
fetotox¡city. 
ToxicoloqicaI overview and estimation of API 
For translation of no effect levels determined in toxicity studies in animals 
into acceptable daily intakes it is necessary to consider the safety factor 
to be used. In conventional considerations, a safety factor of 100 is used to 
allow for extrapolation from animals to man and for variations within the 
human population. In the case of EBDC and ETU a special consideration of the 
required safety factor is needed, in view of the unusual nature of the 
toxicológica! effects. 
There are two main reasons for special consideration of safety factors with 
these materials. The first relates to the mechanism of action which is 
associated with hormonal imbalance, the second relates to the use of the rat 
as a model for human exposure. 
When a mechanism of toxicity is associated with hormonal imbalance it is very 
important to take into account whether continued, persistent hormonal 
imbalance is required to induce toxicologicaI changes. In the case of ETU and 
E B D C s , occasional exposure which may alter thyroid hormone levels would not 
lead to overt toxi co log¡caI change in the thyroid. 
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In using the rat as a model for humans, it is assumed that physiological 
processes in the two species are similar. There are a number of points which 
indicate that In the case of thyroid hormone control, rat and man are very 
dissimilar. Thyroid hormones are transported in blood as plasma protein 
complexes. In humans the main carrier protein is thyroxine binding globulin. 
This carrier protein is not found in rodents, cats or rabbits. As a 
consequence the half .life of T 4 is much longer in man than in rats and 
serum TSH levels are much lower. In addition the response of the thyroid to 
prolonged stimulation is different In rat and man. In rats, thyroid tumours 
are seen, in man, prolonged stimulation, as is seen in regions of endemic 
iodine deficiency, leads to goitres, but does not lead to thyroid tumours. In 
view of these factors it could be argued that a safety factor of 10 rather 
than 100 is Justified. 
A safety factor of 100 is therefore a prudent approach in this situation. 
This prudence is justified in order to make extra allowance for regional 
variations in thyroid function in man. It is known that in certain 
geographical regions, communities exist in which thyroid function is 
depressed In comparison with the majority of the population at large. 
It is difficult to select a crucial no effect level from the range of studies 
conducted with ETU. Many of the experiments were of inadequate design and 
poorly conducted. However, from the studies conducted by Freudenthal (1977) 
and Graham (1975) it would seem appropriate to select a NOAEL of 25 ppm 
equivalent to 1.25 mg/kg bw/day. This would therefore give an ADI of 
0.01 mg/kg bw. For EBDCs themselves the appropriate no effect level is 100 
ppm equivalent to 5 mg/kg bw/day, giving an ADI of 0.05 mg/kg bw. 
Taking into account the no effect level of 15 mg/kg bw/day ETU based on an 
increased incidence of liver tumours in the 2 year mouse study, a large 
margin of safety is present compared to the proposed ADI for ETU. The same Is 
true when the terato logicaI effects of E B D C s are considered, for which no 
effect levels of around 200 mg/kg bw/day for teratogenicity and 
50 mg/kg bw/day for maternal toxicity were established in comparison with the 
ADI of 0.05 mg/kg bw. 
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PTU and PROPINEB 
1. TOXICOLOGI CAL ASPECTS 
1.1. Metabol Ism 
Data on the metabolism of propineb and propylenethiourea (PTU) are available 
only in the rat. 
In male Sprague-Dawley rats, dosed orally with 5 or 50 mg 14C-propI neb/kg 
bw, 60-70% of the radioactivity is absorbed in 48 hours. Arourrd 50% of the 
activity is excreted in the urine and about 40% via the feces within this 
period. Exhalation during the first 24 hours after administration amounted 
to 7% and excretion in the bile to 3% of the administered dose (76, 77, 7 8 ) . 
Peak levels in blood and most organs are reached 3-5 hours after 
administration, whereas in the thyroid the maximum concentration Is attained 
after 24 hours. Within 4 days the total elimination exceeds 99%. The half 
live of elimination from the tissues (except the thyroid) is first rapid than 
slower, varying between 5 and 20 days. Four days post dosing (50 mg/kg) the 
concentration of radioactive material in the thyroid is about 100 times and 
in the kidney and pituitary 3-4 times higher than the average concentration 
for all other organs except the gastrointestinal tract. After 16 days the 
relative concentration factor for the thyroid Is about 30 (79, 80). 
The main metabolites found in the urine of the dosed rats were propylene 
diamine (accounting, on a molar basis, for 12-15% of the renally excreted 
activity), and PTU and propylene urea (PU) [accounting together for 40-45%]. 
A minor metabolite is probably 4-methyIimidazoline (less than 5%). No 
compounds could be considered as potential intermediates for complete de-
gradation to C02 (76, 77). 
PTU is regarded as the main metabolite responsible for the goitrogenic/ 
tumorigenic actions of propineb, but the available data on toxicokinetics are 
even more sparse than those of propineb. The data show remarkable differences 
to those obtained with propineb. 
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Following oral administration of PTU (0.5, 5.0 or 50.0 mg/kg bw) rats 
absorbed approximately 95% via the digestive tract. A total of 85 to 92% of 
the dose applied was eliminated In the urine, 7-14% in the feces and less 
than 0.2% by exhalation within 48 hours. Excretion In the bile amounted to 
22% within 24 hours after ¡ntraduodenaI application, indicating enterohepatic 
circulation in rats (81). 
Peak concentration in the thyroid is reached after 8 hours, being almost 6 
times higher than after an equivalent dose of propineb. After 1-10 days post 
dosing the concentration of radioacti vity in the thyroid after equivalent 
doses of PTU and propineb ranges between 3.3 and 5 times higher-for PTU than 
for propineb (78). Mean tissue concentrations (except of the gastrointestinal 
tract) decreased by a factor of 50 in the course of the first 2 days, and 
thereafter much more slowly, but in the thyroid the radioactivity dropped 
only to about one-seventh between 8 hours and 10 days post application. Since 
there was a strong dose-proportionality in the dose range tested it was 
concluded that residues in the tissues at still lower doses will be 
proportionally lower (81). 
No data were available on the metabolic fate of PTU. 
1.2. Subchronic studies - PTU 
There is only one relevant subchronic toxicity study with PTU. In this study 
rats received daily oral doses of 50 mg/kg bw for 21 days of propineb, PTU, 
ETU, zineb or methy I th iourac i I . PTU was revealed to be as effective as 
methyIthiouraci I in its goitrogenic activity and somewhat stronger than ETU 
(82). 
The subchronic study, summarised in references 77 and 79 deals with the 
comparison of ETU to propylthiouracil, shortened in the original paper 
mis leadingly as "PTU" (83). The same Is true with respect to the paper of 
Cooper (84), summarised in a comparative toxicologica I profile of ETU, 
submitted by Bayer AG (85). 
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1.3. Chronic studies - PTU and PU 
Chronic toxicity studies have been conducted with PTU In rats and mice (Table 
9 ) . 
A 2-year study on WIstar rats was performed with dietary levels of 0 
(Control), 1, 10, 100. and 1000 ppm (equivalent to 0, 0.05, 0.5, 5.0 and 50.0 
mg/kg bw/day). Administration of 1000 ppm caused high and early (up to the 
65th week) mortality accompanied by severe clinical signs,· reduced weight 
gain, impaired hematopoiesis, damage of liver and kidney and extremely high 
cholesterol levels. The thyroid weight was about 6-fold enhanced and the 
level of protein bound iodine (PBI) In plasma was 2-3 times higher than in 
controls. In addition to nodular hyperplasias in the thyroid, adenomas and 
cystadenomas developed, but without signs of malignant transformation. At 100 
ppm there was still an impairment of growth and a raised cholesterol level. 
The increase of the thyroid weight was accompanied by an increased incidence 
of nodular hyperplasia in males and females. In females the nodules were 
accompanied by large follicles, colloid cysts and vacuolated epithelial 
cells. Administration of 1 or 10 ppm did not reveal any significant test 
compound induced thyroid alterations. The NOAEL was estimated to be 10 ppm, 
equivalent to 0.5 mg/kg bw/day (86, 87). 
CFI mice were fed with dietary concentrations of 0 (Control), 1, 10, 100 or 
1000 ppm (equivalent to 0, 0.15, 1.5, 15.0 and 150 mg/kg bw/day) for 2 years. 
The highest dosage was applied alternating every other week for 7 days and a 
satellite group was autopsied after 12 months. Appearance, behaviour, feed 
intake and mortality remaind unaffected in the male and female mice of all 
dose groups. Administration of 1000 ppm resulted in reduced body weight 
development, increased liver weight, elevated activities of alkaline 
phosphatase and AST in plasma. Increased cholesterol level, and enlarged 
thyroids with increased number and size of follicle cells coupled with 
reduction in follicle size in males. Most findings were mentioned also at 100 
ppm, except for changes of the thyroid and of plasma cholesterol. From 10 ppm 
the incidence of hepatocellular adenomas and carcinomas was increased, being 
dose-related for carcinomas in males and females starting at the lowest dose 
and not clearly dose-related for adenomas. The tumour incidence is summarised 
be low: 
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Table 7: Reproductivo toxicity studies of ETU 
No Characteristics of the 
studies (a,b,c)C) 
Lowest dose (ug/kg bw/day) with an 
adverse effect on dan and/or fetus 
saternal 
toxicity 
feto­
toxlclty 
terato­
genicity 
Renarks 
Rabbits 
a. Khera 1973(62) 
b. 10 ­ 80 
Rats 
2.1 
a. Khera ­ 1973(6Z) 
(a) b. 5­40 
c. prematlng ­d 15 
(b) b. 5­80 
c. 6­15 d 
(c) b. 5­40 
2.2 
a. Ruddick 1975(63) 
b. 40 ­ 480 
c. 6 ­ 21 d (one day) 
a. Lu 1978(64) 
b. 40 (t/­ T4) 
c. 7­15 d. 
a. Emmerling 1977(65) 
b. 20­40 (+/­ T3, Τ4) 
c. 7­20 d. 
Hamster 
a. Khera 1983(66) 
b. 600 ­ 2400 
e. 11 d. 
80 
> 40 
> 80 
40 
>5 
>5 
> 1200 
80 
>20 
>}0 
>10 
>1200 
questionable results. Small 
group size and little detail 
pubiIcatlon. 
Tñe most sensitive days of 
gestation were 12­15th. 
Details are given at 240 eg/kg 
Malformations dose related 
Co­adnlnlstration of T4 
reduced but not totally 
abol Ished teratogenic 
potential or ETU. 
T3 or T4 co­adiiiinlstrat ion 
with ETU, markedly reduced 
malfornatIons. 
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a: reference, b: range of doses used In mg/kg/day, c: period (In days) of treatnent durino the Gestation. 
Table 8: Reproductive toxicity studles of EBOC's 
No 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
Characteristics of the 
studies (a,b,c)* 
fliancozeb­rat 
a. Larsson, 1976(67) . 
b. 380 ­ 1320 
c. 11 d 
a. Stevens, 1980(68) 
b. 2­512 
c. 6­15 d 
(+ETU 50 mg/kg) 
mancozeb­rabblts 
a. Solomon, 1987a(69) 
b. 50­110 
e. 7­19 d. 
a. Solomon, 1987b(70) 
b. 10­80 
e. 7­19d 
maneb ­ rat 
a. Hofmann, 1976(71) 
b. 20­500 
e. 6­15 d 
a. Merkle, 1983(72) 
b. 5­80 
e. 6­18 d. 
met¡ram­rat 
a. Palmer, 1979b(73) 
b. 40­160 
e. 6­15 d 
metiram­rabbit 
a. Hellwlng, 1988(74) 
b. 10­120 
e. 7­19 d. 
zlneb­rat 
a. Short, 1980(75) 
b. 200­2000 
e. 6­19 
Lowest dose (ig/kg/day) with an 
adverse effect on dai and/or on fetus 
■aterna 1 
toxicity 
>128 
>100 
80 
500 
80 
>80 
40/120 
2000 
feto­
toxlclty 
128/512 
-
-
500 
-
160 
-
2000 
terato­
genicity 
1320 
128/512 
>100 
-
500 
-
-
-
2000 
Remarks 
The fetotoxlclty and terato­
genicity observed at tho dose 
128 «ig/kg bw/day was 
questionable 
Poor survival precluded 
Investigations at doses 
higher than 100 mg/kg bw/day. 
a: reference, b: range of doses used in mg/kg bw/cray>.4c: period (in days) or day of treatment during 
gestat ion. 
Table 9: Chronic feeding toxicity studles of PTU and PU 
Species Dose* Duration Effects NOAEL 
(sg/kg bw/day) 
Ref 
Rat 0,0.05,0.5, 2 years mortality 
5,50 thyroid weight and 
(PTU) tuiours 
weight gain 
I Iver damage 
0.5 86,87 
Mouse 0,0.15,1.5, 
15,150« 
(PTU) 
2 years · weight gain 
I Iver dasage 
I Iver tumours 
thyrold weight 
0.15 88 
Mouse 0,7,70,300 2 years liver damage 
(PU) I Iver tumours 
no thyroid effects 
89 
ppm in diet converted to mg/kg bw/day 
alternate weeks dosing 
Refs: 
89 
Weber and Patschke, 1979 
Bomhard and Loser, 1980 
Bomhard and Loser, 1981 
Krotl inger and Loser, 1981 
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Table 10: Subchronic feeding toxicity studles of propineb 
Species 
Rat 
Rat 
Rat 
Rat 
Rat 
(male) 
Dog 
Dog 
Dog 
Dose' 
0.100,400 
50 
0.0.25,0.5, 
1.25,2.5,5.0 
0.1,2.5,10, 
25 
0,0.1,0.5, 
2.5,12.5 
0,1.25,12.5 
50 
0,2.5,10,40 
0,2.5,7.5, 
25,75 
Durât Ion 
12; 8 days 
21 days 
13 weeks 
13 weeks 
62 days 
13 weeks 
4 months 
2 years 
Effects 
thyroid weights 
(reversible) 
thyroid weight 
(reversible) 
no thyroid effects, 
enzyme effects 
1 Iver weight, 
Glob/Alb 
Iodine uptake 
T3 + T4 
thyroid weight 
disturbed lipid 
metabolIsm 
urea H 
1 iver weight 
spleen weight 
Impaired hepatic 
function 
NOAEL 
(mg/kg bw/day) 
-
-
1.25 
-
0.5 
-
2.5 
25 
Rof 
90 
82 
91.92 
S3 
94,95 
9G 
97 
9S 
ppm in diet converted to mg/kg bw/day 
Refs: Loser and Lorkc, 1967 
Klmmerle. 1972 
Loser. 1969 
Loser. 1968 
Sterner, et al., 1977 
Weber and Dressier, 1980 
Krotl inger, et al., 1980 
Sterner, et al., 1977 
Loser. 1967 
Loser. 1973 
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Table 11: Chronic feeding toxicity studies of propineb 
Species Dose* Duration Effects NOAEL 
(ag/kg bw/day) 
Ref 
Rat 0,0.25,0.5, 2 years siIght hepatic 
1.25.2.5,5 effects 
no thyroid effects 
2.5 99 
Rat 0.0.05,0.5 
5,50,100. 
400 
2 years ■ortallty 
thyroid weight 
thyroid tumours 
slight hepatic 
effects 
0.5 100 
Mouse 0.7.29.114 2 years I Iver tumours 
thyroid weight 
29 101 
*: ppm In diet converted to mg/kg bw/day 
Refs: 99: Loser. 1974(a) 
100: Loser, 1974(b) 
101: Brune and Deutsch-Wenzel, 1980 
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Table 12: Mutagenicity studles of PTU/PU 
Test Concentration/ 
Dose 
Results Ref 
PTU 
Reverse mutation 
Salmonella Typhlmurlum* 
TA98,TA100,TA1535,TA1537 
Reverse mutation 
Salmonella Typhlmurlum* 
TA98,TA100,TA1535,TA1537 
20-12500 pg/pI ate 
20-12500 /jg/plate 
Negative 
Negative 
102 
103 
E Coll Pol A* 
DNA Investigations in 
CF1 mice 
62-1000 / /g/p late 
100 mg/kg bw 
Negative 
Negative 
105 
106 
PU 
Reverse mutation 
Salmonella Typhlmurlum* 
TA98.TA100.TA1535.TA1537 
20-12500 /zg/plate Negative 104 
with and without activation 
Refs: 102 
103 
104 
105 
106 
Herbold, 1980(b) 
Herbold, 1981(a) 
Herbold, 1980(c) 
Herbold, 1981(b) 
Altmann, et al, 1981 
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Table 13: Mutagenicity studies of propineb 
Test Concentration/ 
Dose 
Results Ref 
Reverse mutation 
Salmonella Typhlmurlum* 
TA98,TA100,TA1535,TA1537 
Reverse mutation 
E Coll WP2 her-* 
Salmonella Typhlmurlum* 
TA98,TA100,TA1535,TA1537 
Ree assay 
B Subtil Is H17 rec+ M45 rec-
CHO-HGPRT assay* 
UOS 
primary rat hepatooytes 
Micronucleus test 
NMR I mice 
Dominant lethal tes t 
NMRI mice 
20-12500 pg/p late 
0.09-864 μς /p la te 
0.9-864 / /g/plate 
0.11-60 /jg/ml 
5-30 ¿tg/mi 
2x1000 mg/kg bw or 
2x2000 mg/kg bw 
500 mg/kg bw 
Negative 
Negative 
Negat ive 
Negative 
Negative 
Negative 
Negat ive 
107 
108 
108 
110 
109 
111 
112 
with and without activation 
Refs: 107 
108 
109 
110 
111 
112 
Herbold, 1980(a) 
Hatano Institute, 1978 
Clfone, 1987 
Lehn, 1988 
Herbold, 1982 
Machenier, 1974(a) 
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Table 14: Reproductive toxicity studles of PTU 
Species Dose* Duration 
(Days pc) 
Maternotox 
at dose 
Teratogenic 
at dose 
NOAEL Ref 
Rat 
Rat 
0.11.25.22.5, 6-15 
45.0,90.0 
0,20.50.75, 13 
100.200 
90 45+90 
50+> 
22.5 113 
20 114 
Rat 240 12 or 13 240(100ï) 115 
*: mg/kg bw/day 
Refs: 113 
114 
115 
Vicari, et al., 1985 
Bleyel and Lewerenz, 1978 
Ruddlck, et al.,1976 
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Table 15: Reproductive toxicity studles of propineb 
Species Dose* Duration Maternotox Teratogenic/ NOAEL Ref 
(Days pc) at dose embryotoxic 
at dose 
Rat 0,3,10,30, 
100 
6-15 100 100 30 116 
Rat 0,25,50,100, 
200 
6-15 100+200 100+200 50 113 
Rat 0.400,760, 
2300 
11 400+> 2300 117 
Rabbit 0,10,30,100 6-18 30+100 
(impl. losses) 
10 118 
*: mg/kg bw/day 
Refs: 113 
116 
117 
118 
Vicari, et al, 1985 
Machemer. 1974 
Larsson, et al, 1976 
Becker, et al, 1988 
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Tumour incidence in % at dietary level (ppm): 
Carcinomas 
Adenomas 
m 
f 
m 
f 
0 
0 
2 
0 
0 
1 
13 
2 
11 
10 
10 
29 
5 
10 
13 
100 
31 
26 
7 
32 
1000 
21 
38 
26 
18 
It was noted that the hepatic tumour incidence in control animals was 
unusually low in this study and that the incidence of tumours at the lowest 
dosage lies inside the historical control range for these neoplastic lesions 
in CFI mice. Based upon comparison with historical control dat-a, the NOAEL 
was estimated to be 1 ppm, equivalent to 0.15 mg/kg bw/day (88). 
A 2 year feeding study in mice with propylene urea (PU) at dietary levels of 
0 (Control), 50, 500 and 2500 ppm (equivalent to 0, 7, 70 and 300 mg/kg 
bw/day) revealed, at 2500 ppm, ocular opacities, impaired kidney function 
and hematopoiesis, liver damage, hyperplasia of the adrenal cortex, and an 
increased incidence of liver cell adenomas and carcinomas. At 500 ppm 
centr i lobular hyperplasia in the liver was noted. Administration of 50 ppm, 
equivalent to 7 mg/kg bw/day, was apparently without any detectable effect 
(89). 
In summary an NOAEL for PTU of 0.5 mg/kg bw/day for rats seems Justified and 
an NOAEL of 0.15 mg/kg bw/day may be derived in mice. 
1.4. Subchronic studies - propineb 
In a number of subchronic toxicity studies with propineb (82, 90-98), the 
thyroid and liver were identified as target organs (Table 10). In general, 
thyroid and liver effects were seen but thyroid effects were not seen in 
dogs. The thyroid changes seen with propineb are qualitatively similar to 
those observed for PTU and those previously discussed for ETU and EBDCs. 
Although direct comparisons are difficult, the data suggest that propineb and 
PTU are more potent inducers of thyroid hyperplasia than EBDCs and ETU. 
Summarising the subchronic studies, an overall NOAEL may be derived in rats 
of 1.25 mg/kg bw/day and in dogs of 2.5 mg/kg bw/day. 
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1.5. Chronic studies - propineb 
Two 2-year Wistar rat feeding studies were reported in 1974 and a long term 
mouse study has also been conducted. The results are summarised in Table 11. 
In the first rat study, performed with dietary levels of 0 (Control), 5, 10, 
25, 50 and 100 ppm (equivalent to 0.25, 0.5, 1.25, 2.5 and 5 mg/kg bw/day), 
there was no effect on food consumption, growth rate and mortality at any 
dose level. Dose-related histopathologlcal changes were not observed in any 
organ, including the thyroid. Treatment with 100 ppm occasionally caused 
slightly Increased ALAT* and ASAT* activities; 50 ppm provided no indication 
of liver damage, fiature, location and frequency of tumours gave no 
indications for any carcinogenic effects of the test compound. An NOAEL of 50 
ppm, equivalent to 2.5 mg/kg bw/day was derived (99). 
The second rat study used dietary levels of 0 (Control), 1, 10, 100, 1000, 
2000 and 8000 ppm (equivalent to 0.05, 0.5, 5.0, 50.0, 100 and 400 mg/kg 
bw/day). Premature death occurred at 2000 and 8000 ppm in all females and at 
8000 ppm in all males. Signs of myasthenia and histological alterations of 
skeletal muscles were observed at 1000 ppm and above. Absolute and relative 
liver weights in males were Increased at 100 ppm and above but histological 
alterations were not observed. Significant enlargement of the thyroids was 
observed in males at 100 ppm and above and in females at 1000 ppm and above. 
Dose related hyperplasias of the thyroid as well as thyroid adenomas 
increasingly occurred starting at 1000 ppm. An NOAEL of 10 ppm, equivalent to 
0.5 mg/kg bw/day was derived (100). 
A 104 week carcinogenicity study was performed in NMR I mice with dietary 
levels of 50, 200 and 800 ppm (equivalent to 7, 29 and 114 mg/kg bw/day). 
Neither clinical signs nor clinical chemistry or urine analysis data were 
affected at any dose level.: There was some indication of increased thyroid 
weight in females and an increase of hepatocellular adenomas was observed in 
males at the highest dose group (controls 8%; 50 ppm 6%; 200 ppm 4%; 800 ppm 
18%). Inter-group differences in the incidence of lung adenomas were observed 
in females, varying from 19% (0 ppm) to 27% (50 ppm), 30% (200 ppm) and 50% 
ALAT - Alanine Aminotransferase, formerly known as GPT 
ASAT - Aspartate Aminotransferase, formerly known as GOT 
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in females, varying from 19% (0 ppm) to 27% (50 ppm), 30% (200 ppm) and 50% 
(800 ppm). These incidences were all within the historical control range and 
may have been affected by the higher survival rates at higher concentrations 
of the test substance, therefore, the NOAEL Is 200 ppm, equivalent to 29 
mg/kg bw/day (101). 
In summary, for propineb, overall NOAEL's of 2.5 mg/kg bw/day for rats and 
29 mg/kg bw/day for mice may be derived. 
1.6. Mutagenicity - PTU and PU 
Mutagenicity tests conducted with PTU and PU are summarised In Table 12. 
The activated and non-activated assay on different strains of Salmonella 
typh. as well as an E.coli pol Al Test (102, 103, 105) revealed no 
indications for point mutations with PTU. Investigation of the interaction of 
PTU with DNA in mice (100 mg PTU/kg bw oral) showed only an enhanced 
sem i conservât i ve DNA synthesis. Binding of PTU to mice liver DNA could not be 
detected and there was no indications of unscheduled DNA synthesis or strand 
breaks (106). No information on possible effects on chromosome aberrations in 
vitro is available, nor on gene mutation in mammalian cells, and it Is not 
possible to draw any firm conclusions regarding the mutagenic potential of 
PTU. 
A SaImonella/microsome test in 4 strains with propylene urea in 
concentrations up to 12500 /ig/plate revealed no evidence for mutagenic 
activity (104). 
1.7. Mutagen ic i ty - propineb 
Mutagenicity assays conducted with propineb are summarised in Table 13. 
All in vitro and in vivo assays performed gave no indications for mutagenic 
actions of propineb. Even cytotoxic concentrations did not result in 
positive findings (107-111). A dominant lethal assay showed impaired 
fertility of male mice, dosed orally with 500 mg/kg bw/day but revealed no 
indications for mutations in germ cells (112). 
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Although', as with PTU, studies on chromosome aberrations in vitro were not 
carried out, it may be concluded that propineb did not demonstrate any 
mutagenic activity. 
1.8. Reproductive toxicity - PTU 
The teratogenic potential of PTU has been investigated in the rat and the. 
study results are summarised in Table 14. 
According to Vicari, 'et al. (113) PTU showed a clear teratogenic activity in 
a conventional rat teratology study at doses which did not show maternal 
toxicity. Earlier studies (114, 115) showed that PTU has- teratogenic 
potential in rats following one or two doses on days 12 or 13 of gestation. 
In summary the NOAEL for teratogenic effects of PTU derived from these few 
studies may be approximately 20 mg/kg bw and effects occur at non or marginal 
maternotoxic dosages. 
1.9. Reproductive toxicity - propineb 
The teratogenic potential of propineb has been investigated in the rat and 
rabbit and general effects on reproductive function have been investigated in 
a mul t¡generat ion study in rats. The results of these studies are summarised 
in Tab le 15. 
The rat teratology study revealed visceral and skeletal abnormalities at high 
doses accompanied by maternal toxicity (113, 116, 117), while in rabbits an 
increased implantation loss was observed, but no fetal abnormalities (118). 
A 3-generation study in rats with dietary levels of 0 (Control), 20, 60, 200 
and 600 ppm (equivalent to 1 , 3, 10 and 30 mg/kg bw/day) resulted in impaired 
well-being of parental animals at 200 and 600 ppm, along with reduced 
pregnancy rate and reduced number of live offspring. An NOAEL of 60 ppm 
(equivalent to 3 mg/kg bw/day) may be derived (119). 
In summary, an overall NOAEL of 50 mg/kg bw/day can be set in rats for te-
ratogenic effects of propineb, being at the margin of maternal toxicity. 
Rabbits show a much lower sensitivity, no evidence of teratogenicity was seen 
at 100 mg/kg bw/day. The 3-generation study in rats resulted in a NOAEL of 3 
mg/kg bw/day. 
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1.10. Observations in humans on propineb 
The health of workers exposed to propineb was reported not to be impaired. 
There were also no indications of malfunctions of the thyroid or irritant or 
sensitizing actions to the skin (120-122). 
ToxicologicaI overview and estimation of API 
The effects of propineb seem chiefly to be due to its main metabolite 
propylenethiourea (PTU). Both propineb and PTU very closely resemble, with 
respect to their toxicologicaI profile as well as to their chemical 
structure, the ethylenebisdithiocarbamates (EBDCs) and their common main 
metabolite ethylenethlourea (ETU). Propineb, PTU, E B D C s and ETU affect the 
function of the thyroid, causing a compensatory enlargement of the gland by 
TSH-stimulation. In addition, liver function becomes altered, resulting in 
disturbances of lipid metabolism, e.g. enhanced cholesterol levels, and 
increased liver weight. Both actions may be connected to each other by the 
thyroid-liver hormonal axis. At higher dosages overstimulation of the thyroid 
by TSH leads to hyperplasia, adenomas and with PTU and ETU also to carcinomas 
of this gland in rats. In mice an increased incidence of hepatomas was 
observed with ETU and PTU (ETU, Ref. 15). Mutagenicity studies revealed no 
indications neither with E B D C s or ETU nor with propineb or PTU, although 
with PTU the data are rather limited. Teratology studies also show strong 
similarities between E B D C s and ETU on the one and propineb and PTU on the 
other hand, both latter compounds being effective slightly below or at the 
border of maternal toxicity. 
In view of the intimate relationships between EBDC's/ETU and propineb/PTU it 
seems justifiable to treat these groups of compounds identically. If 
thresholds are assumed for the tumorigenic effects of EBDC's/ETU this should 
be accepted also for propineb/PTU. With regard to estimation of an ADI the 
crucial no adverse effect level for propineb is considered to be 1.25 mg/kg 
bw/day. Although lower no effect levels were derived for individual studies a 
dose of 1.25 mg/kg bw/day is the highest no adverse effect level which is 
still lower than the actual adverse effect levels from all the studies. For 
PTU, a no adverse effect level of 0.15 mg/kg bw/day can be chosen from the 
mouse study, even though the effects seen in mice might be considered to be 
of no relevance to man. With respect to the teratogenic actions, in rats for 
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propineb a NOAEL of 50 mg/kg bw/day and for PTU of approximately 20 mg/kg 
bw/day, given during the sensitive stages of gestation, can be deduced. These 
NOAEL's are about 50 times higher than the NOAEL's derived from the 
subchronic and chronic studies with PTU and propineb. 
Considering the generally weak database for propineb/PTU In comparison with 
EBDC's/ETU, (in particular the poor metabolism data, the lack of information 
on the conversion of:propineb to PTU and the high degree of uncertainty in 
selecting the no effect level for PTU) It seems prudent to apply at least a 
safety factor of 200 to the NOAEL's of propineb and PTU, to derive an ADI. 
The ADI is thus estimated at 0.006 mg/kg bw for propineb and 0.0008 mg/kg bw 
for PTU. Those values are considerably lower than the ADI's" derived for 
E B D C s of 0.05 mg/kg bw and for ETU of 0.01 mg/kg bw. 
The toxicologicaI potencies of propineb/PTU and EBDC's/ETU seem, based on 
currently available data, to be sufficiently different to require separate 
ADI's. However, the analytical method commonly used to determine residues of 
these materials in food (based on CS2 generation) cannot distinguish between 
residues of propineb and E B D C s . It Is therefore strongly recommended that 
further work be undertaken to develop and validate a new analytical method to 
specifically detect residues of propineb/PTU. 
As long as such a specific method is not available, consideration should be 
given to: 
Use of the ADI's for propineb/PTU for all pesticides giving rise to 
CS2 on analysis, 
Withdrawal of use of propineb in those cases giving rise to residues 
in edible crops, 
Total withdrawal of approval for use of propineb. 
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Table 1: Subchronic feeding toxicity studles of ETU 
N° 
A. 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
B. 
1. 
2. 
C. 
1. 
2. 
Characteristics 
of the studies 
(a, b. c)« 
RATS 
a. 
b. 
c. 
a. 
b. 
c. 
a. 
b. 
c. 
a. 
b. 
c. 
a. 
b. 
c. 
a. 
b. 
c. 
a. 
b. 
c. 
(3) 
50 - 750 
13 K 
(4) 
60 - 750 
13 w 
(5) 
10 - 1.000 
12 W 
(6) 
1 - 625 
13 W 
(7) 
0,625 - 25 
8 w 
(8) 
75 - 150 
7 w 
(9) 
125 - 625 
12 w 
MOUSE 
a. 
b. 
c. 
2 . 
b. 
c. 
(10) 
125 - 2.000 
13 w 
(H) 
1 - 1.000 
13 w 
MONKEY 
a. 
b. 
c. 
a. 
b. 
c. 
(12) 
2 - 250 
22 - 24 w 
(12) 
50 - 450 
26 w 
Lowest dose (In ppm) with an 
body weight and on 
Body weight 
gain 
(decrease) 
100 
500 
-
625 
-(>25) 
•75 
-
>2.000 
>1.000 
>250 
> 450 
Thyroid 
weight 
(Increase) 
50 
— 
159 
— 
-(>25) 
75 
125 
— 
1.000 
--
50 
Thyroid 
hyperplasia 
100 
250 
— 
125 
-(>25) 
125 
500 
100 
50 
50 
adverse effect on 
thyroid 
Thyroid 
tumours 
"adenomas" 
500 
250 
— 
— 
-
— 
-
— 
-
Thyroid 
hormones 
(T3/T4.THS) 
— 
-
-
125 
5 
150 
125 
— 
-
50 
150 
NOAEL 
(In ppa) 
none 
60 (based on thyroid 
weight) 
* 63 (based on thyroid 
weight) 
25 (based on T4 
levels) 
1.25(based on Increa-
sed protein 
bound Iodine) 
(question, findings) 
none 
none 
250 (based on thyroid 
hyperplasia) 
10 (based on thyroid 
hyperplasia) 
10 
none 
a: reference number, b: range of doses used in ppm, c: duration of the experiment In weeks. 
(3): GRAHAM 1972. (4): PETERS 1980, (5): HART 1973, (6): FREU0ENTHAL et al. 1977, (7): LEUSCHNER 1977, 
(8): ARN0L0 1983, (9): LEBER 1977, (10): PETERS 1980, (11): O'HARA 1985, (12): LEBER 1978. 
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Table 2: Chronic feeding (2 years) studles for ETU In rats 
N° 
1. 
2. 
Characteristics 
of the studies 
(a, b, c,)* 
a. rat - (13) 
b. 5 - 5 0 0 
c. 104 w 
a. rat - (14) 
b. 5 - 200 
c. 104 w 
Lowest dose (In ppa) with an adverse effect on 
body weight and on thyroid 
Body weight 
gain 
(decrease) 
5,00 
17 
Thyroid 
weight 
(increase) 
125 
. 60 
Thyroid 
hyperplasia 
? 
Thyroid 
tumours 
"adenomas" 
250 
60 
Thyroid 
hormones 
(T3/T4.THS) 
— 
NOAEL 
( In mg/kg diet) 
25 
Not sufficiently 
we 11 reported to 
set a NOAEL 
a: animal species and reference number, b: range of doses used In ppa, c: duration of the experiment In 
weeks. 
? 
(13) 
(14) 
Inadequate data to establish a NOEL 
GRAHAM et al., 1975. 
GAK et al.. 1976. 
NTP studles are not Included as they have not been fully reported (see pages^2 and 3) at the time of writing. 
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Table 3: Subchronic feeding toxicity studles of EBDCs 
N° 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
Characteristics 
of the stud 1 es 
(a, b, c, d)* 
a. mancozeb 
b. rat - (16) 
C 30 - 1.000 
d. 13 w 
a. metiram 
b. rat - (17) 
c. 50 - 900 
d. 13 w 
a. mancozeb 
b. mouse - (11) 
c. 10 - 10.000 
d. 13 w 
a. mancozeb 
b. dog - (18) 
c. 10 - 5.000 
d. 13 w 
a. mancozeb 
b. dog - (19) 
c. 25 - 1.000 
d. 104 w 
a. maneb 
b. monkey - (20) 
c. 100 - 3.000 
d. 26 w 
a. metiram 
b. monkey - (21) 
c. 5 - 75 
d. 26 w 
Lowest dose (In ppm) with an 
body weight and on 
Body weight 
gain 
(decrease) 
1.000 
900 
10.000 
1.000 
1.000 
3.000 
>75 
Thyroid 
weight 
(Increase) 
— 
__ 
10.000 
5.000 
__ 
300 
75 
Thyroid 
hyperplasia 
1.000 
900 
1.000 
5.000 
1.000 
3.000 
15 
adverse effect on 
thyroid 
Thyroid 
tumours 
"adenomas" 
— 
--
— 
--
--
— 
--
Thyroid 
hormones 
(T3/T4JHS) 
250 
300 
— 
5.000 
1 
300 
15 
NOAEL 
(In ppm) 
125 
100 
100 
100 
100 
100 
5" 
a: product; b: animal species and reference number, c: range of doses used In ppm, d: duration of the 
experiment in weeks-, **: expressed in mg/kg b.w./day. 
(16): GOLDMAN 1986. 
(17): HUNTER 1977. 
(11): 0'HARA 1985. 
(18): COX 1986. 
(19): EORZELLECA et al , 
(20): LEUSCHNER 1977. 
(21): SORTWELL 1979. 
1965a 
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Tablo 4: Chronic feeding (2 years) studlas of EBOCs 
N° 
1. 
2. 
3. 
4. 
Characteristics 
of the studies 
(a, b, c, d)· 
a. mancozeb 
b. rat - (22) 
c. 25 - 1.000 
d. 90 w 
a. maneb 
b. rat - (23) 
c. 30 - 1.000 
d. 132 w 
a. metiram 
b. rat - (24) 
c. 5 - 320 
d. Ill - 119 w 
a. metiram 
b. mouse - (25) 
c. 100 - 1.000 
d. 88 - 96 w 
Lowest dose (In ppa) with an 
body weight and on 
Body weight 
gain 
(decrease) 
>1.000 
1.000 
>320 
1.000 
Thyroid 
weight 
(Increase) 
1.000 
1.000 
>320 
>1.000 
Thyroid 
hyperplasia 
1.000 
>1.000 
>320 
>1.000 
adverse effi 
thyroid 
Thyroid 
tumours 
"adenomas" 
— 
— ■ 
— 
— 
set on 
Thyroid 
horr.ones 
(T3/T4,THS) 
— 
1.000 
320 
-
NOAEL 
(In ppm) 
100 
300 
80 
300 
a: product; b: animal species and reference number, C: range of doses used in ppm. d: duration of the 
experIment In weeks. 
(22): B0RZELLECA et al. 1965b. 
(23): LEUSCHNER 1979. 
(24): HUNTER 1981. 
(25): HUNTER 1979. 
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Table 5: Mutagenicity tests of E T u O 
TESTS 
In vitro 
1. Procarvotes 
( -activation 
-gene mutation { 
( +actlvatlon 
2. Yeasts 
-gene conversioni -activation 
aneuploldy { 
mutation { tactivatlon 
3. Mammalian eel Is 
- gene mutation 
- chromosomal aberration 
- sister chromatid exchange 
- DNA repair 
In vivo 
1. Host-mediated assay 
2. Drosophlla sex linked recessive 
3. Micronucleus test 
4. Chromosomal aberration 
5. Dominant lethal test 
Total No. of 
tests 
31 
30 
9 
7 
3 
3 
3 -
2 
3 
1 
5 
2 
3 
RESULTS 
positive 
+ 
4 
8 
4 
1 
1<2) 
equivocal 
( + ) 
2 
4 
1 
1 
negative 
25 
18 
4 
6 
3 
3 
3 
2 
2 
1 
5 
2 
3 
(1) Based mainly on review by IARC (1987) (26) with additional data from Teramato 1977 (27) and 
McGregor 1988 (28). 
(2) found at 6000 mg/kg bw. 
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Table 6: Mutagenicity tests for EBDCs (coiblned) 
TESTS 
In vitro 
1. 
?. 
3. 
Procaryotes 
{ -activation 
-gene mutation { 
{ +actIvat Ion 
-DNA repair 
Yeasts 
( -activation 
-gone mutation ( 
{ tactlvation 
Mamma 1 Ian ce 1 Is 
{ -act Ivat ion 
-gene mutat Ion { 
( -tact ivat ion 
(-act. 
-chromosomal aberration( 
(tact. 
(-act. 
-sister chromatid exch. ( 
(tact. 
-DNA repa Ir 
In vivo 
1. 
2. 
3. 
■1. 
Host mediated assay 
Chromosomal aberration 
Dominant lethal assay 
Cel 1 transformation 
No of 
tests 
7 
6 
2 
1 
1 
4 
4 
1 
1 
3 
3 
3 
4 
4 
1 
5 
RESULTS 
positive 
1 
1 
2 
2 
equivocal 
1 
1 
negative 
7 
6 
2 
1 
1 
3 -
4 
1 
3 
4 
4 
1 
5 
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REPORT OF THE SCIENTIFIC CC4AIITTEE FOR PESTICIDES 
ON THE TOXICITY OF I PROOIONE 
(Opinion expressed by the SCP on 2 June 1992) 
BACKGROUND AND TERMS OF REFERENCE 
Iprodione is a protectant 3',5'-dichloroaniI ide fungicide with some 
eradicant activity used to control many diseases on a wide range of 
horticultural and agricultural crops. In the context of its work to 
establish maximum pesticide residue levels pursuant to the relevant 
Community legislation, the Commission invited the Scientific Committee 
for Pesticides to examine toxicological data relating to iprodione and 
to estimate its acceptable daily intake. 
Since iprodione is structurally similar to vinclozolin and 
procymidone, both of which have been reported to possess anti-
androgenic potential, the data to be reviewed concentrated on studies 
likely to reveal any ant¡-androgenic effects (subchronic experiments 
in dogs, including a new study specially conducted to define a no 
adverse effect level, and carcinogenicity and reproductive toxicology 
studies). 
The toxicity of iprodione has previously been reviewed by the JMPR in 
1977. when an ADI of 0.3 mg/kg bw was derived. 
1. T0XIC0L0GICAL ASPECTS 
1.1. Toxicity studies in dogs 
In the first study, reported in 1984, groups of 6 male and 6 female 
beagle dogs were fed diets containing iprodione (technical grade, 
96.5%) at concentrations of 0 (Control), 100, 600 or 3600 ppm for 52 
weeks. There were no clinical signs of reaction to treatment. Food and 
water consumption and body weight gain remained undisturbed by 
treatment. Physical examination and urinalysis revealed no treatment 
related effects. Ophthalmoscopy revealed that retinal hyperreflection 
was observed more frequently in treated animals than among controls 
and there was some evidence of a dose related trend among males 
receiving 600 or 3600 ppm. In treated females this finding was more 
persistent than among control females. Haemato log ica I changes 
consistent with haemolytic anaemia were seen at 3600 ppm (decreased 
haemoglobin, red cell count and packed cell volume and increased 
Heinz bodies). A slight increase in Heinz bodies was also seen at 600 
ppm. during the first 18 weeks of the study only. Blood chemistry 
investigations revealed an increased alkaline phosphatase activity 
among dogs receiving 3600 ppm. At the end of the study, liver and 
adrenal weights at 3600 ppm were higher than control values, while 
prostate weights among males at 600 and 3600 ppm were lower than in 
control males. H i s topathology revealed treatment related changes in 
96 
liver and urinary bladder at 3600 ppm (submucosal crystals within 
giant cells and granulomas within the submucosa in the urinary bladder 
and centriacinar hepatic cord atrophy) and stress related changes In 
the adrenals and kidneys at 600 and 3600 ppm. Microscopic examination 
revealed no treatment related change In the prostate to correlate with 
the intergroup difference in weight. These findings indicate that 100 
ppm (equal to 4.2 mg/kg bw/day) was a no adverse effect level in this 
study (1, 2, 3). 
In the second study, reported In 1991, groups of 6 male and 6 female 
beagle dogs were fed diets containing iprodione (technical grade, 
96.1%) at concentrations of 0 (Control), 200, 300, 400 or 600 ppm for 
52 weeks. There were no clinical signs of reaction to treatment. Food 
and water consumption and body weight gain remained undisturbed by 
treatment and ophthaImologiçaI examinations revealed no treatment 
related effects. Although there was some indication of a slight 
reduction in red cell parameters in treated females and in males 
receiving 600 ppm, all values were similar to pre-treatment values and 
within the range of normal biological variation for dogs of this age. 
There was no indication of Heinz bodies in erythrocytes from control 
or treated dogs at any stage. Organ weight analysis and histopathology 
conducted at termination revealed no Indication of any reaction to 
treatment. These findings show that dietary administration of 
iprodione to beagle dogs at levels up to 600 ppm produced no 
indication of a toxic effect in this study (4). 
1.2. Chronic toxicity/Carcinogenicity 
In a rat study reported in 1978, groups of 60 male and 60 female 
Sprague-Dawley rats were fed diets containing 0 (Control), 125, 250 or 
1000 ppm iprodione (purity unspecified) for 24 months (the high dose 
group received 500 ppm for the first 8 days of the study). Mortality 
remained unaffected, while food consumption was slightly decreased in 
treated groups and there was a corresponding decrease in weight gain. 
These intergroup differences in food intake and weight gain; although 
statistically significant, were small and not dosage related in degree 
and were considered to be of no toxicologicaI significance. Clinical 
chemistry, haematology and urinalysis revealed no evidence of reaction 
to treatment. Organ weight data were affected by tf>e minor intergroup 
disparity in body weight. However, there were no consistent changes 
which were considered to be of any toxicologicaI significance. 
HIstopathologica I examination revealed no treatment related effects 
and in particular there was no indication of any tumorigenic potential 
of iprodione. The no observable adverse effect level was considered 
to be in excess of 1000 ppm which was equal to 49 mg/kg bw/day (5). 
In a mouse study reported in 1978, groups of 60 male and 60 female CF-
1 mice were fed diets containing 0 (Control), 200, 500 or 1250 ppm 
iprodione (purity unspecified) for 18 months. There were no clinical 
signs of reaction to treatment and survival rates of control and 
treated mice were similar. Weight gain and food intake remained 
undisturbed by treatment and ophthalmoscopic examination revealed no 
indication of any reaction to treatment. Results of haematology and 
blood chemistry investigations were all within normal ranges and there 
were no consistent intergroup differences. At necropsy at termination 
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of the study there was no evidence of any treatment related 
macroscopic changes, no intergroup difference in organ weights and no 
treatment related h¡stopathologlcal changes. In particular there was 
no indication of any tumorigenic potential of Iprodione. The no 
observable adverse effect level was considered to be in excess of 1250 
ppm which was equal to 182 mg/kg bw/day (6). 
1.3. Reproductive toxicity 
1.3.1. Teratology studies 
In a study reported in 1973 groups of female Sprague Dawley rats were 
given oral doses of 0 (Control), 100, 200 or 400 mg iprodione/kg 
bw/day between days 5 and 15 of gestation. There was a slight decrease 
in body weight gain at the high dose level, and the conception rate 
and mean number of implantations per fertile female were slightly 
lower at the high dose than in controls. Detailed fetal examinations 
showed that there were no embryotoxic or teratogenic effects at any 
dose level. The no observable adverse effect level for maternal 
toxicity was 200 mg/kg bw/day (7). 
In a preliminary dose range finding study reported In 1986, iprodione 
(purity 94.2%) was administered by oral gavage at dose levels of 0 
(Control), 40, 120 240, 400 and 800 mg/kg bw/day to groups of 6 
pregnant female Sprague Dawley rats from day 6 to day 15 of gestation. 
Overt maternal toxicity noted at 400 and 800 mg/kg bw/day consisted of 
reduced food intake and weight gain and severe clinical, signs. One 
high dose animal died and the others were killed for humane reasons. 
One rat treated with 400 mg/kg bw/day was killed and only one other 
animal in this group had viable fetuses. Five late resorptions were 
seen In one litter from a dam treated with 240 mg/kg bw/day. The dose 
levels selected for the main study (up to 200 mg/kg bw/day) were 
therefore considered appropriate (8). 
In the main study reported in 1986, iprodione (purity 94.2%) was 
administered by oral gavage at dose levels of 0 (Control), 40, 90 and 
200 mg/kg bw/day to groups of 20 pregnant female Sprague Dawley rats 
from day 6 to day 15 of gestation. Under the conditions of this test 
iprodione did not produce any adverse maternal or fetal effects (9, 
10, 11). 
In a study reported in 1973 groups of female New Zealand White rabbits 
were given oral doses of 0 (Control), 100, 200 or 400 mg iprodione/kg 
bw/day between days 6 and 16 of gestation. Maternal toxicity was seen 
at the high dose (9 of 17 females died during the treatment period) 
and fetal toxicity was seen at 200 mg/kg bw/day (total resorptions in 
3 of 13 females). Detailed examination of the fetal organs and 
skeletons showed that iprodione was not teratogenic at any of the dose 
levels tested (12). 
In a study reported in 1985, (only a summary of which was submitted 
for review) iprodione was administered by oral gavage at dose levels 
of 0 (Control), 20, 60 and 200 mg/kg bw/day to groups of 18 pregnant 
female New Zealand White rabbits from day 6 to day 18 of gestation. 
Losses in body weight and decreased food consumption were noted at 200 
mg/kg bw/day. during the treatment period. Similar findings, to a 
lesser extent, were also seen at 60 mg/kg bw/day. Seven abortions and 
two total litter resorptions were noted at the high dose. No treatment 
related malformations or developmental variations were seen in any 
group (13). 
-98-
1.3.2. Mul t¡generat ion studies 
In a mul t¡generat¡on study reported ¡π 1976, (only a summary of which 
was submitted for review) groups of 10 male and 20 female Sprague 
Dawley rats received iprodione in the diet at levels of 0 (Control), 
125, 250 or 1000 ppm for 5 weeks. Following this initial period, 
dietary concentrations were increased to 250, 500 and 2000 ppm for the 
remainder of the premating period and throughout mating, gestation and 
lactation. This dosing regimen was repeated through 3 generations, 
with one mating per generation. No evidence of parental toxicity was 
seen at any dose level and no adverse effects on reproduction were 
noted. Evidence of toxicity in the pups was noted in the F2 and F3 
generation (smaller litter sizes and lower pup weights) at the highest 
dietary level. No treatment related lesions were observed at limited 
histopathology of tissues from the F3 generation. The no observable 
adverse effect level for parents and pups was thus 250/500 ppm, 
equivalent to approximately 30 mg/kg bw/day (14). 
Because of the limitations in the study design of the first 
experiment, a second mul t¡generat ion study was carried out and 
reported in 1991. In this latter study, groups of 28 male and 28 
female Sprague Dawley rats received iprodione (purity 96.2%) by 
dietary administration at levels of 0 /.Control), 300, 1000 or 3000 
ppm for 10 weeks prior to mating, and throughout mating, gestation, 
lactation and weaning of F1a and F1b pups. At mating of the F1a 
animals (to produce F2a and F2b pups) the high dietary level was 
decreased to 2000 ppm, since 3000 ppm was considered tc^  exceed the 
maximum tolerated dose. No adverse effects on reproductive performance 
were noted in this study. Lower body weight gains (up to 40% below 
control values) were seen at 3000 ppm, along with a decrease in pup 
survival. A slightly decreased weight gain was also seen at 2000 ppm 
and at 1000 ppm. The no observable adverse effect level in this study 
was thus 300 ppm, equivalent to approximately 21 mg/kg bw/day (15). 
ToxicologicaI overview and estimation of ADI 
Based upon this review of the available data there is no evidence that 
iprodione possesses any ant¡­androgenic potential. This is in contrast 
to the toxicologicaI properties of pesticides with closely related 
chemical structures. Vinclozolin has been reported to cause 
femininizat¡on of male rats (16) and procymidone has been reported to 
cause hormonal imbalance leading to infertility and abnormalities of 
the male sexual organs and testicular tumours in male rats (17), these 
findings being reportedly associated with ant¡­androgenic potential. 
In teratology studies in rats and rabbits the NOAEL for maternal 
toxicity was 200 and 20 mg/kg bw/day respectively. Iprodione was not 
teratogenic in either species at doses up to 400 mg/kg bw/day. 
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With regard to estimation of an ADI the crucial no effect level for 
iprodione is considered to be 18 mg/kg bw/day. This is based on the 
results of the two dog studies. Although a lower no effect level was 
derived for the first study, a dietary level of 400 pprn (equal to 18 
mg/kg bw/day) is the highest no adverse effect level which is still 
lower than the actual adverse effect level. This no adverse effect 
level is further supported by the results of the recent 
mul t¡generat ion study, In which an NOAEL equivalent to 21 mg/kg bw/day 
was derived. 
In view of the fact that the toxicological properties of iprodione do 
not cause undue concern, it Is not necessary to use a safety factor 
higher than 100 in setting an ADI. The ADI Is thus estimated at 0.2 
mg/kg bw. 
An ADI of 0.2 mg/kg bw is lower than that derived by the JMPR in 1977, 
but is based on data not available at that time. Although it must be 
borne in mind that the present review has not considered a complete 
database, examination of further data (such as subchronic studies in 
rodents and mutagenicity studies) would not be expected to have any 
influence on the AD I. 
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REPORT OF THE SCIENTIFIC COMMITTEE FOR PESTICIDES 
ON THE TOXICITY OF ALDICARB 
(Opinion expressed by the SCP on 26 January 1993) 
BACKGROUND AND TERMS OF REFERENCE 
AldLcarb is a soil-applied, systemic carbamate insecticide and nematicide 
used in a wide variety of agricultural crops and in horticulture. In the 
context of its work relating to the establishment of community maximum 
pesticide residue levels in various foodstuffs covered by community 
legislation, the Commission requested the Scientific Committee for 
Pesticides to review the toxicity of aldicarb, with a view to establishing 
an Acceptable Daily Intake and commenting particularly on principles to be 
used in the risk evaluation for consumer exposure to aldicarb resulting 
from use on bananas and potatoes. 
1. BIOCHEMICAL ASPECTS 
1.1. Absorption, distribution and excretion 
Aldicarb is readily absorbed, distributed widely in the body and excreted 
rapidly in manais. Radiolabeled aldicarb was administered orally to male 
rats and residues were analyzed over a 14-day period. Excretion of 
radiolabel in the urine was essentially complete within 4 days (greater 
than 95% of the administered dose). The major concentrations of 
metabolites were observed to have been excreted within 24 hours of dosing. 
Four days following acute oral dosing, residues were not detected in 
tissues. In dogs, the excretion pattern of aldicarb was similar to that 
noted following administration in other species. (Refs. 1-6) 
1.2. Biotransformation 
The metabolic fate of aldicarb has been studied in a variety of animal 
species. Minor biotransformation differences have been found to occur with 
respect to quantities of individual matâbolites. The basic metabolic 
profile of aldicarb in all species exmined appears to be the same. Aldicarb 
is rapidly oxidized to aldicab sulfoxide, a relatively stable metabolite. 
Aldicarb sulfoxide is slowly degraded by both oxidative and hydrolytic 
mechanisms yielding the corresponding aldicarb sulfone and sulfoxide oxime. 
Investigations in plants revealed that aldicarb metabolism proceeds via the 
same routes in plants and.animals. Metabolic transformation in plants is 
such that 'terminal' residues (to which consumers of treated crops may be 
exposed) consist largely of the sulfoxide and the sulfone, with, depending 
on harvest time, a minor residue of parent aldicarb. (Refs. 3, 6-8) 
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1.3. Effects on enzymes and other biochemical parameters 
As noted with other N-methylcarbmate esters, aldicarb is a readily 
reversible inhibitor of Cholinesterase activity and in vitro studies have 
shown that Cholinesterase inhibition induced by aldicarb and its oxidative 
metabolites (aldicarb sulfoxide and aldicarb sulfone) can be rapidly 
reversed by simple dilution. (Refs. 7-9) 
2. TOXICOLOGICAL ASPECTS 
2.1. Acute toxicity 
The acute toxicity of aldicarb and its metabolites has been studied in a 
variety of mammalian species. The acute toxicity of aldicarb is generally 
similar in different species, oral LD 50's being in the range 0.6-1.5 mg/kg 
bw and intraperitoneal LD 50' s being in the range 0.3-0.7 mg/kg bw. The 
acute dermal toxicity is much more variable, depending on the vehicle, 
having greater toxicity in aqueous vehicles and much less toxicity when 
dry. (Refs. 10-19) 
Investigation of the acute toxicity of aldicarb metabolites has shown that 
aldicarb sulfoxide is of approximately equivalent toxicity to aldicarb 
itself. However, in all species tested, the sulfone is some 20-50 times 
less toxic than aldicarb or the sulfoxide and the further dégradâtes 
(sulfoxide oxime and nitrite) are even less toxic. (Refs. 12, 14, 20-22) 
2.2. Short term studies 
Mice 
In seven day dietary studies, aldicarb induced mortality at 1.2 mg/kg 
bw/day but a dose of 0.6 mg/kg bw/day was tolerated without substantial 
effects. A mixture of aldicarb and aldicarb sulfone (1:1) at a dose of 36 
mg/kg bw/day did not induce mortality, but severe cholinergic signs of 
poisoning were observed. Aldicarb sulphone, at a dose of 38 mg/kg bw/day, 
induced significant body weight decrease but there were no significant 
organ weight changes. Cholinesterase activity was not determined 
adequately in any of these studies. (Refs. 23-25) 
Rats 
In seven day dietary studies in rats aldicarb induced mortality at 16 mg/kg 
bw/day (7/10) and at 8 mg/kg bw/day (1/10). Rats survived 4 mg/kg bw/day 
for seven days, with only minor organ weight changes seen at termination. 
In a 93 day study aldicarb induced mortality at 0.5 mg/kg bw/day, but there 
were no other consistent treatment-related effects. Cholinestaerase 
activity was not determined adequately in these studies. (Refs. 26-28) 
In another seven day study, no adverse effect levels, based on erythrocyte 
Cholinesterase depression or decreased body weight gain were: aldicarb -
0.8 mg/kg bw/day; aldicarb sulfoxide - 0.4 mg/kg bw/day; and aldicarb 
sulfone - 2.5 mg/kg bw/day. (Ref. 12) 
In a 56 day study rats received aldicarb sulfoxide in the diet at dose up 
to 1 mg/kg bw/day and aldicarb sulfone at doses up to 16 mg/kg bw/day. 
There was no mortality, but growth was depressed at the highest dose levels 
with both the sulfoxide and sulfone. Cholinesterase depression was noted 
at the high dose levels, but not at lower doses (0.3 mg/kg bw/day 
sulfoxide, 2.4 mg/kg bw/day sulfone). (Ref. 29) 
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In a 29-day study aldicarb sulfoxide and sulfone in a 1:1 ratio were 
administered to rats via the drinking water. Plasma, erythrocyte and brain 
Cholinesterase activitites were depressed at the high dose (1.7 mg/kg 
bw/day) and the NOAEL was 0.5 mg/kg bw/day. (Ref. 30) 
In a series of dietary studies in rats up to 6 months duration carried out 
to investigate the reversibility of Cholinesterase depression induced by 
aldicarb sulfoxide and sulfone, feeding of control diet for 24 hours 
completely reversed any Cholinesterase inhibition induced by treatment. 
NOAEL's were 0.125 mg/kg bw/day for the sulfoxide and 0.6 mg/kg bw/day for 
the sulfone. (Refs. 31-33) 
In 7-day dietary studies in rats the NOAEL for aldicarb oxime was 62.5 
mg/kg bw/day and the NOAEL for 2-methyl-2-(methylsulfinyl)propanol-l (a 
hydrolytic metabolite of aldicarb) was around 500 mg/kg bw/day. (Refs. 21 
and 34) 
Dogs 
A series of dog studies has been conducted to modern standards with 
aldicarb arid aldicarb sulphone. In 2-week dose range finding studies, 
aldicarb was administered via the diet and the overall NOAEL (based on 
acetyl Cholinesterase inhibition) was around 0.1 mg/kg bw/day. In a one 
year study the NOAEL was about 0.05 mg/kg bw/day. In similar studies with 
aldicarb sulphone the NOAEL was about 2.25 mg/kg bw/day. (Refs. 35-40) 
Monkeys 
As a result of reports of alleged illness associated with consumption of 
watermelons and cucumbers illegally treated with aldicarb in 1985, two 
studies were conducted to evaluate the acute toxicity of aldicarb residues 
in food commodities. Two crops were chosen for the studies: bananas and 
watermelon. Each study was performed using three male and three female 
Cynomolgus monkeys, with an additional group of three males and three 
female monkeys serving as a control (total of twelve animals per study). 
Following analytical determination of actual residues in the two 
commodities to be consumed, (approximately 0.3 ppm in bananas and 5 ppm in 
watermelons), intake of the treated crops was adjusted with control fruit 
to provide a dose of exactly 0.005 mg/kg bw aldicarb equivalent. The 
animals were offered the fruit as the first meal of the day, and consumed 
it immediately. In both studies, there was no evidence of acute 
cholinergic distress or any other signs of toxicity in any animal. 
Depression of plasma Cholinesterase activity was evident within one to four 
hours after ingestion. Erythrocyte Cholinesterase activity was not 
depressed in either study. Rapid recovery of all enzyme activity was 
observed. (Refs. 41 and 42). 
2.3. Long term/Carcinogenicity studies 
Mice 
Groups of 50 male and 50 female B6C3F1 mice (25 of each sex were used as 
controls) were administered aldicarb in the diet at dietary levels of 0, 2 
and 6 ppm for 103 weeks in a carcinogenicity bioassay. There was no 
mortality noted attributable to aldicarb in the diet. Gross and 
microscopic examination of tissues, organs and all gross lesions was 
performed and it was concluded that aldicarb was not carcinogenic for the 
B6C3F1 strain of mice of either sex. (Ref. 43) 
Groups of 44 male and 44 female CD-I mice were fed aldicarb in the diet to 
achieve dosage levels of 0, 0.1, 0.2, 0.4 and 0.7 mg/kg bw/day for 18 
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months. Mortality was evident in males at the two highest dosage levels 
and in females at the three highest dosage levels during the first two and 
a half months of the study. Following this period, aldicarb was admixed 
with the diet in a different manner which appeared to eliminate its acutely 
toxic effects. At the high dosage level in males there was a statistically 
significant increase in hepatomas found predominantly in the survivors at 
the termination of the study. An increase in lymphoid neoplasias occured 
in the mice that died, but none of the male mice surviving at the end of 
the study were found to have lymphoid neoplasias. There were no significant 
increases in any other types of tumors at dosage levels of 0.4 mg/kg and 
below. (Ref. 44) 
Groups of 50 male CD-I mice were fed aldicarb in the diet to achieve dosage 
levels of 0, 0.1, 0.3 and 0.7 mg/kg bw/day in an effort to verify the 
results of the previous mouse carcinogenicity bioassay. A group of 150 
mice were used as concurrent controls with a mouse being sacrificed for 
each treated animal that died during the course of the study. Diets were 
prepared by dissolving aldicarb in acetone and mixing the solution with the 
diet. The aldicarb was the same sample as used in the previous study and 
the duration of the study was approximately the same an in the previous 
trial. There was no mortality observed in the study as a result of 
aldicarb in the diet. At the end of 18 months cumulative mortality at all 
dosage levels was the same as noted in controls. There was no effect of 
aldicarb on growth in any of the groups. There was no significant 
association between aldicarb in the diet and the formation of tumors, 
particularly with respect to the incidence of hepatomas, lung adenomas, and 
lymphoid neoplasias. It was concluded that the administration of aldicarb 
at levels up to and including 0.7 mg/kg bw/day for approximately 18 months 
did not result in a higher than normal incidence of tumors and the 
inclusion of aldicarb in the diet of CD-I mice did not result in an 
increased incidence of carcinogenic response. (Ref. 45) 
Groups of Charles River CD-I mice (50/sex/group) were administered 0, 0.15, 
0.6, 2.4 and 9.6 mg/kg aldicarb sulphone via the diet for 18 months. 
Aldicarb sulphone did not affect tumour incidence or produce any 
pathological alteration in this strain of mouse. (Ref. 46) 
Rats 
Groups of 20 male and 20 female rats were fed aldicarb for two years in the 
diet to achieve dosage levels of 0, 0.005, 0.025, 0.05 and 0.1 mg/kg 
bw/day. There was no mortality over the course of the study attributable 
to the presence of aldicarb in the diet. Growth was normal at all dosage 
levels as was consumption of food and behavioural characteristics. Blood 
and brain Cholinesterase activity, measured at 6 and 12 months, were 
normal. Microscopic examination of tissues and organs for histopathologic 
occurrences and neoplasms showed the incidence of lesions to be similar in 
aldicarb-treated and in control groups. (Ref. 47) 
Groups of 50 male and 50 female F344 rats (25 of each sex were used as 
controls) were administered aldicarb in the diet at levels of 
0, 2 and 6 ppm for 103 weeks. There was no mortality noted attributable to 
aldicarb in the diet. Gross and microscopic examination of tissues, organs 
and all gross lesions was performed and it was concluded that aldicarb was 
not carcinogenic for the F344 strain of rat of either sex. (Ref. 43) 
Groups of 20 male and 20 female rats were fed aldicarb for two years in the 
diet to achieve dosage levels of 0 or 0.3 mg/kg bw/day. In addition, 
groups of rats were fed aldicarb sulfoxide (0.3 or 0.6 mg/kg bw/day), 
aldicarb sulphone (0.6 or 2.4 mg/kg bw/day) or a 1:1 mixture of aldicarb 
sulphoxide and aldicarb sulphone (0.6 or 1.2 mg/kg bw/day). In the initial 
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phases of the study, there was a slightly higher mortality noted in the 
high dosage level of aldicarb sulfoxide and in the group receiving the 
combined aldicarb sulfoxide and aldicarb sulfone. A slight increase in 
mortality was also noted at the latter part of the study with aldicarb 
sulfoxide. Growth was slightly depressed at the high dose level of the 
sulfoxide:sulfone mixture, primarily in males. There were no apparent 
effects on growth with respect to the aldicarb, aldicarb sulfoxide or 
aldicarb sulfone administered alone. Gross and microscopic examination of 
tissues and organs showed that sporadically distributed lesions were not 
considered to be indicative of damage induced by aldicarb, its major 
metabolites, or the combintion of the sulfoxide and sulfone and there was 
no evidence of carcinogenicity. (Ref. 48) 
2.4. Reproduction studies 
2.4.1. Multigeneration studies 
Groups of rats (8 male and 16 female rats per group) were administered 
aldicarb in the diet to achieve doses of 0, 0.05 and 0.1 mg/kg bw/day for 
approximately 90 days and mated to initiate a 3 generation, one litter per 
generation reproduction study. In addition to the reproduction indices 
(fertility, gestation, viability and lactation) the F3 generation was 
maintained for an additional period and tissues from these animals were 
histologically examined at either weaning or at 90 days of age. There was 
no effect on reproductive performance and body weights of both male and 
female pups at weaning were similar to control values as were results of 
gross and microscopic examinations of tissues and organs in the F3 weanling 
and 90 day old animals. (Ref. 49) 
Groups of rats (10 male and 20 female per group) were administered aldicarb 
in the diet to achieve doses of 0, 0.2, 0.3 and 0.7 mg/kg bw/day for 100 
days and mated to initiate an additional 3 generation (one litter per 
generation) reproduction study. A larger group was usee for the F2 
generation (15 male and 25 female rats) as male pups of this generation 
were maintained on aldicarb diets for 148 days and subjected to a dominant 
lethal bioassay. Each female in the group was mated with 2 treated males 
and allowed to maintain pregnancy until day 12 when they were sacrificed 
and examined. At the high dose level, body weights of both male and 
female F2 pups were lower than the control values. Overall, there were no 
effects on any of the reproduction indices (fertility, gestation, 
viability, or lactation). Gross and microscopic examinations of the 
parents and pups of the high level and control groups showed no effects 
attributable to aldicarb. (Ref. 50) 
Aldicarb sulphone (99.76% pure) was administered to groups of 10 male and 
20 female rat via the diet to achieve dosages of 0, 0.6, 2.4 and 9.6 mg/kg 
bw/day for approximately 100 days. Rats were then mated to initiate a 
three generation, one litter per generation, reproduction study. Male rats 
fed 9.6 mg/kg bw/day exhibited reduced body weights. There were no 
differences from the control with regard to fertility, gestation survival 
or viability indices. It was determined that aldicarb sulphone, at levels 
up to and including 9.6 mg/kg bw/day, was without adverse effects on 
reproduction under the conditions of this study. (Ref. 51) 
2.4.2. Teratogenicity studies 
Rats 
Pregnant Sprague-Dawley rats were given aldicarb by gavage at levels of 0, 
0.125, 0.25 and 0.5 mg/kg bw/day on gestational day 6 through day 15. 
Maternal toxicity was indicated, at the highest dose, by reduced weight 
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gain and food intake during the treatment and post treatment period as well 
as by the occurrence of three maternal deaths and at the two highest levels 
by reduced food consumption. Gestational parameters, including ovarian 
corpora lutea, number of implantations per litter and sex ratio were 
unaffected by treatment. Foetal body weight per litter was significantly 
reduced at 0.5 mg/kg bw/day. There was no increase in the incidence of 
external or skeletal malformations. A significantly increased incidence of 
dilated lateral ventricles of the brain was observed only at 0.5 mg/kg 
bw/day. No increased incidence of malformation was observed in the absence 
of clear maternal toxicity nor were these malformations accompanied by more 
severe malformations. The no-observed effect level was 0.125 mg/kg bw/day 
for maternal toxicity and 0.25 mg/kg bw/day for fetotoxicity. (Ref. 52) 
The aldicarb sulphone reproduction study incorporated a teratology 
bioassay. The animals were divided into four groups and orally dosed with 
either 0, 0.6, 2.4 or 9.6 mg/kg bw/day at one of the following time 
intervals of gestation: 0-20 days, 6-15 days, or 7-9 days. All animals 
were sacrificed before parturition (day 20) and the foetuses examined for 
skeletal and visceral changes. Malformations were essentially non-existent 
and there was no indication of structural abnormalities produced under the 
conditions of the study at levels up to and including 9.6 mg/kg bw/day. 
(Ref. 51) 
Rabbit 
Pregnant Dutch Belted rabbits (16/dose) were dosed by oral gavage at 0.1, 
0.25, and 0.5 mg/kg bw/day on days 7 to 27 of gestation. Signs of maternal 
toxicity in the treated groups included small amount of faeces, pale 
kidneys and hydroceles on oviducts. A loss in body weight occurred in the 
0.25 and 0.5 mg/kg bw/day dosage groups during gestation days 7 to 27. A 
decline in the number of viable foetuses per doe was observed in all 
treatment groups (8.7, 5.0, 6.5 and 6.2 for the control, 0.1, 0.25 and 0.5 
mg/kg bw/day treatment groups respectively) . This can be explained by an 
unusually high number of implantations in the control group (9.8, 6.1, 7.2 
and 7.8 implantations per doe in the control, 0.1, 0.25 and 0.5 mg/kg 
bw/day treatment groups respectively). There was clearly no dose-effect 
relationship. There were also no increases in post-implantation losses and 
there was no meaningful difference in any of the other developmental 
parameters nor in the number of developmental variations or 'malfunctions 
between the control and treatment groups. Aldicarb did not produce a 
teratogenic response when administered orally to rabbits by gavage at 
dosage levels up to 0.5 mg/kg bw/day. (Ref. 53) 
2.5. Mutagenicity studies 
Results of genotoxicity tests are summarised in Table 1 and Table 2 (for in 
vitro and in vivo tests with aldicarb) and Table 3 (for in vitro tests with 
aldicarb metabolites. 
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Table Is Results of in vitro genotoxicity assays on aldicarb 
Test System Test Object Concentration Purity Results Reference 
Ames test S Typhimurium 50-5000 pg/plate nk Negative 54 
TA98,TA100,TA1535, 
TA1537,TA1538 
Reverse E.Coli WP2 nk nk Negative 55 
mutation assay 
Reverse S Cerevisiae nk nk Negative 56 
mutation assay 
HGPRT forward CHO cells 1000-5000 pg/ml nk Negative 57 
mutation assay 
SCE Human nk nk Weak Positive 58 
mutation assay lymphocytes 
Cytogenetics Human 10-250 f/g/ml nk Weak Positive 59 
mutation assay lymphocytes 
UDS Rat hepatocytes 0.16-5000 pg/ml nk Negative 60 
DNA damage S Typhimurium >500 pg/disc nk Positive 61 
TA 1538 uvrB-
TA 197 8 
nk: not known 
Table 2: Results of in vivo genotoxicity assays on aldicarb 
Test System Test Object Concentration Purity Results Reference 
Micronucleus Mouse 0.001-0.01 93.47% Negative 62 
test mg/kg bw 
Micronucleus ICR Mouse 0.1-0.4 99.7% Negative 63 
test nig/kg bw 
Dominant Wistar rat 0.2-0.7 99.2% Negative 50 
lethal test 
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Table 3: Results of in vitro genotoxicity assays on aldicarb metabolites 
Test System Test Object Concentration Purity Results Reference 
Ames test S Typhimurium 50-5000 pg/plate nk Negative 64 
TA98,TA100,TA1535, Sulphoxide 
TA1537, TA1538 
Ames test S Typhimurium 100-10000 ¿vg/plate nk Negative 65 
TA98,TA100,TA1535, Sulphone 
TA1537, TA1538 
IIGPRT forward CHO cells 500-1500 pg/ml nk Negative 66 
mutation assay Sulphone 
Cytogenetics CHO cells 50-500 pg/ml nk Negative 67 
mutation assay Sulphone 
UDS Rat hepatocytes 0.1-3000 pg/ml nk Negative 68 
Sulphone 
nk: not known 
2.6. Investigative studies on immunotoxicity 
Aldicarb was evaluated for its ability to modulate the immune response in 
two strains of mice. The B6C3F1 mouse was chosen because it is the strain 
used by the U.S. National Toxicology Program for immunotoxicology studies, 
and the hybrid Swiss Webster mouse was included because aldicarb had been 
reported to suppress the splenic plaque-forming cell response to sheep red 
blood cells in an inverse dose-response fashion (Ref. 69). An attempt was 
made to reproduce these findings and to expand the data base using more 
standardised techniques with the B6C3F1 strain. Aldicarb was administered 
in the drinking water ad libitum for 34 consecutive days to 
female mice of both strains at dosages ranging from 0.1 to 1,000 ppb in 10-
fold increments (equivalent to 0.04 to 364 mg/kg bw/day). Aldicarb had no 
effects on body weights or organ weights, on numbers or types of 
circulating white blood cells, or on the microscopic pathology of the 
thymus, spleen, liver, kidneys, or lymph nodes, or on measures of immune 
function. (Ref. 70) 
In another study, adult female B6C3F, mice received distilled water only or 
water containing 1.0, 10 or 100 ppb of aldicarb daily for 34 days. To 
further develop an immune profile of the compound, following aldicarb 
exposure, the ability of splenic natural killer (NK) cells as well as 
specifically sensitized cytotoxic T-lymphocytes to lyse YAC-1 lymphoma and, 
P815 tumor cells, respectively, were evaluated. The results of this study 
demonstrated that aldicarb did not impact upon the functional ability of 
interieron-induced splenic NK cells to lyse YAC-1 lymphoma target cells. 
In addition, aldicarb had no significant effect on body weights, on spleen 
cellularity or cell viability or on absolute weights of lymphoid organs. 
The absence of statistically significant effects on any of these parameters 
indicated that aldicarb did not have adverse effects on the immune system 
of mice in this experiment. (Ref. 71) 
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2.7. Observations in humans 
Groups of 4 adult male volunteers were administered aldicarb orally in 
aqueous solution at dosage levels of 0.025, 0.05 and 0.1 mg/kg body weight. 
Clinical signs of reaction to treatment were recorded and whole blood 
Cholinesterase activity was measured up to six hours after administration 
of the sample. Total urine voided was collected and aldicarb-excretion 
patterns for the initial eight hours after dosing were evaluated. In 
addition, spot samples were taken at 12 and 24 hours. Acute signs, typical 
of anticholinesterase agents, were observed at the high dose level within 
one hour after administration of aldicarb. There were no signs of reaction 
to treatment observed at the 0.05 mg/kg body weight dose level. 
Cholinesterase depression was observed in all volunteers predominantly 
within 1-2 hours after treatment. Within the first six hours of treatment 
almost all Cholinesterase depression and clinical signs were diminished. 
Examination of urinary excretion patterns showed that approximately 10% of 
the administered dose was excreted as carbamates (toxic residues) within 
the first eight-hour interval. Cholinesterase analyses confimed the same 
rapid inhibition and recovery pattern with man as had been observed in 
experimental animals. (Ref. 72) 
In another study, two additional subjects were administered aldicarb in 
water solution at dosage levels of 0.05 and 0.26 mg/kg body weight. Acute 
signs of poisoning were recorded at the higher dose level and atropine was 
administered to aid recovery. No signs of poisoning were recorded with the 
lower dose level. Urinary excretion of carbamate residues within 24 hours 
accounted for approximately 10% of the administered dose. (Ref. 73) 
A double blind, placebo controlled study has ben conducted, in which 
aldicarb was given as a single oral dose to healthy male and female 
subjects. The doses administered were: placebo (22 subjects - 16 males and 
6 females), 0.01 mg/kg bw (8 males), 0.025 mg/kg bw (8 males and 4 
females), 0.05 mg/kg bw (8 males and 4 females) and 0.075 mg/kg bw (4 
males). Subjects were screened before entry by general medical history and 
examination and laboratory tests including haematology, clinical chemistry 
and urinalysis Clinical measurements were made at intervals before and 
after dosing. These included vital signs, (systolic and diastolic blood 
pressure, pulse rate), pulmonary function tests, pupil size, 
electrocardiographs, salivation and clinical signs of nausea, vomiting, 
diarrhoea, sweating, abdominal cramps, involuntary movement and slurred 
speech. Samples were taken for urinalysis, clinical chemistry (including 
red blood cell and plasma Cholinesterase activity) and haematology 
evaluation before and after dosing. Urine and blood were collected for 
aldicarb analysis. The results of these latter analyses were not reported. 
There were no clinically significant changes in vital signs, pupil size, 
pulmonary function, ECG's, salivation, clinical signs, clinical chemistry 
(apart from Cholinesterase), haematology or urinalysis in the study. 
Cholinesterase activity in red cells and plasma was maximally depressed at 
1 hour after dosing and had recovered by 8 hours in all subjects. The fall 
in activity was dose related. Only marginal depression of Cholinesterase 
activity (<20%) was seen in erythrocytes from patients treated with 0.01 or 
0.025 mg/kg bw and in plasma at 0.01 mg/kg bw. Depression in 
Cholinesterase activity >20% was seen in erythrocytes at 0.05 and 0.075 
mg/kg bw and in plasma at 0.025, 0.05 and 0.075 mg/kg bw. No serious 
adverse events occurred. The minor adverse events which were recorded were 
similar to those reported in other volunteer studies. Only one subject 
(0.075 mg/kg bw group, actual dose 0.06 mg/kg bw) developed symptoms which 
were reported to be related to aldicarb. The meeting concluded that the no 
adverse effect level in this study should be based on depression (>20%) in 
erythrocyte Cholinesterase activity. The NOAEL was thus 0.025 mg/kg bw. 
(Ref. 74) 
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Several misuses of aldicarb on watermelons and cucumbers have been reported 
in the literature. Goes, et al, (1980, Ref. 75) reported on a suspected 
food-borne intoxication in Nebraska associated with the consumption of 
aldicarb contaminated hydroponically grown cucumbers. Two episodes were 
reported (April 1977: 9 cases; July 1978: 5 cases). Neither Cholinesterase 
determinations nor urine residue determinations were performed in any of 
these patients. Four cucumbers (two in the supermarket and two in the 
greenhouse were analysed and aldicarb content was 6.6 and 10.7 ppm 
(supermarket) 0 and 9.9 ppm (greenhouse). No data are available on 
cucumbers actually eaten and no attempts to correlate symptoms and aldicarb 
consumption were made. 
Hirsch, et al, (1987, Ref. 76) reported over 300 alleged intoxications in 
Canada following ingestion of aldicarb contaminated cucumbers (residue 
levels up to 26 ppm).' In only five cases involving 13 patients, were any 
remaining portion of the cucumbers consumed still available for analyses. 
Goldman (1990, Ref. 77) reported on four outbreaks of aldicarb poisoning 
having occurred in California and other states in the USA from 1978 to 
1988. 
Outbreak 1 : watermelons, 1985 
Outbreak 2 : watermelons, 1987 
Outbreak 3 : cucumbers, 1988 
Outbreak 4 : cucumbers, 1978 (corresponds to Ref. 75) 
In the first outbreak, 1376 people were allegedly ill due to consumption of 
contaminated watermelons. Of this total, 308 were considered by the 
authors themselves as unlikely (235) or incomplete (73). From the 
remaining cases only 28 were supported by positive findings of aldicarb 
residues in the food commodity. All the other cases were only supported by 
self diagnosis. 
An epidemiologic study of potential adverse health effects of aldicarb 
metabolites in drinking water was made by the South Carolina Pesticides 
Hazard Assessment Program Center. In two surveys conducted on Long Island, 
New York, the major cohorts were selected on the basis of aldicarb levels 
in their drinking water. Levels of contamination were generally 4-12 ppb, 
but a maximum of 400 ppb was reported. Questionaires to determine water 
and food consumption, symptoms experienced, and diagnosed illnesses were 
sent to 1,035 residents of 462 households. Although the initial survey 
indicated a possible association between the incidence of diarrhea and 
levels of aldicarb in the water, the follow-up study, focusing on children, 
did not confirm this association. No relationship was detected between 
food consumption or water source and adverse health symptoms, and self-
reported physician-diagnosed illnesses for 1974-1979 were not significantly 
related to levels of aldicarb in the water. (Ref. 78) 
Another survey attempted to relate self-reported symptoms suggestive of 
peripheral neuropathy to aldicarb levels in drinking water in Suffolk 
County, Nev: York. The response rate was less than 20%. Responses were 
classified as "probably", "possibly", or "vaguely" suggestive of a 
neurologic syndrome. A significant correlation with aldicarb concentration 
was obtained only by combining all three categories of response, including 
reports of just one symptom or of symptoms not forming any cohesive 
syndrome. The authors concluded only that further study was needed. (Ref. 
79) 
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A pilot epidemiological study by Fiore, et al, (1986, Ref. 80) evaluated a 
wide range of clinical immunological parameters in 23 women exposed to 
aldicarb in their drinking water and in a non-exposed control group. The 
groups did not differ in any immunological parameters except in T8-
Lymphocytes: the number was considered as elevated in five exposed and in 
one control. Observation of an elevated stimulation assay response to one 
of the large number of antigens (Candida) was not considered as 
toxicologically significant, nor was it attributed to aldicarb exposure. 
In a follow up study, five women of the preceeding group and still exposed 
to aldicarb were examined versus previous control women plus women 
previously exposed but for whom exposure no longer occurred (e.g. change in 
water supply due to addition of a charcoal filter). According to the 
authors, this follow-up study confirmed the previous results, except for 
increased response to Candida antigens which was no longer present. (Ref. 
81) 
T0XIC0LOGICAL OVERVIEW AND ESTIMATION OF ADI 
Aldicarb is a carbamate insecticide which inhibits acetylcholinesterase in 
a quickly reversible manner. Following administration to animals, aldicarb 
is rapidly absorbed, widely distributed in the body and rapidly excreted. 
Metabolism appears to be similar in all animal species and in plants, 
aldicarb being rapidly metabolised to aldicarb sulphoxide, which is more 
slowly degraded to aldicarb sulphone. Consumers of treated crops are 
exposed to residues which consist largely of the sulphoxide and the 
sulphone, with a minor residue of parent aldicarb. 
Aldicarb has high acute toxicity in a wide variety of mammalian species and 
the signs of toxicity are those commonly associated with 
acetylcholinesterase inhibition. Although aldicarb sulphoxide is of 
approximately equivalent acute toxicity to aldicarb itself, aldicarb 
sulphone is some 20 to 50 times less acutely toxic than either aldicarb or 
the sulphoxide. 
Short term and long term studies have been performed in rats, mice and dogs 
with aldicarb and aldicarb metabolites, both alone and in combination. As 
would be expected, acetylcholinesterase depression is the most significant 
indicator of toxicity that can be evaluated. However, this Cholinesterase 
depression is quickly reversible and careful attention must be paid to the 
methods of sample collection and determination of Cholinesterase activity. 
Continuous administration of aldicarb to the test animals until collection 
of samples for analysis is important, as is rapid analysis under carefully 
controlled conditions. Since these precautions were not followed in many of 
the earlier repeat dode studies, it is considered inappropriate to utilise 
NOAELs from these studies in derivation of an ADI. In acceptable one year 
dog studies performed to modern standards, NOAELs (based on 
acetylcholinesterase inhibition) were around 0.05 mg/kg bw/day for aldicarb 
and 2.25 mg/kg bw/day for the sulphone. 
Carcinogenicity studies in rats and mice with aldicarb and its metabolites 
revealed no indication of any carcinogenic potential. Similarly, from the 
results of a wide variety of genotoxicity tests, it was concluded that 
aldicarb is not genotoxic. 
In multigeneration studies in rats there were no effects on reproductive 
performance at the highest doses tested of 0.7 mg/kg bw/day aldicarb or 9.6 
mg/kg bw/day aldicarb sulphone. Aldicarb did not display any teratogenic 
potential in rats or rabbits in studies which included maternally toxic 
doses. 
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There was no evidence for immunotoxicity of aldicarb in mice in a number of 
functional assays of cell mediated immunity and in host resistance to 
respiratory infection. Epidemiological studies provided no evidence that 
aldicarb could significantly alter immunological parameters in man. 
The anticholinesterase potential of aldicarb has been extensively 
investigated in humans. These studies revealed the same pattern of rapid 
blood Cholinesterase inhibition and rapid recovery seen in experimental 
animals. In a recent double-blind placebo-controlled study, transient 
erythrocyte Cholinesterase depression was seen at 0.05 mg/kg bw, and the 
NOAEL for Cholinesterase depression (discounting changes in plasma enzyme 
only) was 0.025 mg/kg bw. 
There have been a number of food-related aldicarb poisoning incidents in 
humans reported in the literature. These have all been associated with 
misuse of aldicarb and reliable quantification of the dose of aldicarb 
involved has always proved difficult, if not impossible. It was concluded 
that these reports provide no reason to discount the results of controlled 
experiments in animals and man. 
An ADI may be allocated using a 10-fold safety factor applied to the no 
observed adverse effect level for depression of erythrocyte Cholinesterase 
activity in human volunteers, giving an ADI of 0.003 mg/kg bw. 
In comparing this ADI with consumer exposure to aldicarb residues there are 
a number of important factors which must be borne in mind: 
- The toxicity of aldicarb is quickly reversible, and there are no 
known cumulative effects. Consumer exposue therefore amounts to 
repeated acute exposures and it follows that food intake figures used 
in exposure estimations should be based on single "meal-sized" 
portions, rather than average "life-time" figures. 
For the same reason, since it is possible that residues of aldicarb 
and its metabolites in individual tubers/fruits can be variable, 
relevant residues data, based on individual tuber/fruit measurements, 
rather than overall bulk estimates, should be used in estimation of 
consumer exposure to aldicarb and its metabolites. 
- The identity of the exact residue is important. Measurements usually 
combine parent aldicarb with the sulphoxide and the sulphone. Where 
exposure to this total residue exceeds, or is close to the ADI, 
differentiation of the sulphone could provide valuable information, 
since the sulphone is some 20 to 50 times less toxic than aldicarb or 
the sulphoxide. 
- A brief review of the available residues data has indicated that the 
required level of detail may currently not be available. However, it 
is likely that the sulphone is a major component of the residue in 
foodstuffs, particularly in potatoes and bananas where agricultural 
practice generally involves long intervals between application and 
harvest. Therefore, where consumer exposure is close to the ADI, it 
is considered appropriate to allow use of aldicarb to continue while 
the required residue data are generated. 
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SUPPLEMENTARY REPORT OF THE SCIENTIFIC COMMITTEE FOR 
PESTICIDES ON THE TOXICITY OF ALDICARB 
(Residue intake resulting from consumption of potatoes and bananas) 
(Opinion expressed by the SCP on 26 January 1995) 
BACKGROUND AND TERMS OF REFERENCE 
Aldicarb is a soil-applied, systemic carbamate insecticide and nematicide used in a wide 
variety of agricultural crops and in horticulture. In the context of its work relating to the 
establishment of community maximum pesticide residue levels in various foodstuffs covered 
by community legislation, the Commission requested the Scientific Committee for Pesticides 
to review the toxicity of aldicarb, with a view to establishing an Acceptable Daily Intake and 
commenting particularly on principles to be used in the risk evaluation for consumer 
exposure to aldicarb resulting from use on bananas and potatoes. This work was published in 
the Committee's opinion expressed on 26 January 1993. 
After publication of this document the Commission requested the Scientific Committee for 
Pesticides to review the potential consumer exposure to aldicarb resulting from use on 
bananas and potatoes, and comment on these intakes in relation to the Acceptable Daily 
Intake proposed in the Committee's opinion of 26 January 1993. 
1 RESIDUE LEVELS 
There are proposed EU MRLs for aldicarb on potatoes, at 0.5 mg/kg, and bananas, at 
0.3 mg/kg. However, as stated in the Committee's previous opinion, it is possible that these 
levels do not represent the correct residue levels to use for risk assessment purposes. This is 
because the MRLs are based on analysis of residue levels in bulk samples of commodity and 
it is possible that residues of aldicarb and its metabolites in individual tubers or fruits have a 
greater variability than for bulk samples. Since the toxicity of aldicarb is acute and quickly 
reversible, it is important to be able to calculate the residue intake resulting from specific 
exposure events. Relevant residues data to perform these intake estimations should therefore 
be based on individual tuber or fruit residue levels. 
As stated in the Committee's previous opinion, the exact identity of the residue may be 
important. Residue determinations usually combine parent aldicarb with the sulphoxide and 
sulphone metabolites. Although the sulphoxide is of similar toxicity to aldicarb itself, the 
sulphone is some 20 to 50 times less toxic. Differentiation of any sulphone component in the 
residue could therefore provide valuable additional information for risk assessment purposes. 
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1.1 Residue levels in potatoes 
Application rates for aldicarb by broadcast appplication on potatoes vary widely in different 
member states (e.g. Belgium 1 kg/ha, Spain and Netherlands 3 kg/ha, UK and Ireland 3.36 
kg/ha), all applications are at planting. As an alternative to these broadcast applications, 
there is some aldicarb applied 'in furrow' at planting in the UK, at a rate of up to 12.8 
g/100m. Based on these application rates and considering that other differences in 
agricultural practice and climate ought not to affect residue levels markedly, it is concluded 
that agricultural practice in the UK ought to give rise to the highest residues. Assessments of 
consumer intake can therefore be based on residues data relevant to the UK conditions of 
use. 
Results from trials in the UK revealed that residues in composite samples were 
0.3-0.35 mg/kg for early potatoes treated by broadcast application, or <0.05-0.1 mg/kg for 
maincrop potatoes using in furrow treatment. These data support the MRL of 0.5 mg/kg. 
Where analysis of individual tubers was carried out (in early potatoes), residues were 
detected at levels of 0.02-0.76 mg/kg. Where samples were analysed for the individual 
components of the residue, no residue of aldicarb was detected and the residue consisted of 
approximately 78% aldicarb sulphoxide and 22% aldicarb sulphone. 
Potatoes are a commodity which are never eaten in the raw state, and thus it is valid to 
consider the possibility of reductions due to cooking or processing. Processing and cooking 
studies have been conducted with potatoes. The results showed that residues will degrade 
(compared to the raw agricultural commodity) depending on the procedures utilised. Results 
of these studies showed that aldicarb residues are reduced in preparation of potato chips 
(crisps) (17-99%), French fries (25-44%), hash browns (70-76%), canning (50-80%), oven 
baking (53-80%) and boiling (18-88%). Washing and peeling reduced residues by 55-100%. 
Commercial abrasion peeling reduced residues by 15-36%. Microwave baking showed only 
minor or no reduction. The great variability in these reduction factors hampers their general 
application in risk assessment. 
1.2 Residue levels in bananas 
In contrast to the agricultural practice in potatoes, aldicarb is applied to bananas around the 
base stem of the growing plant. Residues in banana fruits arise from root uptake, followed by 
transfer via sap and distribution within the plant. Consequently the residues are more closely 
related to the rate applied and the time between treatment and harvest. Agricultural practice 
in different member states is similar with application rates of 2g per tree and pre-harvest 
intervals of 100-120 days. Results from relevant trials revealed that residues in composite 
samples were 0.05-0.37 mg/kg. These data support the MRL of 0.3 mg/kg. The registrant 
has recently proposed changing this pre-harvest interval, to a minimum of 180 days and they 
propose that this modification leads to a change in the MRL from 0.3 mg/kg to 0.1 mg/kg. 
Very few trials are available for a pre-harvest interval of 180 days, but the limited data 
available revealed residues generally around 0.01 to 0.07 mg/kg, supporting an MRL of 0.1 
mg/kg. The registrant recognises that the residues results on bananas at the new proposed 
pre-harvest interval of 180 days is limited and they are reportedly in the process of 
developing protocols to conduct additional trials to generate further data to support this 
extended pre-harvest interval. 
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The variability of residues in bananas taken individually has been considered in some residue 
trials. The results showed minimal variability between different fruits from the same bunch, 
but more variability between different bunches. The results indicate that the residue 
concentration in individual banana samples is never more than about 2.25 times the residue 
concentration determined for composite samples. In the recent residue trials the analytical 
methodology permitted separate quantification of parent aldicarb and the sulphoxide and 
sulphone metabolites. These results show that the residue is essentially composed largely of 
the sulphoxide. The sulphone is occasionally detected and parent aldicarb is virtually never 
found above the quantification limit. 
Processing and cooking trials are not applicable for a commodity such as bananas, which are 
essentially always consumed raw. However, it is important to look at the variation in the 
residue levei between the fruit pulp and the peel, since the peel is hardly ever consumed. 
Relevant residues data are available and show that there is a trend for the residue 
concentration in the peel to be higher than that in the pulp, but these differences are small. 
For the purposes of consumer risk assessment it may be assumed that the concentration in the 
pulp is the same as that determined in the whole fruit. 
2 CONSUMPTION OF POTATOES AND BANANAS 
As stated in document 6254/VI/92 the toxicity of aldicarb is quickly reversible, and there are 
no known cumulative effects. Consumer exposure therefore amounts to repeated acute 
exposures and it follows that food intake figures used in exposure estimations should be 
based on single "meal-sized" portions, rather than average "life-time" figures. The following 
evaluation is directed towards assessing which consumption habit would be expected to lead 
to the highest intake of residues in different sectors of the general population and then 
evaluating the relevant data available for that situation. 
2.1 Consumption of potatoes 
It is evident from the data presented in section 1.1 that processing and cooking reduction 
factors have a large effect on the intake of aldicarb residues from potatoes. Microwave 
baking has no associated reduction factor, and hence it follows that this situation should lead 
to the highest residue intake. Microwave baking should be considered to be used for all age 
groups of the population, but is restricted to maincrop potatoes. 
New potatoes are also consumed by all age groups of the population, these generally have 
slightly higher residues than maincrop potatoes, but are generally always cooked by boiling, 
with an associated reduction factor. 'Microwave boiling' (microwave cooking using a small 
quantity of water in a.sealed container) is a preparation method increasingly being used for 
new potatoes. No reduction factor data are available for this preparation method. 
Typical consumption values (taken from UK MAFF food portion size database) are presented 
below: 
Baked potatoes (with skin): Small: 100g 
Medium: 180g 
Large: 220g 
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Boiled new potatoes: Small portion: 120g (3 average tubers) 
Medium portion: 175g (4-5 average tubers) 
Large portion: 220g (5-6 average tubers) 
In this assessment it has been assumed that small portions of potatoes are consumed by 
infants, that a medium baked potato, or medium portion of boiled new potatoes might be 
consumed by a 30 kg child, while the large portion sizes are restricted to 60 kg adults. 
2.2 Consumption of bananas 
There are no reduction factors relevant for the consumption of bananas treated with aldicarb 
and bananas are consumed by all age groups of the population. Bananas are, however, 
always peeled prior to consumption, so the consumption figures must relate to weight 
without skin. Typical consumption values (taken from UK MAFF food portion size 
database) are presented below: 
Bananas (without skin): Small: 
Medium: 
Large: 
80g 
100g 
120g 
In this assessment it has been assumed that a two large bananas might be consumed at a 
single sitting by an adult, child or infant. 
3 ACCEPTABLE INTAKES OF ALDICARB 
The ADI for aldicarb, an anticholinesterase carbamate insecticide, has been established at 
0-0.003 mg/kg bw. This is based on the NOAEL for erythrocyte acetylcholinesterase 
depression in a single dose, double blind, placebo controlled, human volunteer study, which 
was 0.025 mg/kg bw. 
When performing risk assessments for 'acute' or 'meal sized' consumer exposure it has been 
questioned whether the ADI (which assumes daily exposure throughout life) is the correct 
toxicological comparison. It has been argued that single doses might be tolerated at higher 
dose levels than multiple repeated doses, or that different aspects of the toxicological 
database may become crucial when only short term administration is considered. 
Aldicarb was found not to be carcinogenic or teratogenic and did not cause toxicities other 
than the cholinergic syndrome. In contrast to many other pesticides, a single dose human 
volunteer study is considered appropriate for use in establishing the ADI since the 
Cholinesterase inhibition caused by aldicarb is rapidly reversible and any chronic exposure to 
aldicarb may be considered as a series of repeated acute exposures. The establishment of an 
acute reference dose for aldicarb, in addition to the ADI, is considered below, by reference to 
data summarised in previous evaluations of aldicarb performed by the SCP and by the JMPR 
3.1 Animal data on acute and short term toxicity of aldicarb and aldicarb metabolites 
The acute oral LD50 of aldicarb is around 0.5-1.5 mg/kg bw in rats, mice, guinea pigs and 
rabbits. There are no data in other species and from the available data it is not possible to 
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establish effect and no effect dose levels. Aldicarb sulphoxide has a similar acute toxicity to 
aldicarb itself, but the acute oral LD50 of aldicarb sulphone is around 20-75 mg/kg bw. 
In short term dietary administration (up to 7 days) rats can tolerate dietary levels of aldicarb 
equivalent to 4 mg/kg bw/day without mortality. Investigations of Cholinesterase activity in 
these rat studies were considered not adequate to determine effect and no effect levels. In 
two small 2 week studies in beagle dogs (which included acceptable investigations of 
Cholinesterase activity), the overall no adverse effect level for clinical signs of cholinergic 
toxicity and Cholinesterase inhibition was 10 ppm (0.32 mg/kg bw/day). Erythrocyte 
Cholinesterase was inhibited at 10 ppm (>25%), but brain Cholinesterase remained unaffected. 
In a similar study with aldicarb sulphone, the no adverse effect level for clinical signs of 
cholinergic toxicity was 100 ppm (3.2 mg/kg bw/day) while the no adverse effect level for 
brain Cholinesterase activity was 30 ppm (0.96 mg/kg bw/day). 
Groups of 3 male and 3 female cynomolgus monkeys were fed treated fruit (bananas and 
watermelons) to give a single dose of 0.005 mg aldicarb/kg bw. There were no clinical signs 
of reaction to treatment and although plasma Cholinesterase activity was depressed by about 
35%, erythrocyte Cholinesterase activity remained undisturbed. 
3.2 Human data on acute toxicity of aldicarb 
Groups of 4 adult male volunteers were administered aldicarb orally in aqueous solution at 
dose levels of 0.025, 0.05 or 0.1 mg/kg bw. Clinical signs of cholinergic intoxication were 
observed at 0.1 mg/kg bw, within 1 hour of dosing and whole blood Cholinesterase activity 
was depressed in all subjects. All Cholinesterase depression and clinical signs of reaction to 
treatment reversed within 6 hours of dosing. 
In another study 2 subjects were administered aldicarb orally in aqueous solution at dose 
levels of 0.05 or 0.26 mg/kg bw. Acute signs of poisoning were recorded at the higher dose 
level. 
In a double blind, placebo controlled study aldicarb was given as single oral doses to groups 
of male and female volunteers, as follows: placebo, 16 males and 6 females; 0.01 mg/kg bw, 
8 males; 0.025 mg/kg bw, 8 males and 4 females; 0.05 mg/kg bw, 8 males and 4 females and 
0.075 mg/kg bw, 4 males. Depression of erythrocyte Cholinesterase activity (>20%) was 
seen at 0.05 and 0.075 mg/kg bw. Only one subject (0.075 mg/kg bw group, actual dose 
0.06 mg/kg bw) developed symptoms which were reported to be related to aldicarb. 
3.3 Assessment 
The ADI for aldicarb was established on the basis of the no adverse effect level for inhibition 
of erythrocyte acetylcholinesterase activity in the human volunteer study. Using a safety 
factor of 10, this gives an ADI of 0.003 mg/kg bw. Since this human volunteer study was a 
cingle dose experiment it can be concluded that exactly the same no effect level and safety 
factor should be used to derive the acute reference dose. 
The animal data on the toxicity of aldicarb and aldicarb metabolites indicates another area 
which ought to be considered in the acute dietary risk assessment for aldicarb. The 
sulphoxide and the sulphone are plant and animal metabolites of aldicarb, which are generally 
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included in the measured total residue of aldicarb. If residue data are available which can 
differentiate the sulphone from the other components of the residue then these data may 
enable further refinement of the risk assessment, since the sulphone is some 10-20 times less 
toxic than the parent aldicarb. 
4 POTENTIAL HIGHEST INTAKES OF ALDICARB 
4.1 Intake from potatoes 
The highest potential intakes have been calculated for adults, children and infants for two 
different consumption patterns. These involve consumption of a single baked potato (which 
may have a residue at the highest level recorded for a single tuber) or consumption of a large 
portion of new potatoes (where one tuber could have a residue at the highest level recorded 
for a single tuber, while other tubers in the portion have residues at the MRL). This process' 
could be considered to result in an over-estimate of aldicarb intake, since it is unlikely that a 
number of fibers would all have residues at the MRL. A more likely scenario would have one 
tuber containing a residue at the highest level recorded for a single tuber, while other tubers 
in the portion have residues at the mean residue recorded in the trials. No processing 
reduction factors have been included since it has been assumed that the maincrop potatoes 
may be microwave baked, and the new potatoes may be microwave boiled. However, if 
these intakes are to be compared with the acute reference dose for aldicarb, a 'reduction' 
factor could be allowed for the content of aldicarb sulphone in the terminal residue. If it is 
assumed that the residue consists of 80% parent and sulphoxide and 20% sulphone, then it 
may be possible to reduce the intakes to 80% of their original value. The resultant intakes 
are tabulated below: 
Commodity/ 
Population subgroup 
Maincrop potatoes 
Adults (60 kg) 
Children (30 kg) 
Infants (15 kg) 
New potatoes 
Adults (60 kg) 
Children (30 kg) 
Infants (15 kg) 
Residue 
(mg/kg) 
0.76 
0.76 
0.76 
0.552 
0.565 
0.587 
Consumption 
(R) 
220 
180 
100 
220 
175 
120 
Intake 
(mg) 
0.167 
0.137 
0.076 
0.121 
0.099 
0.070 
Intake^) 
(mg/kg bw) 
0.003 
0.005 
0.005 
0.002 
0.003 
0.005 
IntakeW 
(mg/kg bw) 
0.002 
0.004 
0.004 
0.002 
0.002 
0.004 
(a): No allowance for sulphone content 
(b): With allowance for sulphone content 
4.2 Intake from bananas 
The highest potential intakes have been calculated for adults, children and infants for one 
consumption pattern. This involves consumption of two large bananas at a single sitting. No 
change is made in this consumption figure for different population subgroups. Although this 
may seem very large for infants and children, this intake is considered to be possible. The 
caculation assumes a residue at the current MRL. Although no allowance is made for the 
possibility of residues in individual fruits being higher than the MRL, this is offfset by 
proposals to change agricultural practice in a manner intended to reduce residues such that an 
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MRL may be proposed at 0.1 mg/kg. In contrast with the situation for potatoes, there is no 
-possibility of using a 'reduction' factor for any sulphone component in the terminal residue in 
bananas. The resultant intakes are tabulated below: 
Population subgroup Residue Consumption Intake Intake 
(mg/kg) (g) (mg) (mg/kg bw) 
Adults (60 kg) 0.3 240 0.8 0.013 
Children (30 kg) 0.3 240 0.8 0.027 
Infants (15 kg) 0 3 240 OS 0.053 
4.3 Intake from potatoes and bananas combined 
Although it is considered feasible to assume that potatoes and bananas may be consumed at a 
single 'meal time' sitting, it is considered not appropriate to combine the overtly large portion 
sizes used in the calculations for the single commodities alone. Intakes have been combined 
for consumption of an 'average' portion of potatoes with one banana. The resultant intakes 
are tabulated below: 
Population subgroup Intake from potatoes Intake from bananas Combined intake 
(mg/kg bw) (mg/kg bw) (mg/kg bw) 
Adults (60 kg) 0.0016 0.0065 0.0081 
Children (30 kg) 0.0023 0.0135 0.0173 
Infants (15 kg) 0.0039 0.0265 0.0304 
5 RISK ASSESSMENT 
It is evident that the highest potential intakes can exceed the acute reference dose, 
particularly in children and infants. It is also obvious that the potential intake from bananas 
far exceeds the intake from potatoes. The highest intake from'bananas varies from 0.013 
mg/kg bw (in adults) to 0.053 mg/kg bw (in infants). These intakes can be compared not 
only with the acute reference dose of 0.003 mg/kg bw, but also with the results of the human 
volunteer studies which indicate that although clinical signs of intoxication were clearly seen 
at doses of 0.1 and 0.26 mg/kg bw, only very minor signs were seen at 0.06 mg/kg bw, and in 
all cases the signs were reversible. It should also be noted that even if the MRL for bananas 
is reduced to 1 mg/kg and this figure were used in the intake calculations, the resultant 
potential intakes would still be in excess of the reference dose. 
Since the individual occurence of these intakes is without adverse, lasting sequelae, the real 
significance of the intakes is therefore governed by the probability of these intakes actually 
occuring in real life. In this analysis data relating to food consumption and residue level have 
been represented by single numbers, erring on the side of caution (using large portion sizes 
and MRLs). It is known that these data points are continuous variables and information is 
available to characterise the distribution of residue and food intake data. Use of statistical 
modelling techniques should enable information to be obtained about the distribution of the 
resultant aldicarb residue intake. 
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REPORT OF THE SCIENTIFIC COMMITTEE FOR PESTICIDES 
ON THE TOXICITY OF CYHEXATIN 
(Opinion expressed by the SCP on 26 January 1993) 
Background 
The toxicology of cyhexatin has been evaluated by the JMPR during 1970-1985. In 1980 an 
ADI of 0.008 mg /kg b.w. was allocated. In 1988 cyhexatin of Dow Chemical was withdrawn from 
the market because of teratogenic effects in rabbits after oral and dermal exposure. Since there 
were other manufacturers of cyhexatin, which supplied additional data, the teratogenicity and 
reproduction aspects were evaluated by the JMPR in 1989 and 1991. On basis of one two-
generation reproduction study with an NOAEL of 0.1 mg/kg b.w. the ADI was lowered to 0.001 
mg /kg b.w. Since azocyclotin (which has not been found teratogenic at dose levels up to 1 
m g / k g b.w.) gives cyhexatin as the main residue In crops the ADI of azocyclotin was also lowered 
to 0.001 m g / k g b.w. 
The EC Commission has requested to review the relevant reproduction studies and comment 
on the recent JMPR conclusions. 
Absorpt ion, d istr ibut ion and excretion 
In rats blood levels of tin following oral administration of cyhexatin peaked in 3-4 hours and 
then declined almost to control values in 24 hours. An oral study in rats using technical and 
micronized cyhexatin resulted in peak blood levels of tin at 3 hours w'rth technical material and 4 
hours with micronized material. Levels with micronized material were higher than those with 
technical material. Dermal exposure of rabbits resulted in similar blood levels of tin with both 
technical and micronized material. Peak values in blood were found at 8 hours in both cases 
(WHO/JMPR, 1991). 
In pregnant rabbits, receiving 3.0 mg technical cyhexatin kg/b.w/day orally on gestation days 
6-18, peak maternal blood tin levels were achieved about 3 hours after dosing. Tin half-life in 
maternal blood was 8.17 hours. Tin levels in amniotic fluid, placentae, and pups were significantly 
increased on day 19. Tin levels in pup brains were also elevated. By day 2G, tin levels in treated 
animals were comparable to those in controls, except in brain where levels were slightly elevated. 
On day 19 mean pup weights were comparable to controls, but they were reduced by day 20 
(WHO/JMPR. 1991) 
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Studies on reproduct ion 
Oral studies 
Ral 
In a two generation study groups of 30 Sprague-Dawley rats/sex were fed diets yielding dose 
levels of 0, 0.1, 0.5, or 6.0 mg cyhexatin (purity 95.6%)/kg b.w./day, for the duration of a two-
generation sludy. In the first generation one litter (F ]a) and in the second generation t/vo litters 
(F2a and F2b) were bred. Observations included clinical signs, mortality, body weight, food 
consumption, mating performance and reproductive parameters. Parents were observed for gross 
and histopalhology. Pups were sexed, weighed and observed for gross abnormalities. 
Body weight of F0 parents was decreased at 6 mg/kg in males and at 0.5 and 6 j n g / k g in 
females. In F, parents body weight gain was depressed at 6 mg/kg in both sexes. Food intake in 
F0 was slightly decreased in both sexes at 6.0, in females at 0.5 and in F, males at 6 mg /kg . 
Gross pathology of F0 and F, parents showed decreased abdominal fat and dark livers of both 
sexes at 6 mg/kg . Histopalhology showed increased bile duct hyperplasia and periductular 
inflammation, as well as reduced hepatic glycogen in both sexes at 6.0 mg/kg. In the F1a, F2a and 
F2b breeding pup weight gain was depressed at 6 mg/kg. In the the F2a and F2b breeding a slight 
decrease in pup survival was noted at 6 mg/kg . The NOAEL for this study appears to be 0.1 
mg/kg b.w. with some indication of decreased F0 female body weight gain at 0.5 m g / k g b.w. (It 
should be noted that nc detailed individual data were available except those on histopathological 
examination) (Breslin et al, 1987). 
A second two-generation study has been reported. In this study two generations were studied 
with one litter in the first genoration and 2 litters in the second generation. The second of these 
litters (F2b) was terminated prior to parturition and examined following ceasarian section. Groups 
of 25 OFA SD rats/sex/dose level were fed diets containing 0, 10, 30 or 100 ppm micronized 
cyhexatin (purity 95%)/kg b.w. All litters were culled to 8 (4/sex where possible) on day 4 post-
partum. 
Observaiions were made for clinical signs, mortality, body weight, food consumption, mating 
performance, reproductive parameters. Pups were sexed, weighed and observed for gross 
abnormalities. 
Body weight gain of all FQ females showed a dose related decrease (significant at 30 and 100 
ppm). Weight gain of FQ males was only decreased al 100 ppm. In the F,a females and males 
body weight gain was reduced in all groups (significant at 30 and 100 ppm). Food consumption 
was reduced in F0 and F, parents at 30 and 100 ppm. In the FQ-F la reproduction phase the 
number oí females with live pups was reduced at 100 ppm as were gestation, viability and 
weaning indices. Total litter loss v/as found in 0, 2, 3 and 4 rats at 0, 10. 30 and 100 ppm. Survival 
lo weaning was reduced in 30 and 100 ppm and pup weights at weaning also showed a dose 
relaled reduclion at 30 and 100 ppm. Liner size and implantations/dam were reduced at 100 ppm. 
Pup eye opening was delayed by about 2 days in the 100 ppm group. In the F,-F2a breeding the 
pre-coital interval between pairing and mating was increased at 100 ppm, but v/as still within one 
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oestrus cycle. At 100 ppm litter size and implants/dam were reduced, incidence of stillbirths was 
slightly increased and pup survival to weaning was decreased. During lactation pup weight gain 
was markedly reduced at 100 ppm and slightly reduced at 30 ppm. Eye opening and incisor 
eruption were delayed at 30 and 100 ppm. At day 21 pupillary reflex was absent in 7 pups from 4 
litters. 
In the F2 b the number of corpora lutea was reduced at 100 ppm. The only malformation in 
this study occurred at 30 ppm (cleft palate and thoracic blood vessel effects). This Is not 
considered as a substance related effect. Uterine dilation and torsion at 100 ppm were increased 
but were within historical control values. Skeletal variants showed an increased incidence of 
sternal ossification defects at 30 and 100 ppm but the incidence of asymmetric sternebrae was 
decreased. There was no evidence of an irreversible structural effect. The NOAEL in this study is 
considered to be 10 ppm, equivalent to 0.5 mg/kg b.w./day (Barrow, 1990). 
Studies on teratology 
Oral studies 
Rat 
Four groups of 30 pregnant Sprague-Dawley rats received day 6 through 15 of gestation by 
■> gavage 0, 0.5, 1.0 or 5.0 mg cyhexatin (purity 95.6%)/kg bw/day suspended in corn oil. On day 
20 of gestation the animals were sacrificed. 
Slight maternal toxicity was observed at 5.0 mg/kg. Microphlalmia was observed in 1, 2 and 
2 (2) fetuses (litters) at 0.5, 1.0 and 5.0 mg/kg , respectively. Tail anomalies (short, short and 
thread-like or short and bent) were observed in 1, 0 ,1 and 3 (3) fetuses (litters) at 0, 0.5, 1.0 and 
5.0 m g / k g b.w., respectively. One fetuses at 5 mg/kg had fused skull bones. The occurrence of 
25 or 27 pre sacral vertebrae was observed at 5 mg/kg in 6 (6) fetuses (litters). The NOAEL is 
considered to be 1.0 mg /kg b.w. based on fetotoxicity (Aldridge, et al 1986). 
Rabbit 
In a probe study groups of 7 pregnant NZW rabbits received day 6 through 18 of gestation 
by gavage 0. 5, 10 or 20 mg cyhexatin (purity not given)/kg b.w./day suspended in corn oil. 
During dosing period 2, 7 and 7 rabbits died at 5, 10 and 20 mg/kg, probably due to wrong 
dosing because lesions in the trachea and lungs were present. The surviving animals had stomach 
erosions or ulcers. Four of the 5 surviving rabbits at 5 mg/kg had resorptions (Berdasco et al. 
1986). 
In a second probe study groups of 7 rabbits of the same strain were dosed wild 0, 1, 5 or 10 
mg cyhexatin/kg in 0 5% aqueous Melhocel on days 7 through 19 o( gestation. Again mortality 
occurred. 2, 1 and 1 deaths at 1, 5 and 10 mg/kg , but there were no indications lor mislubing 
Stomach erosion/ulcers were observed in one animal at 5 mg/kg and in 4 at 10 mg /kg . 
Peritoneal blood was observed in 4 females at 10 mg/kg and was probably duo to recent 
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abortions. Slight maternal toxicity (reduced body weight gain) was observed at 5 and 10 mg/kg . 
At 10 mg/kg 4 females totally resorbed and /or aborted. The remaining two females had 
resorptions and the number ol viable fetuses was significantly reduced compared to controls. At 5 
mg/kg there was an increased incidence of resorptions, with one litter totally resorbed, and a 
decreased number of viable fetuses (Berdasco, 1986). 
As a result of the above probe studies a study was conducted on 4 groups of 20 pregnant 
rabbits of the same strain with dose levels of 0, 0.5, 1.0 and 3.0 mg cyhexatin (purity 95.5%)/kg 
b.w./day suspended in 0.5% aqueous Methocel on days 7 through 19 of gestation. On day 29 of 
gestation all rabbits v/ere sacrificed. 
One rabbit at 0.5 m g / k g and 4 rabbits at 3.0 mg/kg aborted. One rabbit each at 1.0 and at 
3.0 mg/kg delivered spontaneously and one rabbit each at 0.5 and 3.0 mg/kg resorbed their 
litters. The number of viable fetuses per dam was reduced in the 3.0 mg /kg . The number of dams 
with two or more resorptions was increased. Post implantation loss was dose relatedly increased 
at 1.0 and 3.0 mg/kg b.w. Hydrocephalus was observed in 8 (4) fetuses (litters) at 3.0 mg/kg . 
One aborted fetus at 3.0 mg/kg had a dome-shaped head, but was not examined viscerally. The 
NOAEL in this study is considered to be 0.5 mg/kg (Schardein et al, 1986). 
To confirm the results of the study above, another study was conducted with groups of 27 
pregnant NZW rabbits with dose levels of 0, 0.75 or 3.0 mg cyhexatin (purity 94.8-95.5%)/kg 
1 
b.w/day in 0.5% aqueous Methocel during days 7 through 19 of gestation. On day 28 of gestation 
of gestation the rabbits were sacrificed. 
There were 2, 7 and 4 deaths at 0, 0.75 and 3.0 mg/kg , respectively. Most of these rabbits 
had lung or thoracic cavity lesions suggesting dosing problems. Abortions occurred in 3 rabbits at 
0.75 mg/kg and in 12 rabbits at 3.0 mg /kg . In 5 of these hairballs were found in the stomach. At 
3.0 mg/kg maternal toxicity was observed. There was an increased incidence of resorption and a 
decreased number of live fetuses in the 3.0 rng/kg group (according to the WHO/JMPR only 7 
rabbits are remaining in this group instead of the expected 11). The fetuses were observed only 
for external and visceral examination and the total incidences of any malformation v/ere 3 (3), 10 
(7) and 11 (5) fetuses (litters) at 0, 0.75 and 3.0 mg/kg, respectively. The most common finding 
was hydrocephalus with incidences of 2 (2). 7 (5) and 9 (4) fetuses (litters), respectively. Dilated 
cerebral ventricles was observed in one fetus each at 0.75 and 3.0 mg /kg . in litters with no 
hydrocephalic fetuses. The NOAEL for maternal toxicity is considered to be 0.75 mg/kg b.w, 
however for teratogenicity (hydrocephalus) no NOAEL can be established (Kirk et al, 1987a). 
Groups ol 24 maled rabbils (Hybrid HY/Cr While Nev/ Zealand) were given by gavage 0, 3.0 
(technical, 96%) or 3.0 (pure) mg cyhexatin/kg b.w. in 0.5% aqueous carboxymethyl cellulose, on 
days 6 through 18 of gestation. The surviving rabbits were sacrificed on day 29. 
In the control and technical cyhexatin treated groups mortality occurred, but not with the 
pure material. In lhe technical cyhexatin group 3 rabbits aborted. The group given pure cyhexatin 
had slightly fewer viable fetuses as a result of fewer corpora lutea and irnplanlations. In the 
technical group one fetus v/as observed with a dome-shaped head associated with dilated 
ventricles of the brain. One lotus given pure cyhexatin also had dilated ventricles of the brain. The 
total incidence of major malformations was 1, 2, and 2 (2) fetuses (litters) at 0. 3.0 (technical) or 
3.0 (pure) m g / k g (Monnot, 1989a¡ 
In a second experiment 24 pregnant rabbits/group were treated with 0, 0.5, 0.75 or 1.0 mg 
(technical, 96%) mg/kg b.w. There were 1-3 deaths in each group of rabbits, but the incidence 
was not dose related. Abortions were observed in the control group and at 0.5 mg /kg , 
respectively 3 and 2 rabbits. In the 0.5 mg/kg group one fetus was found with a dome-shaped 
head associated with dilated ventricles. The incidence of major malformations was 1 (1), 3 (3), 4 
(4) and 3 (3) fetuses (litters) at 0, 0.5, 0.75 and 1.0 mg/kg . Retinal detachment was observed in 2, 
3 and 1 fetus at 0.5, 0.75 and 1.0 mg/kg (Monnot, 1989b). 
In these latter two studies no apparent treatment related maternal toxicity and 
embryo/fetotoxicity, nor teratogenic effects were observed. The NOAEL was the highest dose 
tested, 3.0 mg /kg b.w. (Monnot, 1989a & b) 
In a recently performed study groups of 14 to 17 pregnant rabbits (New Zealand White) 
received orally 0.75, 1.5 or 3 mg cyhexatin (purity 97%, manufactured in Kentucky)/kg b.w./day 
dissolved in 0.5% methyl cellulose mucilage, days 6-19 of gestation. Three other groups were 
treated similarly, but with cyhexatin of 98% purity (manufactured in the Netherlands). Two 
additional groups of 8 or 9 pregnant rabbits received received 3.0 mg cyhexa,tin (purity 99.7%)/kg 
b.w. dissolved in 0.5% methyl cellulose mucilage or in 1% Cremophor EL. The control group 
received 0.5% methyl-cellulose mucilage. 
Particle size of the three samples was measured, with the following 'results. 
97%, Kentucky 
98%, Netherlands 
99.7%, High purity 
Particle 
%90' 
315 
140 
80 
size (microns) 
%502 
161 
38 
27 
%103 
8 
0 
7 
Surface area 
(m2 /gm) 
0.34 
0.59 
0.60 
1 90% of particles are less than this size 
2 Median particle size 
3 10% of particles are less than this size 
In the study in which Kentucky technical material was used 1/15 rabbits died at 1.5 mg /kg 
and 1/15 rabbits died at 3.0 mg/kg. Abortions occurred in 1/14 and 1/14 rabbits at 1.5 and 3.0 
mg /kg . At 3.0 mg/kg weight gain and food intake wore reduced during the treatment period. 
Incidences of felal skeletal aberrations with a dose-related relationship included 13/13 ribs, or 
short 13 th rib at 3.0 mg/kg . Soft tissue examinations indicated an increased incidence of 
unilateral or bilateral folded retinas at all dose levels, exceeding historical control levels. The 
significance of this is uncertain. Incidence ol slightly increased dilation of lateral 3rd ventricle ol 
the brain was observed in 1/24 and 2/34 heads examined at 1.5 and 3.0 mg/kg , respectively. The 
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historical control range was exceeded only at 3.0 mg/kg b.w./day. Based on folded retinas no 
NOAEL could be established. 
In the study in which The Netherlands technical was used 4/17 maternal deaths v/ere found 
a! 3.0 mg/kg . Abortions occurred at 1/16 and 2/17 rabbits at 0.75 and 3.0 mg/kg . A dose related 
decrease in bodyweighl gain was observed at all dose levels during the treatment period. Food 
consumption was slightly decreased at 1.5 and markedly decreased at 3.0 mg/kg . Two out of the 
remaining 11 rabbits aborted at 3.0 mg/kg . These abortions followed marked maternal weight 
loss. A dose-relaled increased preimplantation loss occurred at all dose levels (12.9, 25.5, 27.3 
and 28.7% at 0, 0.75, 1.5 and 3.0 mg/kg , respectively). Post-implantation losses are increased at 
3.0 mg /kg (19.5%). Litter size was reduced at all dose levels. Incidences of fetal skeletal 
aberrations which showed a dose relationship included an increased incidence of 12/13 ribs and 
increased incidence of thickened ribs at 3.0 mg/kg. Soft tissue examinations indicated an 
increased incidence of unilateral or bilateral folded retinas at all dose levels, exceeding historical 
control levels. The significance of this finding is uncertain. Incidence of slightly increased dilation 
of lateral 3rd ventricle of the brain was observed in 1/36 heads examined at the 1.5 mg /kg group. 
This is within the historical control incidence. Based on preimplantation loss, reduced litter size 
and folded retinas no NOAEL could be established. 
Maternal mortality occurred with the pure cyhexatin suspended in methyl cellulose mucilage 
(2/9), although no maternal deaths occurred in the Cremophor EL group. Abortions occurred with 
the pure cyhexatin in both methyl cellulose (2/9) and Cremophor EL (3/7). Maternal body weight 
was markedly reduced during treatment in both solvent groups. Food intake was markedly 
reduced, especially in the Cremophor EL group. Pre-implantation losses were increased in both 
solvents (39% for Methocel and 36% for Cremophor), due to extremely high levels in one 
individual in each group. Litter size was reduced in both groups. Soft tissue examinations 
indicated an increased incidence of unilateral or bilateral folded retinas with the Cremophor group. 
Incidence of slightly increased dilation of lateral 3rd ventricle of the brain was observed in 1/12 
heads examined in the methocel group. The number of pups was insufficient for a valid 
examination of the skeletal variants (Bailey et al, 1990). 
This study is difficult to evaluate because too many variables v/ere studied in one experiment. 
It seems however that a higher purity, combined with a lower particle size, caused a higher 
maternal and fetal toxicity. The measured incidence of folded retinas, which was found in all tested 
groups is difficult to interpret. If this parameter is excluded the NOAEL's for maternal and 
fetotoxicity in lhe study with Kentucky and the Netherlands malerial are 1.5 ?nd <0.75 mg /kg 
b.w., respeclively. 
Dermal studies 
Rabbit 
Groups of 16 pregnant New Zealand White rabbits were given dermal doses ol 0. 0.5. 1.0 or 
3.0 mg cyhexatin (purity 94.8-95.5%)/kg b.w. on days 7 through 19 of gestation. The test material 
v/as suspended in in 0 5% aqueous Melhocel. The lest material v/as applied to a clipped areas on 
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the back of each animal and covered with an occlusive bandage for a 6-hour period. The animals 
were sacrificed on day 28 of gestation. 
There was a dose related increase in lesions at the site of application (erythema/eschar, 
edema and fissuring/scaling) which increased with dosing. At 3.0 mg/kg acanthosis, 
hyperkeratosis with slight inflammation were seen histologically. Hydrocephalus was observed in 4 
(3) fetuses (litters) in the 3.0 mg/kg group, but not in any other group although dilated cerebral 
ventricles were seen in 3 fetuses from one control litter and one fetus in the 3.0 m g / k g group. 
Since hydrocephalus was also observed in fetuses of rabbits given cyhexatin orally the incidence 
of this lesion is considered to be treatment related. Retroesophageal subclavian was observed in 
one fetuse at 0.5 mg /kg and in one fetus at 3.0 mg/kg. Multiple facial anomalies (including 
anophthalmia) was observed in one fetus at 1.0 mg/kg b.w. and cleft palate and persistent 
truncus arteriosus with ventricular septal defect each in one fetus at 3.0 mg/kg . The cleft palate 
occurred in a fetus with hydrocephalus. The NOAEL for teratogenicity is considered to be 1.0 
m g / k g b.w./day based on hydrocephalus (Kirk et al, 1987b). 
In a similar study groups of 24 pregnant HY/Cr New Zealand White rabbits were given daily 
dermal doses of 0, 0.5, 1.0 or 3.0 mg cyhexatin (96% pure)/kg b.w. days 6-18 of gestation. The 
testmaterial was suspended in 0-5% aqueous carboxymethyl cellulose. The test material was 
applied to shaved areas on the backs of the rabbits so that test material was not applied more 
than twice on the same site without an interval of at least seven days. The test site was given a 
slight massage for about one minute after application of the test material. It iç not indicated if the 
site was occluded or if any other precautions were taken to prevent oral ingestion. On gestation 
day 29 the females were sacrificed. 
Erythema, atonia and desquamation were observed at the treatment site of all three dose 
levels. Cracking of the skin was observed in 6/24 rabbits at 1.0 mg/kg and in 11/24 rabbits at 3.0 
mg /kg . Two females aborted, one at 0.5 mg/kg and one at 3.0 mg/kg . There was no dose-related 
increase in number of malformations. Arthrogyposis was observed in one fetus at 1.0 mg/kg and 
in two fetuses at 3.0 mg /kg . 
There was no indication for teratogenicity. 3.0 mg/kg is considered to be the NOAEL (Monnot, 
1989c). 
Evaluation 
The results of the teratogenicity studies in rabbbits have been summarized in table 1. From 
the studies supplied by Dow Chemical it appears that hydrocephaly was observed in all three 
studies. However, the JMPR concluded that these studies were of uncertain validity because of 
non-homogeneity of the test material and infections in the first study, possible infections in the 
second study and inhomogeneity and severe skin irrilation effects in the third. 
The studies supplied by Oxon did not show embryotoxic or teratogenic effects. In a study in 
which two different batches of cyhexatin were used a possible teratogenic elfect was lound with 
one batch at the highest dose level of 3 mg/kg b.w. The other batch showed high maternal and 
fetotoxicity at all dose levels (LOAEL 0.75 mg/kg b.w.). Apart from the Dow studies an NOAEL lor 
teratogenicity can be put at 1.5 mg/kg b.w. or higher 
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"In the first reproduction study in rals maternal toxicily was observed at 6 and 0.5 mg /kg b.w. At 6 
m g / k g b.w. pup weight gain and pup survival were lower. The NOAEL was 0.1 mg/kg b.w. In the 
second reproduction study malernal toxicly v/as observed at 30 and 100 ppm (equivalent to 1.5 
and 5 m g / k g b.w.) Pup weight gain and pup survival were also decreased at these dose levels. In 
the last breeding the animals were studied for teratogenic and embryotoxic effects. Apart from 
skeletal varianls at 30 and 100 ppm no effects were observed. The NOAEL is 10 ppm, equivalent 
to 0.5 m g / k g b.w. 
In 1980 the JMPR allocated an ADI of 0.008 mg/kg b.w., based on the no effect level (0.75 
m g / k g b.w.) in 2-year dog feeding studies evaluated in 1970. The receipt of the long-term study in 
rats (NOAEL 1 mg/kg b.w./day) and additional studies in dogs justified the-alteration of-the 
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temporary ADI set in 1970 and extended in 1973 and 1978 to a full ADI. In 1990 the JMPR has 
based an ADI on the NOAEL of 0.1 mg /kg b.w. in the first reproduction study on rats. Since this 
level is much lower than the NOAEL for teratogenic effects (1.5 mg/kg b w or higher) or fetotoxic 
effects (<0.75 mg/kg b.w.) this ADI of 0.001 mg/kg b.w can be accepted for the evaluation of the 
occurrence of residues of cyhexatin and azocyclotin in food. 
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FABLE 1. Toxicological evaluation of rabbit teratogenicity studies 
Maternal toxicity Embryo/Foetal toxicity 
Doses(mg/kg) NOAEL Effect NOAEL Effect 
Oral rabbit 
0. 0.5. 0.1 .o 
3.0 
0. 0.75, 3 
0, 3.0 (tech), 
3.0 (pure) 
0. 0.5. 0.75 
1.0 
0. 0.75. 1.5, 
3.0 (Kentucky) 
0. 0.75, 1.5, 
3.0 
0.75 
3 
1 
1.5 
<0.75 
3.0 (Netherlands) 
Dermal rabbi! 
none 
decr. body < 
decr. body 
weight 
decr. body 
v/eight 
//eight 
0.5 
<0.75 
3 
1 
1.51 
<0.75 
incr. post-
implantation loss 
abortions 
skeletal 
aberrations 
incr. pre-
implantation loss 
0.0.5.1.0 <0.5 skin irritation 
3.0 
0, 0.5, 1.0, <0.5 skin irritation 
3.0 
Teratology Reference 
NOAEL Effect 
1.0 
<0.75 
1.5 
hydrocephalus 
hydrocephalus 
dilation of lateral 
3rd ventricle of 
the brain 
hydrocephalus 
Schardein, et al (1987) 
(Dow Chemical) 
Kirk et al, 1987a 
(Dow Chemical) 
Monnot, 1989a 
Monnot, 1989b 
Bailey, 1990 
Bailey, 1990 
Kirk et al, 1987 
(Dow Chemical) 
Monnot, 1989c 
excluding increased incidence of unilateral or bilateral folded retinas 
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REPORT OF TUE SCIENTIFIC COMMITTEE FOR PESTICIDES 
ON THE TOXICITY OF DIMETHOATE 
(Opinion expressed by the SCP on 23 April 1994) 
BACKGROUND AND TERMS OF REFERENCE 
Dimethoate is a contact and systemic insecticide and acaricide which has approvals for use in 
all member states. The toxicity of dimethoate has been considered by the World Health 
Organisation JMPR in 1963, 1965, 1967, 1984 and 1987. In the context of its work relating 
to the establishment of community maximum pesticide residue levels in various foodstuffs 
covered by community legislation, the Commission requested the Scientific Committee for 
Pesticides to review the ADI for dimethoate, with particular reference to data generated 
recently, which may have altered the ADI since last consideration by the JMPR. 
1 ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION 
« "> 
The JMPR evaluation of the FAO/WHO meeting in 1967 indicated that dimethoate is rapidly 
absorbed from the gut and radioactivity, using 32P-labeIled material, was concentrated in the 
liver, bile, kidneys and the urine. There was no accumulation in fat tissue. In rat and man up 
to 90 % of radioactivity was found in the urine after 24 hours; in guinea pigs 25 to 40 % is 
excreted in the faeces. One of the papers reviewed indicated that up to 18% of administered 
activity was excreted in the expired air. Four metabolites with anti- Cholinesterase activity 
have been identified in the rat and man. One seems to result from thiono oxidation leading to 
the formation of the oxygen homologue of dimethoate, i.e. omethoate; this step was followed 
by hydrolysis to a thiocarboxyl product, said to be the main metabolite in rats and man (Ref. 
1). A published paper by Hassan el al. appeared to confirm these indications (Ref. 2). 
2 TOXICITY 
2.1 ACUTE TOXICITY, IRRITATION AND SENSITISATION 
The acute oral toxicity of dimethoate gave LDSO's of approximately 310 mg/kg in rats, 150 
mg/kg in mice and 55 mg/kg in hens. Signs of toxicity were those typical of Cholinesterase 
inhibition; there was no evidence of delayed neurotoxicity in hens. In most acute studies in 
which signs of reaction were seen there were minor reductions in body weight gain and food 
consumption; this deficit was made up in the second week of the observation period. The 
acute toxicity of dimethoate formulations did not differ significantly from that of the technical 
material, when considered in terms of the active ingredient content. Undiluted dimethoate 
formulations were shown to be markedly irritant to the eye. Skin irritation was minimal and 
confined to slight, transient erythema. Dimethoate technical was not a skin sensitiser in 
guinea pigs in a Buehler type test, but when a 32.7% emulsifiable concentrate formulation 
was tested in a similar experiment, a positive sensitisation reaction was seen in one out often 
139 
guinea pigs. In a published German paper, dimethoate was cited in four human cases of 
contact dermatitis and sensitisation was confirmed in these individuals by patch testing (Ref 
3). 
2.2 SUBACUTE/CHRONIC TOXICITY 
In subacute and chronic studies the potential toxicity expressed through administration of 
dimethoate was limited by onset of Cholinesterase inhibition. In studies in rats at dietary 
concentrations of 75 ppm or above, there were minor reductions in body weight gain and 
food consumption. Except in respect of Cholinesterase activity, dimethoate did not affect the 
composition of the blood or urine. The liver weights of animals treated at the higher dosages 
or dietary concentrations, tended to be smaller than those of the control groups; there was, 
however, no microscopic correlation with this and it is unlikely to be of toxicological 
significance. The no effect levels were generally based on reductions, relative to controls, of 
Cholinesterase activity in the brain or erythrocytes. Although several studies did not have no 
effect levels it was possible to identify doses at which no adverse effects were seen. On the 
basis of minimal reductions in Cholinesterase activity in the brain or erythrocytes "of between 
10 and 20 %, the no adverse effect level in dogs was approximately 0.2 mg/kg bw/day. In 
rats the no adverse effect level over a life span study was 5 ppm, equivalent to approximately 
0.25 mg/kg bw/day (Refs. 3, 4 and 5). 
2.3 CARCINOGENICITY 
Based on the results of rat and mouse bioassays conducted by the NCI and reported in 1977, 
and on the results of further studies in rats and mice reported in 1986, it> was concluded that 
dimethoate is not carcinogenic in rodents (Refs. 3, 4 and 5). A review by Reuber (1984) 
suggested that dimethoate is carcinogenic, however this was not substantiated by any data, 
and it was concluded that the Reuber paper could be disregarded (Rcf. 6). 
2.4 MUTAGENICITY 
Dimethoate was considered non-mutagenic in an Ames test, and an HGPRT assay /'/) vitro 
gave no clear evidence of mutagenicity. An in vivo micronucleus assay in mice was negative, 
as was a dominant lethal assay in mice and an in vivo chromosome aberration study in mice. 
Dimethoate was considered positive in two in vitro UDS assays (using different methods of 
assessing uptake of tritiated thymidine into DNA), but negative in an in vivo/in vitro UDS 
assay. This latter study indicated an unusual S-phase activity and it is possible that this effect 
could have had a confounding effect in the in vitro studies. A review of the literature relating 
to the mutagenic potential of dimethoate revealed a number of positive results, notably in a 
salmonella assay using strain TA 100 and in a sister chromatid exchange study in mammalian 
cells in vitro. It was concluded that although in vitro studies indicate that dimethoate has 
mutagenic potential, in vivo assays indicate that this potential is not expressed in vivo (Refs. 
3, 4 and 5). 
2.5 REPRODUCTIVE TOXICITY 
2.5.1 TERATOGENICITY 
The teratogenic potential of dimethoate was investigated in rats, at dose up to 18 mg/kg 
bw/day, and rabbits, at doses up to 40 mg/kg bw/day. Neither species gave any evidence of 
teratogenic effect or fetotoxicity, though maternal toxicity was observed. The no effect level 
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for maternal toxicity was 10 mg/kg bw/day in rabbits and 6 mg/kg bw/day in rats (Refs. 3 
and 5). 
2.5.2 MULTIGENERATION STUDIES 
In a recent multigeneration study in rats, which has never been reviewed in a JMPR 
evaluation, groups of 28 male and 28 female Sprague Dawley rats received dimethoate by 
dietary administration at levels of 0 (Control), 1, 15 and 65 ppm. Treatment was continued 
for 10 weeks prior to mating and then throughout mating, gestation and lactation for at least 
two matings in each of 2 generations. Treatment at 65 ppm was associated, in the parent 
animals, with marked reductions in plasma, erythrocyte and brain Cholinesterase activity in 
both generations, slightly reduced body weight gain, increased food intake and reduced water 
intake, and a reduction in the number of successful matings, along with an associated 
increase in the number of apparently infertile males and females. In the offspring, at 65 ppm, 
a marked reduction in brain Cholinesterase activity was seen, along with lower litter size at 
birth, increased pup mortality and slower pup growth. Similar effects were seen at 15 ppm, 
although to a much lesser extent, but it is notable that litter size, pup mortality and pup 
growth were still adversely affected at this dose. Treatment at 1 ppm (equivalent to 
approximately 0.08 mg/kg bw/day) was without adverse effects on adults or offspring (Ref. 
7). 
In an inadequate mouse multigeneration study conducted in 1965, there was no overt effect 
on reproductive capacity at dietary levels up to 50 ppm, even in the presence of cholinergic 
toxicity (Ref. 4). 
2.6 OBSERVATIONS IN MAN 
The JMPR documents reviewed indicated a no adverse effect level of 0.2 mg/kg bw/day in 
humans given that dosage for 39 days (Refs. 1, 4 and 5). 
3 OVERVIEW AND ESTIMATION OF ADI 
The World Health Organisation most recently evaluated dimethoate for acceptable daily 
intake in 1984 and 1987, using much of the data available for this review. In 1984 it was 
concluded that a temporary ADI of 0.002 mg/kg would be appropriate since the data base 
was incomplete. In 1987, when the data base was considered complete, an ADI of 0.01 
mg/kg bw was established, based on the no effect level in humans (0.2 mg/kg bw/day), with a 
safety factor of 20. With the addition of the most recent data from the multigeneration 
study, in which an NOAEL of 0.08 mg/kg bw/day was derived, the maintenance of the ADI 
at 0.01 mg/kg bw would give a safety factor of only 8. A conventional safety factor of 100 is 
considered necessary and the ADI would therefore be 0.0008 mg/kg bw. It is considered not 
appropriate to base the ADI on the results of the human volunteer study, since the crucial 
end point (reproductive performance) was not assessed in the study in man. 
141 
REFERENCES 
1) FAO/WHO (1968). Pesticide Residues in Food. Report of the 1967 Joint Meeting 
of the FAO Working Party of Experts on Pesticide Residues and the WHO Expert 
Committee on Pesticide Residues. 
2) Hassan, et al., Metabolism of organophosphorus insecticides - XI; Metabolic fate of 
dimethoate in the rat. Biochemical Pharmacology, 1969,18, 2429-2438. 
3) Ministry of Agriculture, Fisheries and Food, United Kingdom, Evaluation Document 
on Dimethoate, November, 1993. 
4) FAO/WHO (1985). Pesticide Residues in Food. Report of the 1984 Joint Meeting 
of the FAO Working Party of Experts on Pesticide Residues and the WHO Expert 
Committee on Pesticide Residues. 
5) FAO/WHO (1988). Pesticide Residues in Food. Report of the 1987 Joint Meeting 
of the FAO Working Party of Experts on Pesticide Residues and the WHO Expert 
Committee on Pesticide Residues. 
6) Reuber, M. D., Carcinogenicity of Dimethoate, Environmental Research, 19S4, 34, 
193-211. 
7) The effect of dimethoate on reproductive function of two generations in the rat. 
Unpublished report from Huntingdon Research Centre, UK, January 1992. 
142-
REPORT OF THE SCIENTIFIC COMMITTEE FOR PESTICIDES 
ON THE TOXICITY OF VINCLOZOLIN 
(Opinion expressed by the SCP on 23 April 1994) 
BACKGROUND AND TERMS OF REFERENCE 
Vinclozolin is a protectant 3',5'-dichIoroanilide fungicide used to control many diseases on a 
wide range of horticultural and agricultural crops. In the context of its work .to establish 
maximum pesticide residue levels pursuant to the relevant Community legislation, the 
Commission requested the Scientific Committee for Pesticides to examine toxicological data 
relating to vinclozolin and to estimate its acceptable daily intake. 
Since vinclozolin is structurally similar to procymidone, which has been reported to possess 
anti-androgenic potential, the data to be reviewed concentrated on studies likely to reveal 
any anti-androgenic effects (subchronic experiments in dogs and reproductive toxicology 
studies). 
The toxicity of vinclozolin has previously been reviewed by the JMPR in 1986 and 1988, 
when an .ADI of 0.07 mg/kg bw was estimated. 
1. TOXICOLOGICAL ASPECTS 
1.1. JMPR .ADI 
In 1986 the JMPR evaluated vinclozolin for the first time. Although the data package was 
considered incomplete, sufficient information was provided to estimate a temporary ADI. It 
was noted that a plant metabolite (Metabolite T) had been identified, which was not found 
in rats. It was concluded that vinclozolin had a low order of acute toxicity, that 
carcinogenicity studies demonstrated no potential for oncogenicity and that no specific 
effects were noted in mutagenicity, teratogenicity or reproduction studies. The temporary 
ADI was estimated as 0.04 mg/kg bw using the no effect level of 7 mg/kg bw/day based on 
histological changes in spleen, prostate and bone marrow in a six month dog study and a 
200 fold safely factor. ( R e f i ) 
In 1988 the JMPR evaluated limited toxicity data on metabolite Τ (acute toxicity and 
mutagenicity) and noted that the chemical was a transient residue in only two commodities. 
A full .ADI was estimated as 0.07 mg/kg bw, using the same no effect level as that used in 
1986. and a safety factor of 100. (Ref. 2) 
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1.2. Further toxicity study in dogs 
In a sludy reported in 1986 (but not evaluated by the JMPR in 1986 or 1988), beagle dogs 
(6'sex/dose) were fed diets containing 0, 35. 75, 150 or 1500 ppm vinclozolin for 12 
months. There were no deaths and no clinical signs of toxicity. Food consumption and 
body weight gains were not significantly affected by treatment. Haematological, clinical 
chemistiy and urinalysis investigations were conducted predosing and at weeks 13, 26 and 
52. At 1500 ppm. reticulocyte counts were increased in both sexes. Platelet counts were 
increased in males at 1500 ppm. Mean cell volume was increased in females at 1500 ppm. 
Total bilirubin concentrations were increased in both sexes at 1500 ppm. Pathology 
revealed a number of treatment-related changes, some of which were indicative of an anti-
androgenic effect. Adrenal weights were markedly increased at 1500 ppm. and were 
slightly increased at 150 ppm in both sexes. The adrenals appeared enlarged in all males 
and in 5'6 females at 1500 ppm. The mean width of the adrenal cortex was increased in 
both sexes at 1500 ppm and was slightly increased in females at the lower dose levels. 
However, at these dose levels a dose-response relationship was not. observed. 
Histopalhology revealed progressive transformation and increased lipid content of the 
adrenals in all males and 5/6 females at 1500 ppm. Testes weights were increased in a dose-
related fashion. At 1500 ppm. testes weights were markedly increased and at 150 ppm 
relative weights were significantly increased. At 1500 ppm, diffuse hyperplasia of lhe 
Leydig cells was observed in 5/6 males. Prostates of 1/6 and 2/6 males at 150 and 1500 
ppm. respectively were reduced in size microscopically. Histopathology revealed that 2/6 
males at 150 ppm had slightly or moderately atrophied prostates and 5'6 males at 1500 ppm 
had slightly (1/6) or severely (4 6) atrophied proslates. This effect was also seen lo a 
minimal extent in 16 males at 0. 35 and 75 ppm. Liver weights werc^increased in a non-
dose-related fasliion at up to 150 ppm and were markedly increased at 1500 ppm in males. 
Increased haemosiderin deposition was observed in livers of males at 1500 ppm and females 
at 150 and 1500 ppm. Spleen and thyroid weights were increased in males al 1500 ppm. 
Spleen weights were also slightly increased in females at 1500 ppm. The no adverse effect 
level was 75 ppm. equal to 2.4 mg kg bw/day based on treatment-related pathological 
effects indicative of anti-androgenicity observed at 150 and 1500 ppm. (Ref. 3) 
1.3. Reproductive toxicity 
1.3.1. Teratology studies 
1.3.1.1. Mouse 
In a study reported in 1974, NMRI female albino mice were fed diets conlaining vinclozolin 
from day 1 to 19 of gestation in two different lests. In the first test, females received 0 or 
60000 ppm vinclozolin. and the numbers of mice used were 24 and 28 respectively. In the 
second test, females received 0. 600 or 6000 ppm vinclozolin, and the numbers of mice 
used were 30 in each case. Females were killed on day 19 of gestation. Females treated al 
6000 ppm did no! increase in weight during gestation and had a decreased food 
consumption in the first six days of treatment. Females treated at 60000 ppm lost wcighl 
and had a markedly decreased food consumption. One female treated al 6000 ppm died on 
day 11. and all females treated at 60000 ppm died within the first nine days. Clinical signs 
of toxicity were observed at 60000 ppm only, and included ruffled coats and. prior lo death. 
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apathy and signs of pronounced diuresis. Gross pathology revealed severe emaciation, slight 
atrophy of musculature and considerable loss in perirenal fatty tissue in animals which died. 
No implantation sites were detected in any female at 6000 or 60000 ppm, and hence no 
fetuses were observed at (hese dose levels. At the only dose available for studying effects 
on fetuses. 600 ppm. there were no treatment-related adverse effects observed. The no 
adverse effect levels for maternal toxicity and fetotoxicity were 600 ppm, equivalent to 
approximately 90 mg/kg bw/day. Teratogenicity was not observed at 600 ppm. (Ref. 4) 
1.2.1.2. Rabbit 
a) Study 1 
In a study reported in 1980, New Zealand White female rabbits (15/dose level) were, orally-
dosed at 0. 20, 80 or 300 mg/kg bwday from day 6 to 18 of gestation. The animals were 
killed on day 29. There were no signs of toxicity or deaths which were obviously 
attributable to treatment. Body weight gain was not affected by treatment. There were no 
treatment-related effects on numbers of live young, sex ratio, embryonic deaths, pre-
implantation losses, litter weights or fetal weights. Post-implantation losses were slightly 
increased non-dose-dependently in treatment groups, but within historical control values. 
There were no treatment-related major malformations or visceral anomalies. However, 
there was a slight non-dose-dependent increase in minor skeletal anomalies, but these were 
within historical control values. The no effect levels for maternal toxicity and fetotoxicity 
were >300 mg/kg bwday. There was no evidence of teratogenicity. (Ref 5) 
b) Study 2 
In a study reported in 1989, Himalayan female rabbits (15/dose level) were orally dosed at 
0. 50, 200 or 800 mg kg bw/day from day 7 to 28 of gestation. The animals were killed on 
day 29. At 200 mg/kg bw/day. 1 female aborted on day 26 and was killed. At 800 mg/kg 
bw/day, 1 female died. 1 female aborted and died, and 11 females aborted and were killed. 
Abortions occurred between days 21 and 27. Clinical signs of toxicity included 
reddish-brown discoloration of the urine in 13/15 females and apathy, hunched posture, 
conjunctivitis and urine-smeared fur in 1 to 2 animals at 800 mg'kg bw/day. At 200 mg/kg 
bw/day. the female which aborted displayed vaginal haemorrhage, and discoloration of the 
urine. A second female at this dose showed vaginal haemorrhage on day 24. Food 
consumption at 800 mg kg bw/day was significantly reduced during the treatment period. 
At 200 mg kg bw/day. food consumption was reduced, mainly from days 7 to 19. At 50 
and 200 mg kg bw/day, there were no treatment-related increases in pre-implantation and 
post-implantation losses. The only dam at 800 mg/kg bw/day with viable fetuses (4) had 3 
post-implantation losses, as early resorptions. There were no treatment-related resorptions 
at 50 or 200 mg kg bw day. Sex ratios, numbers of live fetuses, placental weights and fetal 
weights were not affected by treatment at 50 or 200 mg/kg bw/day. There were no 
Ireatment-related external malformations or visceral abnormalities. At 800 mg/kg bw/day, 
1/4 viable fetuses displayed malformations of the stemebrae. The relevance of this finding 
is questionable due to the small numbers of fetuses available for examination at 800 mg/kg 
bw/day. Al 50 mg kg bwday, 1/94 fetuses displayed malformations of the stemebrae, but 
these were also present in the historical control data in the range 0 to 1 % (mean 0.2%). No 
Ireatment-related changes to the male fetal genital organs were observed. The no effect 
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level for maternal toxicity was 50 mg/kg bw/day, based on reduced food consumption, 
abortion and clinical signs of toxicity at 200 mg/kg bw/day. The no effect level for 
embryoloxicity/fetotoxicity was 200 mg/kg bw/day, based on 3/7 resorptions as a 
consequence of maternal toxicity in the female alive at termination in the high dose group. 
There was no evidence of teratogenicity at 50 or 200 mg/kg bw/day. (Rcf 6) 
c) Study 3 
In a supplementary stud}' reported in 1989, Himalayan female rabbits (20/dose level) were 
orally dosed at 0 or 400 mg/kg bw/day from day 7 to 28 of gestation. The animals were 
killed on day 29. At.400 mg/kg bw/day, 1 female aborted and died on day 19 and 9 females 
aborted and were killed between days 20 and 27. Clinical signs of toxicity included blood in 
the bedding of 2 treated females, one of which aborted. Of the treated group, 8/20 had 
red/brown discoloured urine. Food consumption was reduced at 400 mg/kg bw/day 
between days 7 and 26. Body weight gain was impaired in the same dose group between 
days 7 and 25. Pre- and post-implantation losses were increased in the treatment .group, and 
as a consequence of the latter early resorptions were also increased. Numbers of live fetuses 
per litter were slightly decreased at 400 mg/kg bw/day. The ratio of males: females was 
decreased at 400 mg^g bw/day (1 to 1.16 in the controls and 1 to 1.8 at 400 mg/kg 
bw/day). However, no treatment-related changes to the male fetal genital organs were 
observed. Fetal weights were increased in the treatment group, probably as a consequence 
of slightly decreased litter sizes. There were no external or soft tissue malformations at 400 
mg/kg bw/day. Separated origins of the carotids was increased in the treatment group (10% 
in controls and 36% at 400 mg/kg bw/day). Incidences at 400 mg'Tkg bw/day were slightly 
lugher than for the historical control data (mean = 19% and range 10 to131%). There were 
no skeletal malformations in either group, and no treatment-related skeletal variations or 
retardations. No malformed stemebrae were observed at 400 mg'kg bw/day. which 
indicaled that in the previous study, this effect was not treatment-related at 50 mg/kg 
bw/day. The no effect levels for maternal toxicity and embryotoxicity/fctotoxicity were 
<400 mg'lcg bw/day. There was no clear evidence of teratogenicity at 400 mg/kg bw/day. 
However, the increased incidence of separated origins of the carotids al 400 mg/kg bw/day 
indicated a potential for teratogenicity at this severely maternally toxic dose level. (Rcf. 7) 
1.2.1.3. Rat 
a) Study 1 
In a study reported in 1987. female Wistar rats (25/dose level) were orally dosed at 0, 15, 
50 or 150 mg kg bw day from day 6 to 19 of gestation. The animals were killed on day 20. 
There were no deaths, no clinical signs of toxicity, no abortions and no treatment-related 
effects on food consumption and body weights. Haematological investigations performed al 
day 20 revealed no treatment-related findings. At gross necropsy, no adverse findings were 
noted. There were no Ireatment-related effects on pre- or post-implantation losses, 
resorptions, numbers of live feluses. fetal weights or placental weights. The anogenital 
distances were decreased in male fetuses at 150, and to a lesser extent al 50 mg/kg bw/day. 
l h e reductions in anogenital dislances in males were considered in the study report to be 
indicative of the beginning of feminization of male fetuses, and may be caused by a possible 
hormonal (anti-androgenic) aclion on sexual differentialion. There were no olher Irealment-
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related elfecls on male or female fetuses. No maternal toxicity was observed, and hence the 
no effect level was >150 mg/kg bw/day. No embryotoxicity or fetotoxicity were observed, 
and hence the no effect level was >150 mg/kg bw/day. The no effect level for teratogenicity 
was 15 mg/kg bw/day, based on reductions in anogenital distances al 50 and 150 mg/kg 
bw/day. (Rcf. 8) 
b) Study 2 
In a study reported in early 1988, female Wistar rats (25/dose level) were orally dosed at 0, 
50, 100 or 200 mg/kg bw/day from day 6 to 19 of gestation. The animals were killed on day 
20. There were no deaths, no clinical signs of toxicity, no abortions and no ireatment-
related effects on food consumption and body weights. Haematological investigations 
performed at day 20 revealed no treatment-related findings. At necropsy, no treatment-
related adverse signs were noted. There were no treatment-related effects on pre- or post-
implantation losses, resorptions, numbers of live fetuses, placental weights or fetal weights. 
The only possible Ireatment-related morphological effect observed in the fetjises was a 
significantly increased incidence of symmetrically dumbbell-shaped thoracic vertebral bodies 
at 200 mg/kg bw/day. Such effects are indicative of retarded development. A slight, but 
not statistically significant, increase was observed at 100 mg/kg bw/day. Similar effects 
were observed in a follow-up study later in 1988. The no effect level for maternal toxicity 
was >200 mg'kg bw/day. The no effect level for fetotoxicity was 100 mg/kg bw/day, based 
on the possible treatment-related increase in symmetrically dumbbell-shaped thoracic 
vertebral bodies al 200 mg kg bw/day. A no effect level for teratogenicity could not be 
established as no measurements of the anogenital distance of fetuses were performed. (Ref. 
9) 
c) Study 3 
In a study reported later in 1988, female Wistar rats (25/dose level) were orally dosed at 0. 
200 or 400 mg kg bw/day from day 6 to 19 of gestation. The animals were killed on day 20. 
There were no deaths, no clinical signs of toxicity, no abortions and no treatment-related 
effects on food consumption and body weights. Haematological investigations performed at 
day 20 revealed no treatment-related findings. At gross necropsy, no treatment-related 
adverse signs were noted. There were no treatment-related effects on pre- or post-
implantation losses, resorptions, numbers of live fetuses, fetal and placental weights or sex 
ratio. The anogenital distances were decreased in male fetuses in a dose-related fashion at 
both 200 and 400 mg/kg bw day. These reductions in anogenital distances were indicative 
of the beginning of feminization of male fetuses, as reported previously. A treatment-
related increase in dilated renal pelvis and hydroureter was also observed in fetuses of both 
sexes. Increases were statistically significant in fetuses at 400 mg/kg bw/day. These 
findings are considered to be indicative of a transient developmental delay. There was also 
a significant increase in numbers of fetuses with symmetrical dumbbell shaped thoracic 
vertebral bodies al 200 and 400 mg/kg bw/day. This was also seen in a previous study, and 
is indicative of retarded development. At 400 mg/kg bwday. numbers of fetuses with 
accessory 14th ribs were also significantly increased. The no effect level for maternal 
toxicity was >400 mg kg bwday. The no effect level for fetotoxicity was <200 mg/kg 
bw/day. based on lhe increased incidences of symmetrical dumbbell shaped thoracic 
vertebral bodies at 200 and 400 makg bw/day in both sexes. The no effect level for 
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teratogenicity was <200 mg/kg bw/day, based on the reductions in anogenital distance in 
male fetuses al 200 and 400 mg/kg bw/day. (Ref 10) 
d) Study 4 
In another study reported in 1988, female Wistar rats (10/dose level) were orally dosed at 0, 
600 or 1000 mg/kg bw/day from day 6 to 19 of gestation. The animals were killed on day 
20. There were no deaths and no abortions. Clinical signs of toxicity included unsteady gait 
in 1 female al 600 mg'kg bw/day and 7 females at 1000 mg/kg bw/day, and piloereclion in 2 
females at 1000 mg/kg bw/day during the study. Food consumption was reduced at 1000 
mg'kg bw/day from days 6 to 13. During the treatment period, water consumption was 
increased at 600 and 1000 mg/kg bw/day. Body weight gain of females at 1000 mg/kg 
bw/day was slightly impaired from day 8 to 10. Haematological investigations performed at 
day 20 revealed no treatment-related findings. Liver and adrenal weights were increased in 
a dose-related fashion. There were no treatment-related effects on pre- or post-implantation 
losses, resorptions, numbers of live fetuses, or placental weights. Fetal weights were 
decreased at 1000 mg'kg bw/day. When the sex ratio was determined by measuring the 
anogenital distance. 68 and 99% of fetuses at 600 and 1000 mg/kg bw/day were deemed to 
be female. However, internal examination of the fetuses showed that 39 and 52% were 
female fetuses'at 600 and 1000 mg/kg bw/day. The anogenital distances were decreased in 
treated male fetuses. At 1000 mg/kg bw/day. incidences of symmetrical dumbbell shaped 
thoracic vertebral bodies were increased in fetuses. The no effect level for maternal toxicity 
was <600 mg/kg bwday. based on increased liver and adrenal weights and necropsy 
findings at 600 and 1000 mg'kg bwday. The no effect level for fetotoxicity was <600 
mg kg bw/day. based on increased incidences of hydroureler at 6ÖÖ and 1000 mg/kg 
bw/day. The no effect level for teratogenicity was <600 mg/kg bw/day, based on reductions 
in anogenital distance in male fetuses at 600 and 1000 mg/kg bw/day. (Ref. 11) 
e) Study 5 
In a range finding study reported in 1989, female Wistar rats (10/dose level) were dermally 
administered 0. 300. 900 or 2500 mg/kg bwday for 6 hours/day from day 6 to 19 of 
gestation. The test substance was applied on the dorsal area of the trunk under an occlusive 
dressing and the animals were killed on day 20. In females at all dose levels, adrenal and 
liver weights were increased, but not in a dose-related fashion. In male fetuses, anogenital 
distances were reduced but not dose-dependently. Incidences of dilated renal pelvis in 
fetuses were increased in a dose-related fashion in all dose levels, with statistical significance 
at 900 and 2500 mg kg bw/day. The absence of dose relationship in some of the effects 
observed in this study was probably attributable to the limited dermal absorption of the 
ralhei- pasty test substance suspension al 2500 mg'kg bw/day. (Ref. 12) 
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In lhe main sludy reported in 1989, female Wistar rals (15/dose level) were dermaliy 
administered 0, 60, 180 or 360 mg/kg bw/day for 6 hours/day from day 6 lo 19 of gestation. 
The lesi substance was applied on the dorsal area of the trunk under an occlusive dressing 
and (he animals were killed on day 20. In females, (here were no deaths, no abortions and 
no signs of toxicity. There were no treatment-related effects on body weights or food 
consumption. Haematological investigations performed at day 20 revealed no treatment-
related findings. Absolute liver weights were slightly increased at 180 mg/kg bw/day and 
significantly increased at 360 mg/kg bw/day. Absolute adrenal weights were significanti}' 
increased al 180 and 360 mg/kg bw/day but not dose-dependently. There were no 
treatment-related macroscopic pathological findings. There were no treatment-related 
effects on implantation losses, resorptions, numbers of fetuses, sex ratio, weights of fetuses 
or weights of placentae.: The anogenital distances were decreased in males at 180 and 
360 mg/kg bw/day. There were no other treatment-related malformations, variations or 
relardalions in treated fetuses. The no effect level for maternal toxicity was 
60 mg/kg bw/day, based on increased absolute adrenal and liver weights at 180 and 
360 mg'kg bw/day. The nõ adverse effect level for fetotoxicity was >360 mg/kg bw/day. 
The no effect level for teratogenicity was 60 mg/kg bw/day. based on reductions in 
anogenital distances in male fetuses at 180 and 360 mg/kg bw/day. (Ref 13) 
1.3.2. Multigeneration studies 
a) Study 1 
From 1975 lo 1977. a 3 generation study was performed using Sprague Dawléy rats 
(20 se\<dose lev;el) fed diets containing 0, 162. 486 or 1458 ppm. Theìre were 2 litters per 
generation, and the second litters were used as parent animals (F0, Fl and F2). The pre-
maling dosing period was approximately 8 weeks for F0 males and 16 weeks for F0 
females, 15 weeks for Fl and F2 males and 24 weeks for Fl and F2 females (including 
lactation). In pups and parents, there were no treatment-related deaths or clinical signs of 
toxicity. There were no treatment-related effects on food consumption and body weights. 
There were no ireatment-related effects on litter size, malformations, birth weight of pups, 
sex ratio and behaviour. In parents, there were no treatment-related effects on fertility, 
pregnancy rate, duration of pregnancy, lactation or viability. Auditory acuity and 
ophthalmoscopic findings were nol affected by treatment. At necropsy, there were no 
treatment-related effects on organ weights or at gross or microscopic examination. The no 
effect level was >1458 ppm. equivalent to approximately 73 mg/kg bw/day. since no 
treatment-related effects (including effects on general reproductive performance) were 
observed in the study. The results of this study are not in accordance with more recent 
work. However, the present study did not include investigations of anogenital distance in 
males, and diets were not analysed for lhe test substance, vinclozolin. (Ref 14) 
b) Study 2 
In a second multigeneration study, Wistar F0 parent rais (24/sex/dose) were fed diets 
containing 0. 50. 300. 1000 or 3000 ppm vinclozolin. Following a pre-mating period of 10 
weeks. F0 animals were mated, twice, to produce Fla and Fib pups. Fla animals were 
used as Fl parenis lo produce F2a and F2b animals. Some Fib rals were raised lo 
adulthood lo observe development of sexual organs (FX animals). Similarly some F2a and 
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F2b rals were also raised to adulthood (FY and FZ respectively). The results of lhe study 
may be summarised in Ihrce sections: those findings indicative of general toxicity, effects on 
reproductive performance and signs of developmental toxicity, as tabulated below: 
a) General toxicity 
Dietary level Finding 
(ppm) 
50 
300 F0 Increased relative liver weight, marginal signs of anaemia (females), 
lenticular degeneration 
Fl As F0. plus increased adrenal weight, Leydig cell hyperplasia 
F2 As Fl 
1000 F0 Reduced food intake and weight gain, anaemia (females), increased liver, 
adrenal and testes weights, lenticular degeneration, hepatic single cell 
necrosis. Leydig cell hyperplasia 
Fl As F0. plus vacuolation of pituitary cells, lipidosis and hypertrophy of 
adrenal cells 
3000 F0 Reduced food intake arid weight gain, lenticular degeneration, anaemia 
(females), increased liver, adrenal and testes weights, hepatic single cell 
necrosis, lipidosis and hyperplasia of adrenal cells, vacuolation of 
pituitary cells, Leydig cell hyperplasia 
Fl As F0. plus benign Leydig cell tumours in some animals. 
b) Effects on reproductive performance 
Dietary level Finding 
(ppm) 
50 
300 F0 -
Fl Possible reduction in fertility in males (all males eventually proved fertile) 
1000 F0 -
Fl Infertility of all males due to feminization of outer genital organs 
3000 F0 Increased total litter loss, decreased number of delivered pups, infertility 
in males 
Fl Infertility of all males (feminization), infertility of 6 females 
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c) Signs of developmental toxicity 
Dietary level Finding 
(ppm) 
50 Fl -
F2 Reduced epididymides weigh! (no morphological changes) 
300 FI Siigli! funclional reduction of prostate and coagulating gland, reduced 
epididymides weigh! 
F2 As FI, plus siigli! inlerslitial cell hyperplasia in testes and ovaries, some 
pups with reduced morphological development (delayed eye opening and 
pinna unfolding) 
1000 Fl Decreased pup survival, feminization of males, reduced body weight 
gain, slightly reduced morphological pup development, reduced size and 
function of secondary male genital organs, atrophy of seminiferous 
tubules, interstitial cell hyperplasia in testes and ovaries 
3000 Fl Increased number of still-bom pups, decreased pup survival, feminization 
of males, reduced body weight gain, retarded morphological 
development, atroph}' of primary and secondary male genital organs, 
inlerslitial cell hyperplasia in testes and ovaries. 
In conclusion, it was shown that all Fl males and females at 300 ppm were fertile either at 
the F2B mating or by additional matings performed thereafter for those animaLs which could 
not prove their fertility in at least one of the scheduled matings for the F2.4/F2B litters. The 
registrants therefore consider that "clear adverse effects on fertility were noted only at 1000 
and 3000 ppm. whereas 300 and 50 ppm were without an}' adverse effects on male and 
female fertility in both parental generations". However, it must be noted that rals arc 
particularly fertile animals and effccLs observed particularly at 300 ppm may be indicative of 
sub-fertility. 
A dietary level of 50 ppm (equivalent to approximately 4.5 mg kg bw/day) is considered to 
be a marginal effect leveL based on a possible treatment-related reduction in fertility of Fl 
males at 300 ppm. signs of delayed development at 300 ppm (reduction in numbers of pups 
with pinnae unfolding and eyes opening at the expected time) and reduced epididymal 
weigh! in F2 animals at 50 ppm. (Ref 15) 
Toxicological overview and estimation of API 
In (he toxicity sludies. vinclozolin andor its metabolites caused toxic effects which were 
indicative of anti-androgenic activity. Anti-androgens are substances which prevent 
androgens from expressing their activity at target sites. 
In reproductive toxicity sludies the no adverse effect levels in teratology sludies were 
substantially higher than those seen in the multigeneration studies. The crucial dose level to 
use for establishing an .ADI could be considered to be 50 ppm (4.5 mg'kg bw/day), based 
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on a possible trcatmenl-relaled reduction in fertility at 300 ppm in the 2 generation 
reproductive toxicity study. A larger than normal safety factor is considered necessari' 
because this dose is not a clear no effect level and the effects seen in the study at high doses 
(abolition of reproductive capacity) are considered severe. Furthermore lhe mechanism of 
action of vinclozolin has not yet been clearly established, and the results of the teratology 
and multigeneration studies with vinclozolin suggest that the crucial dosing period for the 
expression of the anti-androgenic potential of vinclozolin could be quite early in pregnane}', 
at a time when many women may be unaware that they are pregnant. A safety factor of 
500 is considered necessary. 
A further multigeneration study in rats, long term studies in rats and mice, and investigative 
studies relating to the mechanism of toxicity of vinclozolin are known lo be ongoing. The 
Scientific Commiltee for Pesticides has already reviewed preliminary results from some of 
these experiments and will review these formally when complete reports are available. 
The no effect level in the 12-month dog study was equivalent to approximately 2 mg/kg 
bw/day, based on paihological changes indicative of anti-androgenicily. Although a safety 
factor of 100 could be considered appropriate for these effects, currently the 
mulligeneration sludy is considered more crucial in detcnninalion of lhe ADI in view of lhe 
higher safely factor required. A temporary ADI of 0.01 mg/kg bw mav therefore be 
derived, pending review of results of the ongoing studies. 
The committee drew attention to the fact that the JMPR ADI for vinclozolin is 0.07 mg'kg 
bw. but noted thai lhe JMPR has not reviewed many of the studies included in the present 
document. Members requested that the commission draw the attentionOf the JMPR to the 
conclusions of this current review. 
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REPORT OF TUE SCIENTIFIC COMMITTEE FOR PESTICIDES 
ON THE TOXICITY' OF CHLORPROPHAM 
(Opinion expressed by the SCP on 26 January 1995) 
BACKGROUND AND TERMS OF.REFERENCE 
Chlorpropham is a residual herbicide and potato sprout suppressant which has approvals for 
use in all member states. Chlorpropham is the common name for isopropyl 3-
chlorocarbanilate (IUPAC). It is often referred to as CEPC or isopropyl N(3-
chlorophenyl)carbamate. The structure of the molecule is shown below: 
NH.CO.OCf-KCHg); 
In the context of its work relating to the establishment of community maximum pesticide 
residue levels in various foodstuffs covered by community legislation, the Commission 
requested the Scientific Committee for Pesticides to review the ADI for chlorpropham. 
1. ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION 
Following oral dosing in rats, chlorpropham was rapidly absorbed and quickly eliminated. 
Within 24 hours, using ring labelled chlorpropham, approximately 80% of the administered 
dose appeared in the urine and 3% in the faeces. Using isopropyl labelled chlorpropham, 
approximately 45% was excreted in urine, 3% in faeces and 20% in [I4CJO2. ^ w a s stated 
that cnterohepatic circulation occurred. Chlorpropham levels rapidly declined in tissues of 
adult rats, with biological half lives generally around 3-6 hours. Highest tissue levels were 
detected in kidney, intestine, liver, blood and lung. (Ref. 1) 
Chlorpropham was metabolised to compounds including sulphate and glucuronide conjugates 
of chloroanilinc derivatives. Although the identity of all metabolites was not confirmed with 
certainty, the main metabolite appearing in rat urine was considered to be 4-hydroxy 
chlorpropham. (Refs. 1 and 2) 
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Experiments were carried out in pregnant rats and chlorpropham was slowly transferred to 
fetuses from dams. Transfer of chlorpropham via milk to pups was shown to occur. The 
extent of transfer appeared to be influenced by individual variations in dams. Investigations 
of intracellular distribution of chlorpropham in livers and kidneys of rats indicated that 
significant levels were found in the nuclear fraction of the liver, with less in the kidney 
nuclear fraction. (Refs. 1 and 3) 
2 TOXICITY 
2.1 ACUTE TOXICITY, IRRITATION AND SENSITISATION 
Chlorpropham is of low acute oral and intraperitoneal toxicity. The oral LD30 in rats is 
between 5 and 7.5 g/kg bw, while the intraperitoneal LD50 in rats is around 700 mg/kg bw. 
Clinical signs of toxicity consisted of listlessness, bradypnea, ataxia, haemodacryorrhoea, 
epistaxis, haemorhinorrhoea and exophthalmos. These signs appeared at 2-4 hours after 
dosing and reached a peak at 8-48 hours. The main necropsy finding was a marked irritant 
gastroenteritis. In rabbits the oral LDJ0 is around 5 g/kg bw. In a skin irritancy study in 
rabbits, only very slight irritancy was observed after 4 hours exposure to 0.5g of 
chlorpropham. Chlorpropham was not a skin sensitiser in a Magnusson and Kligmann assay. 
(Refs. 4-8) 
2.2 SUBACUTE TOXICITY 
In a summary paper on chlorpropham, published in 1959, it is stated that groups of 10 rats 
were fed chlorpropham for 90 days at concentrations of 20000, 5000, 1250 and 310 ppm in 
dry casein diet. All the treated groups were reported as surpassing the control group in 
mean body weight and food consumption. The mean liver weights of the 20000, 5000, and 
1250 ppm groups were significantly increased over those of the control group, although no 
microscopic abnormality was found at termination. (Ref. 9) 
Further 90-day studies were performed in rats and mice. The rats were dosed orally at dose 
levels of 0 (Control), 17, 70, 300 or 1200 mg/kg bw/day. At the two highest dose levels 
there were significant reductions in red blood cell counts and haemoglobin and haematocrit 
values and there was also a dose-related increase in the count of morphologically altered red 
blood cells and the reticulocyte count. In addition, absolute and relative liver and spleen 
weight were significantly increased at doses of 300 and 1200 mg/kg bw/day. Histological 
examination showed that chlorpropham increased production of red blood cells in the bone 
marrow and increased accumulation of red blood cells in the liver and spleen. A NOEL of 
70 mg/kg bw/day was determined in rats. In the mouse study, doses of 0 (Control), 105, 
210, 420 or 840 mg/kg bw/day were used. As was observed with rats, haematological 
examinations showed that chlorpropham affected red blood cells, particularly in males. A 
NOEL of 420 mg/kg bw/day was determined. (Ref. 10) 
In a 1960 publication, beagle dogs (2/sex/dose) were fed diets containing 0, 200, 2000 or 
20000 ppm chlorpropham for 1 year. An overall slight body weight loss was seen in animals 
at the top dose level. Food consumption in these animals was correspondingly reduced. 
There were no deaths and no overt signs of toxicity. Haematology investigations revealed 
reduced haemoglobin and haematocrit values at 1-6 months in animals at 20000 ppm. 
Urinalysis revealed no treatment-related findings. At the top dose, liver weights were 
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moderately increased and spleen weight markedly increased. Histopathological 
investigations revealed no treatment-related findings apart from splenic congestion in 2 dogs 
fed at the top dose. The NOAEL was 2000 ppm, equivalent to 50 mg/kg bw/day. (Ref. 11) 
2.3 CHRONIC TOXICITY/CARCINOGENICITY 
In an experiment of 116 weeks duration, reported in 1972, mice (25/sex/dose) showed no 
evidence of carcinogenicity when fed diets containing 1000 ppm chlorpropham or when 
subcutaneously dosed 9 times with 1 g/kg bw chlorpropham. Urethane, the positive control 
which is structurally related, caused multiple lung tumours (Ref. 12). In a study reported in 
1969, 18 mice/sex/strain from 2 hybrid strains were dosed from days 7-28 with 464 mg/kg 
bw and subsequently administered diets containing 1112 ppm chlorpropham until 18 months. 
There was no evidence of carcinogenicity. (Ref. 13) 
In a 1958 publication, the authors concluded that orally dosed chlorpropham has weak 
initiating activity in the presence of the promoter croton oil. Propham was also considered 
to be a weak initiator and urethane had a stronger initiating capability (Ref. 14). In a 1972 
publication, there was no evidence of carcinogenic potential in hamsters treated with 
2000 ppm chlorpropham or propham. A possible treatment-related increase in testicular 
atrophy was seen in groups treated with either propham or chlorpropham. (Ref. 12) 
In a study reported in 1960, rats (25/sex/dose) were fed diets containing 0, 200, 2000 or 
20000 ppm chlorpropham. These animals showed reduced body weight gain but increased 
food consumption when administered 20000 ppm chlorpropham in the diet. During the last 
13 weeks of the 2 year test period, mortalities in male rats were increased at 20000 ppm. 
Haemoglobin and haematocrit values were reduced mainly at 3 months, and liver and spleen 
weights appeared to be increased at 20000 ppm. Very few rats were alive at the end of the 
study. The apparent no effect level was 2000 ppm in the diet, equivalent to approximately 
100 mg/kg bw/day. (Ref. 11) 
2.4 MUTAGENICITY 
In in vitro studies chlorpropham was negative in Salmonella mutation assays, in a 
mammalian cell gene mutation assay and in chromosome aberration assays using human 
lymphocytes. Chlorpropham, however, does have some antimitotic activity in animal and 
plant cells. Investigative studies indicate that microtubules are not the primary target of 
chlorpropham action but that the primary site of action may be at the level of microfilaments, 
with microtubule disassembly resulting from this. (Refs. 15-26) 
In ;'/( vivo studies chlorpropham was negative in a sperm head abnormality assay in mice. 
(Rcf. 27) 
Chlorpropham was one of 42 chemicals tested in a range of experiments as part of an 
evaluation of short term tests for carcinogens in the late 1970's. A report was published of 
this international collaborative programme in 1981. Conflicting results were seen for 
chlorpropham and the conclusions of the report state that the responses observed could be 
interpreted in two separate ways depending on the data selected for consideration. The 
alleged non-carcinogenicity of chlorpropham was supported by negative responses in 19 
different bacterial mutation assays using two different marker organisms and a wide range of 
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protocols, the negative responses in the two independent UDS assays studied, and three 
negative responses in separate cytogenetic assays one conducted in vivo. Nonetheless, 
several positive responses were observed in assays sensitive to the carcinogen urethane, 
which is structurally related to chlorpropham and these activities, especially positive results 
in two cell-transformation assays, led the group to conclude that chlorpropham should be re-
evaluated for carcinogenic properties. Although this suggestion was triggered by the 
positive transformation responses, it is important to also note that chlorpropham also gave 
clear positive responses in the yeast aneuploidy and mitotic recombination assays. The 
report draws attention to the fact that the assays that find chlorpropham positive are, in 
general, among the least used for screening purposes, those most used finding it negative. A 
re-evaluation of the carcinogenicity of chlorpropham would present an opportunity either to 
confirm the need for such assays or to increase reliance on the more traditional ones such as 
bacterial mutation and cytogenetics. (Ref. 28) 
2.5 REPRODUCTIVE TOXICITY 
2.5.1 TERATOGENICITY 
In a study published in 1990, mated female Wistar rats (25/dose) were administered orally by 
gavage from day 6 'to 15 post coitum with 0, 50, 200 or 800 mg/kg bw/day of chlorpropham 
(99.3% pure) and killed on day 21. There were no deaths, although overt signs of toxicity 
were seen at 800 mg/kg bw/day, on nearly every day during the treatment period. 
Throughout the treatment period, food consumption was significantly decreased at 800 
mg/kg bw/day, while at 200 mg/kg bw/day, there was slight decrease from day 6 to 11. 
Body weight gain was reduced in a dose-related fashion at 200 and 800 mg/kg bw/day 
mainly during the first half of the dosing period. There were no treatment-related effects on 
numbers of implantations, pre-and post-implantation losses or numbers of live fetuses. 
Examination of fetuses revealed no treatment-related affects on sex ratios or any external or 
visceral malformations/variations related to treatment. At 800 mg/kg bw/day, reduced body 
weights were observed in both fetal sexes. As a consequence of the delayed development in 
these fetuses, retarded ossification was noted to a greater extent in some fetuses at 800 
mg/kg bw/day. At 800 mg/kg bw/day, a possible treatment-related increased incidence in 
fetuses with supernumerary ribs was observed. The authors state that this was within the 
normal range of deviations for the rat strain used. The no effect level for maternal toxicity 
was 50 mg/kg bw/day, based on reduced body weight gain and food consumption at 200 and 
800 mg/kg bw/day. The no effect level for fetotoxicity was 200 mg/kg bw/day based on 
reduced fetal body weights and associated retarded ossification at 800 mg/kg bw/day. There 
was no evidence of teratogenicity at any dose level. (Ref. 29) 
In a US National Cancer Institute study of 48 compounds over the period 1963-68, 
chlorpropham was given subcutaneously in DMSO at 1000 mg/kg bw (maximum tolerated 
dose) to BL6 pregnant mice. Dosing occurred over days 6-14 of gestation, and the animals 
were killed on day 18. There were only 6 litters. Maternal weight gain, liver weight and the 
amount of amniotic fluid per fetus were significantly increased. Crown-rump length was 
decreased compared to controls. The authors did recommend that a further pre-natal study 
was needed as the study performed was limited by the number of litters in the treatment 
group. In a post-natal study in BL6 mice incorporating the same dosing regime, neonates 
were examined at birth and at day 8 and then were killed. There were only 13 litters, and 
these were compared only with 4 control litters. The average number of live nconales/litter 
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was low. Mortality between days 1-8 was relatively high. However, control mortalities 
were also high. As with the pre-natal study, further investigations would be required in order 
to clearly ascertain the post-natal effects on pups exposed in utero. (Ref. 30) 
2.5.2 MULTIGENERATION STUDIES 
A 2-generation reproduction study was performed on rats at dietary levels of 0 (Control), 
1000, 3000 and 10000 ppm. It was concluded that chlorpropham does not affect fertility and 
reproduction at the doses administered. Spleen and liver weight were clearly affected and 
reduced weight gain was observed in adults at the highest dietary level, along with increased 
mortality in FI offspring. The same dose also produced significantly lower body weights in 
Fl generation on day 21 and in the F2 generation on days 14 and 21. The high dose level 
(equivalent to approximately 750 mg/kg bw/day) also caused significantly decreased kidney 
and spleen weight in F2 males. The NOAEL was 3000 ppm, equivalent to approximately 
150 mg/kg bw/day.. (Ref. 10) 
3 OVERVIEW AND ESTIMATION OF ADI 
The only quantitative data relating to no effect levels can be taken from the one year dog and 
two year rat studies. In each of these studies, dietary levels of 2000 ppm were no effect 
levels, with relatively non-specific toxicity seen at higher doses. In dogs, a dietary level of 
2000 ppm is equivalent to 50 mg/kg bw/day, while in rats the same dietary level equates to 
about 100 mg/kg bw/day over two years. However, these experiments were conducted 
some years ago and it is difficult to -assess the quality of the studies from the available 
reports. In view of this inadequacy of the database, and to take account of the resultant 
uncertainty on the toxicity of chlorpropham, a higher than normal safety factor is considered 
necessary. Using a 500 fold safety factor, it may be concluded that the temporary 
Acceptable Daily Intake should be in the order of 0.1 mg/kg bw pending review of a 
complete up to date database. 
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REPORT OF THE SCIENTIFIC COMMITTEE FOR PESTICIDES 
ON THE USE OF ETHEPHON 
(Opinion expressed by the SCP on 26 January 1995) 
BACKGROUND AND TERMS OF REFERENCE 
Ethephon is the common name for 2-chloroethylphosphonic acid which is a plant growth 
regulator, which has been marketed in member states since 1971. In the context of its work 
to establish maximum pesticide residue levels pursuant to the relevant Community 
legislation, the Commission requested the Scientific Committee for Pesticides to examine 
toxicological data relating to ethephon and to estimate its Acceptable Daily Intake. 
Ethephon is readily absorbed by plants and releases ethylene, which is also a natural plant 
hormone. Ethylene influences physiological processes such as ripening or maturation. 
Ethephon was reviewed by the JMPR in 1977, 1978, 1983 and 1985 but no ADI could be 
estimated because toxicological data were not made available. The Scientific Committee has 
been requested to establish an ADI, several new studies now being available. Since then the 
JMPR has reviewed ethephon again in 1993 and an ADI has been estimated. The present 
evaluation summarises data available to the Scientific Committee which were considered 
relevant to the derivation of an ADI. The toxicological evaluation of the Scientific 
Committee has been compared with that of the JMPR. 
TOXICOLOGY AND METABOLISM OF ETHEPHON 
Physical and chemical properties 
The active ingredient is a white solid substance with a purity of 93.4%. This product is a 
waxy solid which is difficult to handle as such. Therefore a technical product is marketed 
named Base 250 containing 71.3% of ethephon and 21.7% of water. The main impurities arc 
ethane-1,2-diphosphonic acid (3.5%), mono-2-chloroethylester of ethephon (3%), the mono-
2-chIoroethylester of 1,2-ethane diphosphonic acid (2.2%), the monocthylethcr of ethephon 
(1.5%) and phosphonic acid (0.5%). All dietary concentrations mentioned.in this report have 
been corrected for purity and arc expressed as pure ethephon. 
The density of the pure compound is 1.6, the melting point 74-75°C and the vapour pressure 
<2.78 hPa at 25°C. The compound is very soluble in water, methanol, acetone and 
cthylacetate, but poorly or non-soluble in n-hexane, toluene or dichloromethane. The log 
Pow(n-octanol/water) is -0.22 at 25°C. The dissociation constants are pKI=2.5 and 
pK2=7.2. Ethephon is stable at pH=3 and lower. It decomposes, liberating ethylene at 
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higher pH values and the transformation is almost complete in alkaline medium. 
In animal studies ethephon inhibits plasma and erythrocyte Cholinesterase, although this is not 
expected from the chemical structure. It is possible that impurities in the ethephon 
formulation might cause the inhibition of Cholinesterase. Ethephon has never been found to 
inhibit brain acetyl Cholinesterase in any of the animal species tested. Physico-chemical 
properties could prevent crossing of the blood.brain barrier. 
Absorption, distribution and excretion 
1.Rat studies 
Four groups of five male and five female rats were used. In the first three groups a single 
dose of 50 mg/kg bw of 14C-ethephon was administered intravenously, orally and orally 
following 14 oral doses (50 mg/kg bw/day) of non-labelled ethephon respectively. The 
fourth group received a single oral dose of 1000 mg/kg bw 14C-ethephon. For the low oral 
dose around 90% of the administered radioactivity was recovered after 120 h, most of it 
after 16h. In urine and faeces 50-60% and 4-6% were found respectively. In expired air 18-
20% was recovered as ethylene. Tissue concentrations were low or non-detectable. When 
ethephon was given orally at the high dose level, around 86% of the dose was recovered in 
120h, most of it being eliminated in 24h. The substance was principally found in urine (47-
49%), in expired air (17-20%) and faeces (6.5%). Tissue concentrations were again low or 
non-detectable at 120h. After pre treatment with non-labelled ethephon the recovery of the 
labelled substance was comparable with the single dose. Comparison of excretion data after 
intravenous and oral administration and oral administration indicated that absorption after 
oral administration was higher than 70%. No major sex differences were observed. 
Two additional groups, receiving respectively 50 and 1000 mg/kg bw, were used to 
determine kinetic parameters. Animals were killed 168h after dosing. Following a dose of 
50 mg/kg bw, whole blood parameters indicated that Cmax was rapidly attained (Tmax 0.5-
2h). Thereafter, concentrations of radioactivity declined to levels near background in 12-
24h. After 1000 mg/kg bw blood levels peaked initially at 0.5h, then again at 4h, thereafter 
falling rapidly in a similar manner as with the low dose (1). 
2.Dog studies 
Three dogs were dosed orally with 180 mg/kg bw 14C-ethephon. Urine, blood, expired air 
(ethylene and C0 2 ) and faeces were collected at intervals. Ethephon was rapidly absorbed 
and blood levels decreased from peak levels after 3 h to traces after 22h. Ethephon was 
excreted rapidly in urine and faeces and via air as ethylene. After 72h only traces remained in 
the tissues. Plasma and erythrocyte Cholinesterase activities in blood were depressed, but 
recovered in a few hours (plasma) or days (erythrocytes) (2). 
Biotransformation 
Ethylene in expired air has to be considered as a major metabolite in both species tested (rats 
and dogs). Formation of ethylene is also the transformation route in plants. Following oral 
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dosing of 14C-ethephon to rats, 4 TLC-peaks were observed in urine. Approximately 50% of 
the radioactivity was identified as parent compound. Two metabolites were identified as di-
and mono-sodium salt and the other remained unidentified. In faeces the same metabolites 
were found. The metabolism of ethephon was sex, dose and route independent (3). 
In the urine of dogs, dosed orally with '4C-ethephon only unchanged ethephon was found. 
Acute toxicity studies 
The oral LD50 of ethephon (technical or purified) in male mice was 1920 mg/kg bw (5). 
The oral LD50's in rats were 3730 and 2210 mg/kg bw, equivalent to 2650 and 1570 mg/kg 
bw pure ethephon for male and female rats respectively (6). The oral LD50 of purified 
ethephon in female rabbits was higher than 562 mg/kg bw (7). No characteristic clinical 
signs were observed. Male and female Sprague-Dawley rats were exposed for four hours to 
aerosol concentrations of 6.1, 3.3 or 2.1 mg/l Base 250. The LC50 for both male and female 
rats was 4.5 mg/l equivalent to 3.2 mg/l of pure ethephon (8). The acute dermal LD50 of 
Base 250 in male and female New Zealand rabbits was 1710 and 1390 mg/kg bw respectively 
(equivalent to 1219 and 991 mg/kg bw of pure substance) (9). 
Ethephon was corrosive in a 4-hour skin irritation test in rabbits (10). In a 1-hour test it was 
irritant showing only erythema (10). Ethephon was tested in 2 sensitisation tests. 
Sensitisation was not observed in either the Magnusson-Kligman or in the Buehler test (11a 
and l ib) . 
Subacute toxicity studies 
1. Mouse 
In a 28-day study, groups of 10 mice of each sex were fed with ethephon in the diet for 30 
days at concentrations of 0, 225, 900, 1800 or 3600 ppm. Ethephon did not induce 
detectable effects in behaviour, body weight or food consumption, but liver weights were 
decreased in males at doses of 1800 and 3600 ppm. Red blood cell Cholinesterase activity 
was depressed at 900 ppm and higher in the males and at 450 ppm and higher in the females 
after 4 weeks. Plasma Cholinesterase was depressed also at dosages of 450 ppm and higher. 
The NOAEL was 225 ppm based on erythrocyte Cholinesterase inhibition (12). 
In a second 28-day study ethephon was administered to male and female CD-I mice at 
concentrations of 0, 30, 100, 300, 1000 and 3000 ppm. No effects were observed in clinical 
signs or mortality, food consumption, body weight, organ weights or liver enzymatic 
functions. Plasma and erythrocyte Cholinesterase activity was inhibited in both sexes after 2 
and 4 weeks of exposure at 1000 and 3000 ppm. Plasma Cholinesterase was inhibited in the 
300 ppm group at 2 weeks also. Brain Cholinesterase was not inhibited at any dose level. 
The NOAEL, based on erythrocyte Cholinesterase inhibition, is 300 ppm, equal to 51 mg/kg 
bw/day (13). 
In a third 28-day study, conducted to establish a maximum tolerated dose, ethephon was 
administered in the diet of CD-I mice at concentrations of 0, 3000, 10000, 25000 and 50000 
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ppm. No effects were observed in the incidence of clinical signs or mortality. Food 
consumption was reduced in the high dose group at week 1 and body weight reduction 
occurred in the 25000 and 50000 ppm dose groups throughout the study. Dose-related 
inhibition of plasma and erythrocyte Cholinesterase activity was observed in both sexes at all 
dose levels after 2 and 4 weeks. No brain Cholinesterase inhibition was observed at any dose 
(14). 
2. Rats 
In a 28-day study CD-rats were given diets containing ethephon at concentrations of 0, 625, 
1250, 2500, 5000 and 10000 ppm. As in mice no incidence of mortality, clinical signs or 
liver enzymatic dysfunction was observed at any dose in either sex. Plasma and erythrocyte 
Cholinesterase were inhibited dose-relatedly in both sexes. Based on erythrocyte 
Cholinesterase inhibition, the NOAEL for males was 1250 ppm, but an NOAEL could not be 
established for females (15). 
A second rat study was conducted to establish a maximum tolerated dose in CD-rats fed with 
diets containing ethephon at concentrations of 0, 10000, 25000 and 50000 ppm for 28 days. 
Decreased food consumption and body weight gain were observed at the two highest dose 
levels, while animals at the highest dose level had diarrhoea from day 10 onwards. Neither 
mortality, nor brain Cholinesterase inhibition was observed. Inhibition of plasma and 
erythrocyte Cholinesterase was dose related in both sexes (16). 
3.Rabbits (dermal) 
In the first study male and female New Zealand rabbits received repeated dermal exposures 
at 300 and 600 mg/kg bw Ethrel (ethephon 39.5% in aqueous solution) per day, 5 days per 
week for 3 weeks. No systemic toxicity was observed but moderate to severe dermal 
irritation up to ulceration occurred (17). 
In the second study groups of rabbits were exposed to 0, 20, 60 or 180 mg/kg Ethrel 
(ethephon 31.5%) on intact or abraded skin, 5 days a week for 3 weeks. No clinical or 
biological changes were recorded except acanthosis in two high dose animals (18). 
4.Dogs 
Ethephon was administered daily in the diet of male and female beagle dogs at levels of 0, 
100, 300, 1000 or 2000 ppm for 52 weeks. Animals at 2000 ppm showed soft stools. There 
was a significant decrease in terminal body weight and in spleen weight at the highest dose of 
2000 ppm. There were no histopathologic^ findings in the spleen and no effect on 
haematology was reported. The NOEL was 1000 ppm, based on body and spleen weight 
changes. However, an NOAEL can not be estimated because measurements of 
Cholinesterase activity were not performed (19). 
A two-year study with ethephon technical was conducted in beagle dogs at 0, 30, 300 or 
1500 ppm in the diet. Initially the highest dose was 3000 ppm, but was decreased to 2000 
ppm at week 4, decreased again to 1000 ppm at week 6 and increased to 1500 ppm from 
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week 25-104. Soft stools and intermittent emesis were the only clinical signs reported in the 
dose groups of 300 ppm and higher. Plasma Cholinesterase activities in treated male and 
female dogs were decreased in all dose groups, but erythrocyte Cholinesterase was inhibited 
only at 300 and 1500 ppm. There were no effects on brain Cholinesterase. Macroscopic 
post-mortem examination indicated thickened stomach and intestinal wall in dogs from all 
groups. Histopathologically, smooth muscle hypertrophy in the stomach and small intestines 
was found at 300 and 1500 ppm. The dose level of 30 ppm, equal to 0.86 mg/kg bw/day is 
considered as the NOAEL (20). 
Special studies on delayed neurotoxicity 
Groups of 10 white Vantress hens were intubated with 1000 mg/kg bw/day of either 
technical or formulated ethephon for 5 days. This dose caused mortality and doses were 
reduced to 500 and 200 mg/kg bw/day for additional 5 or 9 days. No signs of neurotoxicity 
were noted and no gross pathology in the spinal cord or sciatic nerve was observed in any of 
the necropsied hens (21). 
Mature White Leghorn hens were dosed with 3850 or 3160 mg/kg pure ethephon. Nearly all 
animals at 3850 mg/kg died after 24h. In the 3160 mg/kg group signs of lethargy and ataxia 
were present following dosing. The surviving hens showed no signs of toxicity after 21 days. 
They were given a second dose of 2370 mg/kg bw and again observed for 21 days. No signs 
of neurotoxicity or treatment related histomorphological changes in the neural tissues were 
observed (22). 
Long term/carcinogenicity studies 
l.Mice 
In a study conducted with ethephon 4 groups of Swiss albino mice (85 animals/group/sex) 
were fed diets containing 0, 30, 300 and 1000 ppm of pure ethephon for 78 weeks. Survival 
was reduced among males fed 300 and 1000 ppm, but the report claimed that death was due 
to inter current infections. Plasma and erythrocyte Cholinesterase activities were decreased 
in both male and female animals at 300 and 1000 ppm. Females appeared to be more 
sensitive than males. Brain Cholinesterase activity was not affected. The NOAEL could be 
established at 30 ppm (equal to 4 mg/kg bw/day). There was no treatment related increase in 
tumour incidence in this study (23). 
A dietary oncogenicity study was conducted exposing male and female CD-I mice to 0, 100, 
1000, 10000 and 50000 ppm ethephon for 78 weeks. Animals dosed at 50000 ppm were 
sacrificed after 1 week due to excessive morbidity and mortality. These results are in 
contrast with the 28-day study in mice (14), in which the animals survived 50000 ppm 
ethephon. At all other dose levels no adverse changes were observed in mortality, clinical 
signs, haematology and clinical chemistry (except Cholinesterase inhibition) or gross and 
microscopic pathology. Weight gain was depressed at 10000 ppm only. Toxicologically 
significant Cholinesterase inhibition in erythrocytes was observed at 1000 and 10000 ppm 
while brain Cholinesterase activity was unaffected. The NOEL was claimed to be 1000 ppm 
based on weight gain, but based on erythrocyte Cholinesterase inhibition the NOAEL is 100 
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ppm, equal to 14 mg/kg bw/day. Again, ethephon did not induce treatment related tumours 
in this study (24). 
2.Rats 
Ethephon was fed to Sprague-Dawley CD rats at nominal levels 0, 30, 300 and 3000 ppm for 
two years. No clinical signs or effects on gross or microscopic pathology were observed in 
any of the animals. Cholinesterase activity was inhibited in plasma and red blood cells at 300 
and 3000 ppm. Brain Cholinesterase was not affected and there were no signs of CNS effects 
at any dose level. Ethephon did not increase tumour incidence in the rat. Taking into 
account the slight Cholinesterase inhibition at 300 ppm in females, the NOAEL is 30 ppm, 
equivalent to 1.5 mg/kg bw/day (25). 
Ethephon was administered to Sprague-Dawley CD rats at dietary levels of 0, 300, 3000, 
10000 and 30000 ppm for 97 (males) and 104 (females) weeks. Treatment related effects 
were observed at the two highest dose levels including depression in food consumption, 
decreased body weight gain and decreased urinary pH. At 30000 ppm kidney weight was 
increased. Ethephon inhibited plasma and erythrocyte Cholinesterase at all dose levels, but at 
300 ppm erythrocyte Cholinesterase inhibition was less than 20%. No inhibition of brain 
Cholinesterase activity was found. Animals from the two highest groups showed some 
evidence of recovery when they were maintained for 4 weeks on control diet following 52 
weeks of exposure. This recovery was not complete for body weight gain and Cholinesterase 
inhibition. An NOAEL could be established at 300 ppm, equal to 13-16 mg/kg bw/day, 
based on erythrocyte Cholinesterase inhibition. Ethephon was not carcinogenic even at the 
highest dose tested in this study of 30000 ppm (26). 
Reproduction studies 
1. Two-generation reproduction 
A 2-generation reproduction study has been performed with Sprague-Dawley rats (28 
animals per sex per group) receiving dietary concentrations of 0, 300, 3000 or 30000 ppm 
ethephon. Animals were dosed for 10 weeks prior to breeding for the Fla and Fib 
generations. Dosing continued throughout mating, gestation, parturition and lactation. The 
Fib generation was used to produce the F2a and F2b generations under the same regimen. 
Parental body weights were consistently reduced at 30000 ppm and sporadically affected at 
3000 ppm. Similar effects occurred in the pups of both generations. The number of pups 
dying in the Fib generation was increased at 30000 ppm. Deaths generally occurred in the 
perinatal period (postnatal days 0-7). The incidence of soft stools was consistently increased 
at 30000 ppm. Mating, fertility and gestation were not affected by ethephon. The NOAEL is 
300 ppm, equivalent to approximately 25 mg/kg bw/day, for reproduction parameters and 
offspring (27). 
2.Rat teratology/embryotoxicily 
The teratogenic potential of ethephon was studied in Charles River rats. Pregnant animals 
(25 per group) were dosed with 0, 200, 600 and 1800 mg/kg bw./day on days 6-19 of 
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gestation. There were no biologically meaningful differences in appearance or behaviour, 
mean maternal body weight, caesarean section observations and embryo/fetotoxicity of the 
rats in the 200 or 600 mg/kg group compared to the control. The dosage level of 1800 
mg/kg bw/day produced excessive maternal toxicity, 14/25 animals died during the treatment 
period and only 9 litters with viable fetuses were available for evaluation. The NOAEL was 
600 mg/kg bw/day, based on maternal and fetotoxicity (28). 
In another (preliminary) teratology study 12% mortality was observed in females dosed with 
600 mg/kg bw/day. The main study was conducted using CD rats (25 per group) dosed by 
gavage with 0, 125, 250 or 500 mg/kg bw/day on days 6-15 of gestation. No dose related 
alterations in any maternal or fetal parameter were observed. The NOAELs for maternal and 
embryo/fetotoxicity were 500 mg/kg bw/day (29). 
3.Rabbit teratology/embryotoxicity 
New Zealand white rabbits (17 per group) received daily oral gavage doses of 0, 50, 100 or 
250 mg/kg bw/day ethephon during days 6-19 of gestation. Animals dosed with 250 mg/kg 
bw/day showed decreased activity during and after dosing interval. There were 1, 2, 4 and 8 
mortalities in the 0, 50, 100 and 250 mg/kg bw/day groups respectively. The mortality in the 
100 and 250 mg/kg bw/day groups was considered as treatment related. Animals of the 250 
mg/kg bw/day group had a transient decrease in body weight gain but returned to nonna! 
during the post-dosing interval. No treatment-related gross lesions were found at necropsy. 
No differences occurred with regard to the mean number of corpora lutea or implantations. 
At 100 and 250 mg/kg bw/day an increase in the resorption rate occurred, which was 
statistically significant at the highest dose only. There were no effects on the fetuses. The 
NOAEL in this study is 50 mg/kg bw/day for both maternal and embryo/fetotoxicity (30). 
In a second study New Zealand white rabbits (22 per group) received daily oral gavage doses 
of 0, 62.5, 125 or 250 mg/kg bw/day ethephon during days 7-19 of gestation. Treatment-
related mortality (17/22) occurred in the 250 mg/kg bw/day group and gross lesions in the 
stomach were recorded. The principal treatment-related clinical signs in the 250 mg/kg 
bw/day group before death were ataxia, lethargy, prostration and anogenital staining. Post 
implantation loss and percentage of early resorptions were considerably higher and number 
of live fetuses lower at 250 mg/kg bw/day. Transient decreases in body weight gain 
occurred in the 125 mg/kg bw/day group. No differences were found with regard to the 
mean number of corpora lutea or implantations, the number of dams with live or resorbed 
fetuses or in fetal body weight up to 125 mg/kg bw/day. The NOAEL is 125 mg/kg bw/day 
for both maternal and fetal toxicity (31). 
Ethephon did not demonstrate teratogenic potential in any of the studies with rats or rabbits. 
Mutagenicity 
Ethephon was evaluated in the Ames Salmonella assay. The results were negative with 
strains TA-98, TA-100, TA-1537 and TA-1538, but positive in strain TA-1535 (base-pair 
substitution) with and without metabolic activation (32). 
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All other tests were found negative. No mutagenic activity was observed in three 
CHO/HGPRT-tests (33, 34 and 35), a chromosomal aberration test in CHO-cells (36), two 
rat hepatocyte DNA-repair tests (37 and 38), a micronucleus test in mice (39) and a 
dominant lethal test in rats (40). 
According to these results ethephon is considered not to be mutagenic. 
HUMAN DATA 
Two male individuals received oral doses of ethephon (88%) in propylene glycol ranging 
from 5.4-220 mg per day over a 7 week period. There were no effects on plasma or 
erythrocyte Cholinesterase throughout the study. Transient feelings of urinary urgency were 
experienced by both subjects at the beginning of the study (41). 
A group of 5 men and 5 women received orally approximately 125 mg technical ethephon 
per day (divided into 3 doses) by capsule for 28 days. A placebo was given to 3 men and 3 
women. Cholinesterase activity was unaffected, but the subjects experienced transient 
complaints of urgency of bowel movements and urination and an increased urination 
frequency (42). 
A group of 10 men and 10 women received 0.5 mg/kg bw/day of ethephon, divided into 3 
doses, orally by capsule for 16 days. They were compared to a group of 10 persons 
receiving a placebo. Clinical signs and symptoms, haematology and blood chemistry were 
unaffected by ethephon treatment. There was a statistically significant decrease in plasma 
Cholinesterase activity in the treated group throughout the dosing interval, but the enzyme 
activity was comparable to control values at the end of the recovery period (day 29). Red 
blood cell Cholinesterase was not inhibited at this dose level (43). 
Twenty human volunteers in good health received orally by capsule, without knowing to 
which group they were assigned, 0 (3 males, 3 females), 0.17 (3 males, 4 females) or 0.33 (4 
males, 3 females) mg/kg bw/day of ethephon. The substance was given divided in three daily 
doses for 15 consecutive days. Clinical signs and symptoms, haematology, blood chemistry 
and urine volume were not affected by the treatment. Plasma Cholinesterase was marginally 
inhibited throughout the treatment and recovery periods (8 and 15 days and up to day 36) at 
0.17 mg/kg bw/day. The inhibition was more prominent at 0.33 mg/kg bw/day. Erythrocyte 
Cholinesterase was unaffected at either dose (44). 
OVERVTEW AND ESTIMATION OF ADI 
1. Ethephon, a systemic plant growth regulator, is readily absorbed by plants and releases 
ethylene, which has an influence on maturation of plants. It is also readily absorbed by 
animals and eliminated rapidly, mainly in the urine as unchanged ethephon (>50%) and in 
expired air as ethylene (20%). In faeces only a relatively small amount is found. Most of the 
elimination takes already place within 24 hrs. Apart from ethylene only a small fraction of 
metabolites (mono- and di- sodium salt of ethephon) are found. 
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2. Ethephon is an inhibitor of Cholinesterase in plasma and erythrocytes, but has never been 
found to inhibit brain Cholinesterase in any of the animal species tested. 
3. The acute oral toxicity is low, with an LD50 for rats of >2000 mg/kg bw for pure 
ethephon. The dermal toxicity for rabbits is moderate, with an LD50 of around 1000 mg/kg 
bw. This may be caused by the acidic and corrosive properties of ethephon for the skin. The 
compound is not sensitizing. 
4. Ethephon has no teratogenic potential and the no effect level for reproductive effects in a 
multigeneration study was equivalent to approximately 25 mg/kg bw/day. It is neither 
carcinogenic in long term studies in rats and mice, nor genotoxic in various mutagenicity 
studies. No delayed neurotoxicity was found in hens. 
5. In subchronic and chronic toxicity studies in mice, rats and dogs ethephon inhibits plasma 
and erythrocyte Cholinesterase. The lowest NOAEL of 30 ppm, equal to 0.86 mg/kg bw/day 
is found in a two-year dog study. In a chronic mouse study 100 ppm, equal to 14 mg/kg 
bw/day can be considered as the NOAEL. In the first long term rat study a slight effect on 
erythrocyte Cholinesterase was observed at 300 ppm in females, but in the second (more 
recent study) no meaningful inhibition was found at 300 ppm, equal to 13-16 mg/kg bw/day, 
so this level can be considered as the NOAEL for rats. All the NOAELs are based on 
Cholinesterase inhibition in red blood cells. 
6. Several studies have been carried out in human volunteers. In the most recent studies a 
dosage of 0.5 mg/kg bw/day is chosen as the NOAEL, based on the absence of 
Cholinesterase inhibition in red blood cells. 
7. The animal studies confirm that the end point examined in the human volunteer studies 
(Cholinesterase inhibition) is the crucial end point for estimation of an ADI for ethephon. It 
was therefore decided to use the NOAEL in humans of 0.5 mg/kg bw/day as the basis for 
estimating the ADI, using a safety factor of 10, since the no effect level is derived in humans. 
Therefore an ADI of 0.05 mg/kg bw can be established. This is the same ADI as was 
estimated by the JMPR in 1993. 
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REPORT OF THE SCIENTIFIC COMMITTEE FOR PESTICIDES 
ON THE TOXICITY OF MECARBAM 
(Opinion expressed by the SCP on 26 January 1995) 
BACKGROUND AND TERMS OF REFERENCE 
Mecarbam (S-(N-ethoxycarbonyl-N-methylcarbamoylmethyl) 0,0-diethyl phosphorodi-
thionate) is an organophosphorus insecticide which has approvals for use in some member 
states. In the context of its work relating to the establishment of community maximum 
pesticide residue levels in various foodstuffs covered by community legislation, the 
Commission requested the Scientific Committee for Pesticides to review the ADI for 
mecarbam, by reference to previous reviews carried out by the World Health 
Organisation/Food and Agriculture Organisation Joint Meeting on Pesticide Residues. 
Mecarbam has been reviewed by the JMPR in 1980, 1983, 1985 and 1986. Data relevant to 
the establishment of an ADI are summarised below. These summaries haVe been prepared by 
reference to JMPR reports, not the original study reports. 
1. ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION 
Following oral dosing in rats, ethoxy-radiolabelled mecarbam was rapidly absorbed and 
quickly eliminated. Within 48 hours approximately 92% of the administered radiolabel 
appeared in the urine, 2% in the faeces and 5% in expired C02. There was no accumulation 
in tissues. (Ref. 1) In further studies in rats, using carbamoyl-labelled mecarbam, 
approximately 80% of administered radiolabel was eliminated in urine within 48 hours, 
approximately 3% in the faeces and negligible amounts (0.4%) in expired C02. (Ref. 4) The 
apparent differences in the results of these studies could be associated with the different 
radio-label position used. 
Mecarbam was metabolised in the rat to at least 10 non-conjugated and one conjugated 
compound. Although the identity of all metabolites was not confirmed with certainty, 
hydrolysis, oxidative dcsulphuration and degradation of the carbamoyl moiety appear to be 
the major metabolic reactions. (Ref. 4) 
2 TOXICITY 
2.1 ACUTE TOXICITY 
Mecarbam has been tested for acute oral and intraperitoneal toxicity. The oral LDJ0 in rats is 
between 20 and 50 mg/kg bw, while that in mice is around 100 mg/kg bw. The 
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intraperitoneal LD30 in mice is around 120 mg/kg bw. Clinical signs of toxicity were 
consistent with Cholinesterase inhibition. (Ref. 1) 
2.2 SUBACUTE TOXICITY 
Groups of 15 female rats were fed diets containing 0, 1, 5, 10 or 50 ppm mecarbam for 26 
weeks. There were no deaths and weight gain and food intake remained unaffected by 
treatment. Overt signs of toxicity (muscular tremors) were noted at 50 ppm. Cholinesterase 
activity was depressed in red blood cells and brain at 10 and 50 ppm. Gross pathology and 
histopathological investigations revealed no treatment-related findings. The NOAEL was 
5 ppm. (Ref. 1) 
Groups of 4 male and 4 female beagle dogs were fed diets containing 0, 10, 20 or 50 ppm 
mecarbam for 26 weeks. There were no deaths and no overt signs of toxicity and weight 
gain and food intake remained unaffected by treatment. Cholinesterase activity was 
depressed in red blood cells and brain at 20 and 50 ppm. Gross pathology and 
histopathological investigations revealed no treatment-related findings. The NOAEL was 10 
ppm, equal to 0.35 mg/kg bw/day. (Ref. 1) 
Groups of 4 male and 4 female beagle dogs were fed diets containing 0, 1, 5 or 50 ppm 
mecarbam for 2 years. There were no deaths and no overt signs of toxicity and weight gain 
and food intake remained unaffected by treatment. Cholinesterase activity was depressed in 
red blood cells and brain at 50 ppm. Gross pathology and histopathological investigations 
revealed no treatment-related findings. The NOAEL was 5 ppm, equal to 0.15 mg/kg 
bw/day. (Ref. 1) Ί 
2.3 CHRONIC TOXICITY/CARCINOGENICITY 
Groups of 25 male and 25 female Sprague Dawley rats were fed diets containing 0, 1, 5 or 
50 ppm mecarbam for 104 weeks. Animals receiving 50 ppm showed reduced body weight 
gain but food consumption remained unaffected. There was some indication of increased 
mortality among treated animals, but the small group size precluded adequate evaluation. 
Cholinesterase activity was depressed in red blood cells and brain at 50 ppm. Gross and 
microscopic examination of tissues revealed no treatment related findings and there was no 
indication that mecarbam had any carcinogenic potential. The NOAEL was 5 ppm in the 
diet, equal to 0.2 mg/kg bw/day. (Ref. 1) 
2.4 MUTAGENICITY 
In ;'/; vitro studies mecarbam was negative in a Salmonella mutation assay, negative at non­
toxic dose levels in a mammalian cell gene mutation assay at the TK locus in L5178Y cells 
and negative in a DNA repair assay using HeLa cells. In in vivo studies mecarbam was 
negative in a micronucleus test in mice. Results of an in vivo metaphase analysis test in rats 
were inconclusive, but the study design was considered inadequate. (Ref. 2) 
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2.5 REPRODUCTIVE TOXICITY 
2.5.1 TERATOGENICITY 
Groups of 24 mated female Sprague Dawley rats were administered orally by gavage from 
day 6 to 19 post coitum with 0, 1 or 3 mg/kg bw/day of mecarbam and killed on day 20. 
There were no deaths, although overt signs of toxicity (salivation and body tremors) were 
seen at 3 mg/kg bw/day and body weight gain was reduced at 3 mg/kg bw/day. There were 
no treatment-related effects on numbers of implantations, pre-and post-implantation losses or 
numbers of live fetuses. Examination of fetuses revealed no treatment-related affects on sex 
ratios or any external, skeletal or visceral malformations/variations related to treatment. 
Overt malformations were seen in 4 fetuses from a single litter at the high dose, but these 
were not considered to be treatment related in the absence of effects in any other litters. 
(Ref. 2) 
2.5.2 MULTIGENERATION STUDIES 
A 2-generation (2 litter/generation) reproduction study was performed on groups of 25 male 
and 25 female rats at dietary levels of 0 (Control), 2 and 50 ppm. An investiagtion of 
teratology was incorporated into this study, in which 5 females per group from the second 
litter of each generation were killed and examined on day 19 or 20 of gestation. It was 
concluded that mecarbam does not affect fertility and reproduction at 2 ppm. In contrast, at 
50 ppm, there was a decrease in the number of pups bom alive, an increased pup loss during 
lactation and. a reduced pup weight at weaning, in both litters of both generations. Reduced 
weight gain was observed in adults at the high dietary level. Evaluation of fetuses removed 
by caesarean section did not reveal any teratogenic effects, but did reveal a reduced number 
of implantation sites and corpora lutea and an increased number of resorbtion sites at 50 
ppm. The NOAEL was 2 ppm, equivalent to approximately 0.1 mg/kg bw/day. (Ref. 1) 
2.6 SPECIAL STUDIES ON NEUROTOXICITY 
The potential of mecarbam to induce delayed neurotoxicity in hens was investigated. These 
studies revealed no indication of any neurotoxic potential. (Refs. 1 and 2) 
3 OVERVIEW AND ESTIMATION OF ADI 
At the JMPR meeting in 1980 a temporary ADI was established at 0.001 mg/kg bw. This 
conclusion was confirmed at the 1983 meeting, but further data were required to be 
submitted by 1985. These data were not submitted and at the 1985 meeting the temporary 
ADI was lowered to 0.0005 mg/kg bw. The required data were reviewed at the 1986 
meeting and a full ADI was established at 0.002 mg/kg bw. 
The available data indicate that the toxicological profile of mecarbam is that of a typical 
organophosphorus compound. Acute and short term toxicity investigations are considered 
adequate and mecarbam does not induce delayed neuotoxicity in hens. The long term rat 
toxicity/carcinogenicity study is small by modem standards and there is no carcinogenicity 
study in a second species. However, an adequate mutagenicity package is available for 
mecarbam, which does not raise any cause for concern. In view of this, and taking into 
account the toxicity of organophosphate compounds in general, the inadequacy of the 
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carcinogenicity investigations is considered not to be of such great concern. An adequate 
multigeneration study is available together with an acceptable teratology study in rats. 
Potential teratogenicity has not been investigated in a second species. Overall it is concluded 
that the available data do support the establishment of a temporary ADI for mecarbam. 
However, in view of the inadequacies in the data this should be allocated on a conservative 
basis. Taking the lowest no effect level of 0.1 mg/kg bw/day, and using a safety factor of 
200, would give a temporary ADI of 0.0005 mg/kg bw, pending review of a complete up to 
date database. This is considered to be a very cautious approach since the lowest no effect 
level is derived from the multigeneration study in which there is a large difference between 
the no effect and effect levels. 
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OPINION OF THE SCIENTIFIC COMMITTEE FOR PESTICIDES ON THE 
GENETICALLY MODIFIED MAIZE LINES NOTIFIED BY CIBA-GEIGY 
(Opinion expressed by the SCP on 9 December 1996) 
Background and Terms of reference 
In the context of notifications pursuant to Council Directive 90/220/EEC of 23 April 
19901 on the deliberate release into the environment of genetically modified 
organisms, the Commission invited the Scientific Committee for Pesticides to 
express an opinion on the possible adverse effect on the environment of the 
possible development of insect resistance to Bt - toxin. The Commission 
requested the Committee to give an opinion on the following two questions: 
a) The impact on human health and the environment from the use of the 
herbicide gluphosinate ammonium on the genetically modified maize lines notified 
by Ciba-Geigy which will be assessed under Directive 91/414/EEC2 before 
authorization is given for the use of the above-mentioned herbicide on maize. 
b) Possible development of insect resistance to the Bt-toxin cannot be 
considered an adverse environmental effect, as existing agricultural means of 
controlling such resistant species of insects will still be available. 
OPINION OF THE COMMITTEE 
a) The impact on human health and the environment from the use of the 
herbicide gluphosinate ammonium on the genetically modified maize lines 
notified by Ciba-Geigy will be assessed under Directive 91/414/EEC before 
authorization is given for the use of the above-mentioned herbicide on 
maize. 
1. Glufosinate-ammonium has not so far been authorized for direct 
application onto maize plants and should not, therefore, be used 
postemergence on the genetically modified maize without authorization 
in accordance with the provisions of Directive 91/414/EEC. 
2. The use of this herbicide on genetically modified maize plants will raise 
questions of metabolic pathways, residues safety for consumers and 
impact on the environment, which should be thoroughly evaluated. The 
Committee wants to emphasise that the evaluation of metabolites 
should include studies carried out on genetically modificed maize to 
fully assess the safety of eventually modified metabolic pathways. The 
Committee is of the opinion that Directive 91/414/EEC covers all these 
aspects. 
' O J N ° L 117,6.5.1990, p. 15 
2 OJN°L230, 19.8.1991, p. I 
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3. In the event of an authorization for postemergence use of glufosinate-
ammonium on genetically modified maize, the Scientific Committee 
would like to have the opportunity to comment. 
b) Possible development of insect resistance to the Bt-toxin cannot be 
considered an adverse environmental effect, as existing agricultural means of 
controlling such resistant species of insects will still be available. 
1. On the basis of the currently available data, the Scientific Committee for 
Pesticides is of the opinion that the possible development of insect 
resistance to the Bt-toxin3 arising from the cultivation of maize plants 
containing. the Bt-toxin would not be an adverse effect on the 
environment; in effect, it would not allow the Bt-resistant cornborer to 
cause any adverse effect that is not already associated with the non-
resistant cornborer. 
2. The development of insect resistance to the Bt-toxin would be mainly an 
agricultural problem. If resistance does develop, Bacillus thuringiensis 
formulations may not be an alternative measure but other existing pest 
control and agronomic methods, e.g. control by beneficial insects or by 
conventional pesticides, are available for use to overcome any potential 
problems. 
3. The speed of possible development of insect resistance to the Bt-toxin 
in the genetically modified maize will depend on the selection pressure 
on the pest species affected by factors including : 
• The area grown and the frequency that the transgenic maize is 
grown 
• The extent of refuge areas for comborers. 
• The simultaneous cultivation of normal and transgenic maize seeds, 
> crop rotation, 
> the maintenance of adequate Bt-toxin levels in the maize 
throughout the growing period, 
> further development of genetic transformation of maize plants. 
Resistance management strategies are typically needed during the 
years of actual use of any pesticide, Bt-sprays included. Therefore, 
the Committee feels that implications of resistance management, 
including monitoring for possible development of insect resistance 
to the Bt-toxin in the genetically modified maize, should be fully 
considered. 
3 Bacillus thuringiensis endotoxin 
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FURTHER REPORT OF THE SCIENTIFIC COMMITTEE FOR 
PESTICIDES ON THE USE OF GENETICALLY MODIFIED MAIZE LINES 
(Opinion expressed on 12 May 1997) 
BACKGROUND AND TERMS OF REFERENCE 
In the context of notifications pursuant to Council Directive 90/220/EEC1 of 
23 April 1990 on the deliberate release into the environment of genetically modified 
organisms, the Commission invited the Scientific Committee for Pesticides to express 
an opinion the possible adverse effect on the environment of the possible development 
of insect resistance to Bt-toxin. The Committee expressed its opinion on 9 December 
1996 ¡ 
Austria submitted to the Commission, in its letter dated 14 February 1997" its 
intention to prohibit by ordinance the marketing of Ciba-Geigy's maize in Austria 
from 14 February 1997, pursuant to Article 16 of Directive 90/220/EEC : the Austrian 
authorities annexed to their letter the reasons for their decision. 
The Commission requested the relevant Scientific Committees in March 1997 to give 
an opinion on the following two questions: 
(a) Docs the information submitted by Austria constitute new relevant scientific 
evidence which was not taken into account by the Committee at the time its opinion 
was delivered ? 
(b) Would this information thus cause the Committee to consider that this product 
constitutes a risk to human health or the environment ? 
OPINION OF THE COMMITTEE 
The evaluation of the SCP was limited to consideration of the possible risk to the 
environment arising from the use of genetically modified maize seed. In this context, 
the Committee identified four items contained in the reasons and the information 
submitted by the Austrian authorities which it considered of relevance to its remit. 
1. Qualitative and quantitative differences between genetically modified 
(GMO) plants expressing BT-toxin and conventional pesticides. 
2. Effects on non-target organisms, particularly in soil. 
3. Development of insect resistance. 
4. Resistance management. 
'OJN°L 117,6.5.1990, p. 15 
183-
1. Qualitative and quantitative differences between genetically modified plants 
expressing BT toxin and conventional pesticides. 
The Committee recognised the complexity of comparing the exposure of a pest to 
genetically modified plants, where exposure may be prolonged and maintained, and 
conventionally applied pesticides, with shorter and repeated exposure. The potential 
for development of resistance could be either accelerated or retarded. 
The Committee noted that in the case of genetically modified maize, the effect of the 
genetically incorporated toxin is more targeted than in the case of a spray application 
which involve a range of Bt-toxins. The exposure scenario in the case of GMO maize 
is comparable to multiple applications of insecticides, but the impact of the 
Bt-genetically incorporated toxin on the environment is considerably lower than 
traditionally applied pesticides. 
2. Effects on non-target organisms particularly in soil 
Based on the available information, soil exposure from the GMO maize plants will be 
less than the exposure resulting from a single conventional spray application including 
the run-off from plants. Only trace amounts of the toxin can be detected in the roots of 
the maize and furthermore, normal agricultural practice would involve removal of the 
greater part of the plant at harvest. The plant remains are often shredded and 
transformed into silage for use as animal feed at a later stage. Bt toxin concentration 
can be increased as a result of binding and adsorption by soils'", but a recent study 'v 
has shown that transgenic plant material did not persist at a high level in the soil. 
Considering the exposure of the soil ecosystem, and exposure in earthworms or 
Collembola, the Committee noted that these issues were addressed satisfactorily in the 
dossier submitted by the notifier vThis assessment also agrees with the evaluation of 
the US EPA.vi 
3 & 4. Development of insect resistance and resistance management. 
The Committee stated in its previous report of the 9 December 1996 that resistance 
management strategies are needed during the years of use of any pesticide, 13t-sprays 
included. The Committee drew attention once again to the need for effective 
resistance management, including monitoring on agronomic grounds, to prolong the 
effectiveness of Bt toxin both in conventional sprays and in genetically modified 
maize. It also felt that the submission of a satisfactory monitoring and resistance 
management programme should be a requirement for the authorisation to use 
genetically modified maize seeds expressing Bt-toxin. 
CONCLUSION 
The Committee considered that the reasons and information submitted by the Austrian 
Authorities did not add new relevant evidence to that already considered by the 
Committee and that none of its conclusions on the risk to the environment were 
affected by the Austrian arguments. 
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